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General Introduction and Outline of Thesis 
 
I. Normal Function 
The heart contains two fluid pumps: the right heart pumps blood through the lungs 
and the left heart pumps blood through the rest of the body. Upon exercise, the 
heart can adapt its output through a unique property, being the length-dependent 
force generation. One pump cycle has four phases: the filling phase that has 
started with opening of the atrioventricular valve while the output valve is closed, 
the isovolumetric contraction phase occurring with both valves closed, the 
ejection phase during which the output valve is open whereas the atrioventricular 
valve is still closed, and the isovolumetric relaxation phase occurring with both 
valves closed (see Figure 1). During filling of the chamber the enlargement of the 
chamber by the incoming blood mass occurs at low filling pressures (≈5 mmHg), 
which demonstrates the compliance of the chamber during diastole. During 
systole the chamber shows a progressive stiffness, necessary to expel a mass of 
blood from the chamber in an artery with quite high blood pressure. 
 
 
          
 
Figure 1. The pressure-volume loop describing one contractile cycle of the left ventricle. 
The four phases distinguished by the pressure-volume loop are the filling phase (a), 
isovolumetric contraction phase (b), the ejection phase (c), and the isovolumetric relaxation 
phase (d). ESV and EDV represent left ventricular end-systolic and end-diastolic volumes, 
respectively. SV represents stroke volume. ESPVR (the end-systolic pressure-volume 
relationship) represents the line that connects all end-systolic points of loops generated 
during changes of preload.  
 
Thus, myocardial tissue should have compliant passive properties, given by 
relaxed cardiomyocytes and the extracellular matrix (ECM), whereas during 
systole the myocardial tissue should be stiff which is produced particularly by 
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contracted cardiomyocytes. The myocardial tissue consists of cardiomyocytes 
(≈75 vol%), interstitium (≈15 vol%), and capillaries, venules and arterioles (≈10 
vol%).  
For proper cardiomyocyte function, calcium homeostasis is of utmost importance. 
Ca2+ ions are released from the SR upon Ca2+ influx through the sarcolemmal L-
type Ca2+ channels associated with phase 2 of the action potential. The Ca2+ 
release channels of the SR are blocked by ryanodine and are called the 
ryanodine receptors (RyR). Ca2+ release from the SR causes a rise of intracellular 
Ca2+ concentration ([Ca2+]i) leading to formation of cross-bridges between myosin 
and actin, and contraction. Subsequent uptake of Ca2+ by the SR via the Ca2+-
ATPase pumps (SERCA) restores low diastolic Ca2+ concentrations, leading to 
relaxation [1]. 
 
ECM Composition, Synthesis and Degradation 
The ECM is a network composed of fibrillar collagens, basement membrane 
components and proteoglycans. The major part of the ECM is synthesized by 
interstitial fibroblasts that are –in number- the most abundant cells in the 
myocardium. The ECM provides a scaffold for cardiomyocytes, fibroblasts, 
endothelial cells, and the vasculature to align and build a network. The weave of 
ECM proteins behaves quite elastic at stretch, but becomes stiff if stretched fully. 
Collagens type I and type III are the predominant interstitial collagens in the 
myocardium that generate structural integrity for the adjoining cardiomyocytes, 
providing the means by which cardiomyocyte shortening is translated into overall 
ventricular pump function. The network of collagen fibers exists at three levels: 
endomysium, epimysium and perimysium (see Figure 2). Endomysium surrounds 
individual muscle fibers, while the epimysium network surrounds a group of 
muscle fbers. The perimysium consists of thick, spiral-shaped bundles of collagen 
that connect epimysial and endomysial networks.  
Basement membrane components include laminin, entactin, fibronectin, collagen 
type IV and fibrillin. Fibronectin and laminin are important for cell adhesion and 
cell-cell interaction. Proteoglycans include chondroitin sulfate dermatan sulfate, 
and heparan sulfate. Syndecans are transmembrane proteoglycans, with a family 
of four members, syndecan-1 to -4. The main protein comstituents of ECM of 
vascular tissue are collagen and elastin, with elastin being the most abundant 
protein in large arteries that are continually subjected to pulsatile pressures.  
 
 









ECM integrity is maintained by a balance in the activity of matrix 
metalloproteinases (MMPs) (see Table), and their tissue inhibitors (TIMPs). The 
proenzymes of MMPs are secreted by several cell types, including 
cardiomyocytes. Proenzymes may be converted into active enzymes by other 
MMPs (e.g. by MMP14, or MT1-MMP) or by proteinases such as urokinase. 
Inflammatory cytokines, such as interleukin-1β, interleukin-6, and tumor necrosis 
factor-α, decrease collagen synthesis by cardiac fibroblasts, whereas anti-
inflammatory cytokines, such as transforming growth factor-β, are potent 
stimulants of collagen synthesis. Cytokines also influence the synthesis and 
secretion of proMMPs, and MMPs are capable to process or activate cytokines 
from a latent form into an active form. This way, a complex feedback loop may 
occur whereby high MMP activity leads to increased cytokine bioactivity, further 
contributing to ECM remodeling.   
MMPs are Ca2+ and Zn2+-dependent proteases that are primarily synthesized as 
inactive zymogens (proMMPs), requiring activation by the removal of an amino-
terminal propeptide domain either by autoproteolysis or processing by another 
MMP or serine protease. To date, 24 MMPs have been identified in vertebrates 
and classified in a number of ways; numerically, according to ECM substrate 
specificity, or based on shared functional domains (see Table 1). Beyond the 
ECM proteins, MMPs are now recognized to have non-ECM substrates including 
a number of growth factors and cytokines. Localization of a protease is an 
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important determinant in its actions. Membrane-type MMPs (MT-MMPs) are 
covalently linked to the cell membrane. Some of the secreted MMPs also localize 
to the cell surface by binding to an integrin [3], cell surface hyaluranon receptor 
CD44 [4], through interaction with cell surface associated heparin sulfate 
proteoglycans, collagen type IV, or the extracellular matrix metalloproteinase 
inducer (EMMPRIN) [5]. In the myocardium, MMPs are expressed by fibroblasts 
[6] and cardiomyocytes [7], and primarily function extracellularly [5].  In 
cardiomyocytes MMP2 is present where it colocalizes with troponin I and -actinin 
along the Z-lines of the sarcomere [7,8]. 
  
 
Table. Matrix metalloproteinases in vertebrate tissues, including descriptive name and 




Descriptive name Mol. weight 
(latent/active) 
 
       Substrate  
MMP1 collagenase 52/43 kDa collagens (I, II, III, VII), 
basement membrane proteins 
MMP2 gelatinase A 72/62 kDa fragments of a number of 
collagens (I, III, IV, V) 
MMP3 stromelysin  52/43 kDa fibronectin, laminin, collagens 
(II, IV, IX)             
MMP7 matrilysin 28/19 kDa  
MMP8 collagenase 2 75/55 kDa  
MMP9 gelatinaseB 92/82/65 kDa fragments of a number of 
collagens (I, IV, V) 
MMP10 stromelysin 2 52/44 kDa  
MMP11 stromelysin 3 51/46 kDa  
MMP12 macrophage 
elastase 
52/20 kDa  
MMP13 collagenase 3 52/42 kDa collagens (I, II, III) 
MMP14 MT1-MMP 64/54 kDa fibronectin, gelatin, laminin-I, 
fibrillar colIagen 
MMP15 MT2-MMP 71/61 kDa  
MMP17 MT4-MMP 62/51 kDa  
 
 
Besides MMPs, certain metalloproteinases also contain a unique integrin-binding 
domain. These enzymes are called A Disintegrin And Metalloproteinase (ADAM). 
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To date, 34 ADAMs have been identified in a variety of species, with 19 in 
humans [9].These membrane-anchored enzymes bring about the shedding of 
numerous cell surface and matrix-bound proteins and are thus also called 
sheddases [10]. Among the cell surface molecules processed by ADAMs are 
growth factors, including heparin-binding epidermal growth factor (HB-EGF), and 
transforming growth factor- (TGF), and cytokines, such as TNF, IL-1 and IL-6 
[11]. These molecules are known to influence myocardial remodeling by 
introducing hypertrophy and/or apoptosis. Thus, the diversity of substrates now 
linked to metalloproteinase activity show that the role of MMPs and ADAMs in the 
myocardium extends beyond ECM degradation to their involvement in in cardiac 
structure, function and response to injury by regulating the release of ligands 
critical to cardiomyocyte hypertrophy and apoptosis.  
Activity of MMPs is controlled by a series of endogenous inhibitors. TIMPs are 
specific MMP inhibitors in the tissue compartment and have a complex role. They 
reversibly inhibit activated MMPs through binding with MMPs in a 1:1 
stoichiometry. There are four TIMPs in vertebrates. TIMP1 and TIMP3 are 
transcriptionally induced by growth factors and cytokines, while TIMP2 and TIMP4 
are mostly constitutively expressed. TIMP1, TIMP2 and TIMP4 are present in 
soluble form, while TIMP3 binds to the ECM via heparin sulfate proteoglycans 
within the ECM [12]. TIMPs efficiently inhibit MMPs albeit with different specificity 
and affinity. In addition to inhibiting a broad spectrum of MMPs, TIMP-3 is also an 
effective inhibitor of ADAMs, as well as ADAMs with thrombospondin domain (e.g. 
ADAMTS-4 and ADAMTS-5) [13]. TIMP1 reportedly inhibits ADAM-10 and 
ADAMTS-1 [14]. 
Besides MMPs and ADAMs there is a protein called Extracellular MMP Inducer, 
abbreviated by EMMPRIN, also known under the name of basigin and CD147. It 
has been demonstrated that EMMPRIN is a cell surface glycoprotein that belongs 
to the immunoglobulin superfamily. It forms a complex with α3β1-integrin [15]. It is 
highly expressed on the surface of tumor cells and stimulates adjacent fibroblasts 
or tumor cells to produce MMPs. EMMPRIN also stimulates expression of 
vascular endothelial growth factor (VEGF) and hyaluronan, which leads to 
angiogenesis and anchorage-independent growth/multidrug resistance, 
respectively [16].  
Collagen synthesis in tissues is coupled to the release of aminoterminal 
propeptide of type I procollagen (PINP) and aminoterminal propeptide of type III 
procollagen (PIIINP) in blood. Collagen degradation in tissues is coupled to the 
release of carboxyterminal cross-linked telopeptide of type I collagen (CITP or 
ICTP) in blood (see Figure 3) [17]. 
The natriuretic peptides and NO, both of which function via the second 
messenger cGMP, demonstrate anti-fibrotic actions by inhibiting collagen 
synthesis and by stimulating MMP activity. On the other hand, norepinephrine, 
angiotensin II and endothelin-1 directly stimulate fibroblast proliferation and 
collagen synthesis, thereby increasing myocardial fibrosis [18,19]. In addition, 
aldosterone stimulates collagen synthesis in cardiac fibroblasts in vitro and in rat 
hearts in vivo [20,21]. 








Excessive collagen synthesis leads to stiffness of the chambers and consequent 
impairment of diastolic properties, whereas overdigestion of the ECM results in 
myocyte-to-myocyte slippage and subsequent ventricular dilatation [22].   
The connections of ECM and cardiomyocytes are located at the integrins. 
 
Integrins and Integrin Signaling 
Myocardial tissue comprises of fibers of serially coupled cardiomyocytes with 
parallel running capillaries embedded in a weave of extracellular matrix, mainly 
composed of collagen. The cardiomyocytes bind to the extracellular matrix by 
integrin receptors. Integrins are transmembranous heterodimeric receptors 
composed of an α- and a β-subunit. At the integrin receptors, the extracellular 
forces (via extracellular matrix), e.g. myocardial stretch, are transferred to the cell 
where the cellular cytoskeleton, including microfilaments, microtubules and 
intermediate filaments, maintains the shape and structure of the cell. The 
cytoplasmic terminus of integrin interacts with the cytoskeleton via a number of 
proteins that are part of the molecular machinery initiating the signaling response. 
These proteins include talin, vinculin, -actinin, paxillin, filamin, zyxin, p130CAS, 
Src, focal adhesion kinase (FAK) and melusin. FAK is a cytoplasmic tyrosine 
kinase playing a major role in integrin signaling [23]. Clustering of integrins leads 
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to the recruitment of FAK to the cell-matrix adhesions and results in activation of 
FAK via autophosphorylation at Tyr-397. Even soluble integrin receptor ligands, 
the so called RGD peptides that contain the -Arg-Gly-Asp- sequence, could 
induce FAK phosphorylation in cardiomyocytes [24]. 
Several groups have demonstrated that soluble integrin receptor ligands cause a 
decrease of the L-type calcium currents or a decrease of [Ca2+]i  in arteriolar 
smooth muscle cells [25-27]. The α5β1 integrin appears to regulate a Tyr-
phosphorylation cascade involving Src and several focal adhesion proteins that 
control the function of the L-type Ca2+ channels [28].  
Chan et al. reported that pretreatment with ryanodine (blocker of the ryanodine 
receptor (RyR) of the SR) completely eliminated the RGD-induced Ca2+ response, 
suggesting a role of integrin signaling and downstream effects on RyR, leading to 
Ca2+ release from the SR [29]. This result was corroborated by Van der Wees et 
al. who demonstrated that the RGD-induced Ca2+ release from SR is blocked by a 
NOS inhibitor, L-NMMA, while integrin stimulation by RGD was associated with 
elevation of intracellular NO, probably by NOS1, a NO-synthase isoform that is 
localized to the SR [30].    
Ingber and colleagues proposed that upon extracellular forces integrins and 
cytoskeleton reorganise to form focal adhesions that transfer mechanical signals 
across the cell surface [31]. At these focal adhesion complexes several 
components of the cell’s signal transduction systems are organised, including 
tyrosine kinases, inositol lipid kinases, ion channels, and certain growth factor 
receptors [32]. Signaling activities that have been shown to be modulated by 
mechanical distortion or fluid shear stress and to be mediated by integrins of focal 
adhesions in the cell include Src, focal adhesion kinase (FAK), extracellular 
receptor kinase-1 and -2 (ERK1/2), Shc, Grb2, protein kinase C (PKC), nuclear 
factor-κB (NF-κB), Akt, phosphatidyl-3-P kinase (PI3K), Ca2+ ions, cAMP, various 
stress-sensitive ion channels, actin polymerisation, and expression of genes 
encoding platelet derived growth factor (PDGF), endothelin-1 (ET1), and sterol 
regulatory element-binding protein-1 (reviewed in [33]). In skeletal muscle cyclic 
mechanical stretch induced the expression of β1D-integrin, which, in turn, 
stimulated NO production and activated the downstream signaling proteins of the 
integrin pathway, FAK and RhoA. Activated FAK was assessed by FAK 
phosphorylation at Tyr397 and activated RhoA was assessed by activity assay. 
Stimulated NO production was considered to be due to NOS3 activation [34].  
 
NO-Synthases and NO 
NO-synthase (NOS) catalyzes the conversion of L-arginine to L-citrulline + nitric 
oxide (NO). In the heart three NOS isoforms are present: NOS1, or neuronal NOS 
(nNOS), NOS2, or inducible NOS (iNOS), and NOS3, or endothelial NOS 
(eNOS). NOS1 and NOS3 are constitutively present enzymes and their enzyme 
activity is Ca2+-dependent [35]. NOS2 is absent in the healthy heart, but its 
expression is induced by inflammation, mediated through cytokine-inducible 
transcription factors, such as IFN regulatory factor-1 and NF-κB to elements 
within the NOS2 promoter [36,37]. Massive quantities of NO generated by NOS2 
induced by exogenously interleukin-1β, interferon-γ and lipopolysaccharide (LPA) 
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added to neonatal rat cardiomyocytes are shown to be toxic [38].  NOS2’s 
enzyme activity is Ca2+-independent.  
As will be seen in the following paragraphs dealing about NOS isoforms and sub-
cellular NOS compartmentalization, NO produced by a specific NOS isoform does 
not act as a freely diffusible messenger within the cardiomyocyte. In the tissue 
NO has two main effects: (i) NO stimulates the activity of guanylate cyclase, an 
enzyme that produces cGMP from GTP, and (ii) NO nitrosylates tyrosine residues 
in proteins and thiol-groups of cysteine in proteins. Upon nitrosylation proteins 
may change their properties, comparable to (but different from) the changes 
induced by phosphorylation, isoprenylation, geranyl-geranylation and 
palmitoylation [39-41]. Cellular proteins that may undergo S-nitrosylation are L-
type Ca2+ channel [42-44], Kv1.5 channel [45], Ca2+-activated ATPase of the 
sarcoplasmic reticulum (SR) [46], and the ryanodine receptor-2 of the SR [47,48]. 
This NO-induced post-translational modification of proteins serves as a major 
effector of NO bioactivity and an important mode of cellular signal transduction. 
Animals deficient in S-nitrosoglutathione reductase (GSNOR) show increased 
steady-state levels of circulating S-nitrosylated proteins at basal conditions and 
elevations of S-nitrosothiols in tissues following challenge by cytokines [49,50]. 
Thus, formation of S-nitrosothiols and their subsequent clearance are 
characteristics of NO-related signaling, and have analogies in phosphorylation of 
proteins by kinases and subsequent dephosphorylation by phosphatases. Thus, 
S-nitrosothiol turnover is considered to contribute to physiologic signaling. The 
systems affected most by GSNOR deficiency include the liver, immune system, 
and cardiovascular system.         
NO exerts anti-apoptotic effects by S-nitrosylating and thereby inhibiting caspases 
3 and 9, the kinase activities of both apoptosis signaling kinase-1 and c-Jun N-
terminal kinase, and the transcriptional activity of jun [51-55].  
 
NOS3 
Under normal circumstances NO exerts several direct functions in the 
myocardium which are probably not related to the vasodilatory function of NO, 
such as acceleration of relaxation [56,57]. This effect is attributed to cGMP-
dependent, protein kinase (PKG)-mediated phosphorylation of troponin I, leading 
to a reduction in myofilament Ca2+ sensitivity [58-60]. Apparently, these effects 
are exerted by stimulated NO release from  vascular NOS3, as studies in hearts 
from NOS3-/- mice have not shown changes in myocyte relaxation [61], nor LV 
diastolic function [62], nor force-frequency response [63]. Myocardial NOS3 is 
mostly localized at the sarcolemmal and T-tubular caveolae, sites where caveolin-
3 is also localized and where several signal transduction pathways have been 
shown to be modulated by NO [64]. Thus, sarcolemma-bound NOS3 inhibits the 
L-type Ca2+ channel and attenuates the β-adrenergic receptor-stimulated increase 
in myocardial contractility [62,65]. In mice with cardiomyocyte-specific NOS3 
overexpression the line with highest level of transgenic NOS3 protein expression 
had increased heart weights. All lines displayed depressed LV peak systolic 
pressures, which was partially reversed by administration of L-NAME, suggesting 
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a net negative inotropic effect of NOS3-derived NO due to a blunted myofilament 
Ca2+ sensitivity [66].      
NOS3 has been reported to co-purify with RyR [67] and to increase RyR open 
probability (Po) and the amplitude of the calcium transient under conditions of 
sustained myocardial stretch via a cGMP-independent mechanism [68].  
Angiotensin-converting enzyme (ACE) inhibitors have been shown to enhance 
NOS3 expression and NO bioavailability (reviewed in [69]). Such a mechanism 
may contribute to the beneficial effects of ACE inhibitors in patients with heart 
failure. Moreover, NOS3 plays an important anti-atherogenic role: NOS3-derived 
NO inhibits (i) proliferation of rat aortic smooth muscle cells in a cGMP dependent 
way [70], (ii) monocyte adhesion to aortic endothelial cell monolayers [71], and 
(iii) collagen-induced platelet aggregation [72]. However, Garg & Hassid reported 
that NO from NO-donors like S-nitroso-N-acetylpenicillamine and isosorbide 
dinitrate, administered to BALB/c 3T3 fibroblasts, decreased DNA-synthesis and 
cell proliferation in these cells, without any effect on cGMP accumulation [73]. 
 
NOS2 
Upregulation of NOS2 by interleukin-1β and interferon-γ increases apoptosis in 
neonatal rat cardiomyocytes by a process that is independent of guanylate 
cyclase activation and cGMP [74]. These authors also demonstrated that 
cytokine-induced apoptosis and peroxynitrite-induced apoptosis of 
cardiomyocytes are prohibited by treatment with a peroxynitrite scavenger.  
Generally spoken, NOS2-derived NO is considered to have detrimental effects on 
the myocardium.  Mice with myocardial NOS2 overexpression suffered from 
cardiac fibrosis, cardiomyocyte death, cardiac hypertrophy, and cardiac dilatation. 
While a few NOS2-overexpressing mice developed overt heart failure, most 
animals died suddenly from atrioventricular block and asystole [75]. These data 
suggest that increased myocardial NOS2 activity is capable of initiating a process 
of cardiac remodeling that is characterized by ventricular hypertrophy, dilatation 
and sudden cardiac death.     
 
NOS1 
Myocardial NOS1 is normally localized at the sarcoplasmic reticulum (SR) 
membrane vesicles, where it influences the activities of calcium-handling genes 
[76,77]. The ryanodine receptor (RyR2) of the SR is also regulated by FKBP12 
subunits, calmodulin, and protein kinases [78].    
Myocardial NOS1 stimulates SR Ca2+ release and reuptake, facilitating Ca2+-
induced Ca2+ release and potentiation of the cardiac force-frequency response 
[63,79], probably by S-nitrosylation of calcium-handling proteins.  
Accordingly, in NOS1-/- mice β-adrenergic receptor stimulation elicits a smaller LV 
inotropic response compared to control mice [65,80].  NOS1-/- mice had increased 
basal contraction, both in isolated LV cardiomyocytes as in their hearts in vivo. 
NOS1 disruption increased Ca2+ current and prolonged the slow time constant of 
inactivation of ICa significantly, leading to an increased Ca
2+ influx and a greater 
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calcium load in SR in NOS1-/- cardiomyocytes [77]. Also the Ca2+ transient peak 
amplitude was greater in NOS1-/- cardiomyocytes than in cardiomyocytes from 
wild-type mice. The contractile response to β-adrenergic stimulation was greatly 
enhanced in NOS1-/- cardiomyocytes as well as in cardiomyocytes from wild-type 
mice treated with a specific NOS1 inhibitor, vinyl-L-N-5-(1-imino-3-butenyl)-L-
ornithine (L-VNIO) [81].  
NOS1 inhibits xanthine oxidoreductase activity, both enzymes co-localizing in the 
SR. Thus, in NOS1-/- mice xanthine oxidoreductase-mediated production of 
oxyradicals (ROS) is increased, leading to depression of myocardial excitation-
contraction coupling [82].  NOS1 deletion or inhibition leads to increased Ca2+ 
current through the L-type Ca2+ channels and reduction in SR SERCA2A activity, 
leading to increase of contraction and impairment of relaxation [57].  However, the 
positive force-frequency relationship in wild type mice is considerably attenuated 
in NOS1-/- mice, which suggests that NOS1-derived NO may enhance the force-
frequency relationship [63]. This suggestion was rejected when the same authors 
found out that the force-frequency relationship in NOS1-/- mice normalized upon 
administration of allopurinol, an inhibitor of xanthine oxidoreductase [82]. Thus, 
Khan and coworkers concluded that a ROS-mediated reduction in myofilament 
Ca2+ sensitivity may be the mechanism underlying the reduced force-frequency 
relationship in NOS1-/- mice [82]. 
Isolated cardiomyocytes from mice with myocardial-specific overexpression of 
NOS1 demonstrated lower Ca2+ current density, lower amplitude of the Ca2+ 
transient, and lower amplitude of cell shortening, while their hearts in vivo 
revealed reduced contractility as judged from lower LV ejection fraction and lower 
dP/dtmax compared to nontransgenic littermates [83].    
NO activates skeletal and cardiac ryanodine receptors, thereby regulating force in 
striated muscle [84]. NO-induced S-nitrosylation of ryanodine receptor-2 of the SR 
can increase the RyR open probability (Po) through this mechanism [47,48]. There 
is evidence that S-nitrosylation of RyR2 and the L-type Ca2+ channel is 
preferentially mediated by NOS1-derived NO [85]. However, also NOS3 has been 
reported to co-purify with RyR [67] and to increase Po of RyR as well as the 
amplitude of the calcium transient under conditions of sustained stretch via a 
cGMP-independent mechanism [68].  
Like many signaling proteins, the activity of NOS1 can be regulated by 
phosphorylation. If phosphorylated by calcium calmodulin-dependent protein 
kinase II (CaCMKII), NOS1 activity diminished, but after phosphorylation by 
protein kinase C (PKC) NOS1 activity demonstrated a modest increase [86].  
 
II. Hypertrophy 
Upon continuous overload of the heart, either by pressure or by volume, the 
myocardial tissue undergoes adaptation-like reactions of which growth is the most 
prominent. This myocardial growth is mainly produced by growth of the existing 
cardiomyocytes (cell hypertrophy), whereas the non-myocytes of the myocardium, 
e.g. the fibroblasts, undergo hyperplasia to keep non-myocyte density more or 
less constant. Other reactions observed upon initiating myocardial hypertrophy is 
the expression of genes encoding proteins that were expressed in the fetal stage 
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only, such as atrial natriuretic factor in ventricular tissue and α-skeletal muscle-
actin in ventricular tissue, whereas several other genes are downregulated (e.g. 
Ca2+-activated ATPase of the sarcoplasmic reticulum [87]) or upregulated (e.g. 
Na+,Ca2+-exchanger, β-myosin heavy chain). Although gene expression profiles in 
hypertrophied myocardium of rats subjected to pressure overload and to volume 
overload are similar for several genes, such as increased expression of B-type 
natriuretic peptide, lysyl oxidase-like protein-1 and metallothionein-1, other genes 
had overload-specific expression changes [88].  
The hypertrophic ventricle suffers, due to a thicker wall, from impaired diastolic 
filling, leading to higher filling pressures.  
A special type of cardiac hypertrophy is the hypertrophy usually observed in 
athletes of endurance sports, such as elite cyclists. These athletes have a 
“physiologic” hypertrophy that serves their exercise well, being large chambers 
that can fill with large volumes of blood and with preserved contractile properties. 
At rest, these athletes have a cardiac output that is produced by ≈40 beats per 
minute.  
A cell model of mechanical loading is the in vitro mechanical stretch model of 
cultured NRCMs. Upon stretch of these cells intracellular Ca2+ concentration 
increases [89], thereby activating several Ca2+-dependent processes, such as 
calcineurin activation [90]. This Ca2+/calmodulin-activated phosphatase is 
responsible for dephosphorylation of NFAT3 leading to nuclear translocation and 
transcriptional activation of numerous hypertrophy genes [91].    
 
ECM Composition, Synthesis and Degradation 
The extent of ECM remodeling depends partly on a balance between pro-
inflammatory and anti-inflammatory cytokines, which can be differentially 
activated depending on the type of myocardial insult or the stage of disease 
progression. Pressure overload-induced myocardial stress is associated with 
increased concentrations of inflammatory cytokines.  Components of the ECM, 
such as fibronectin, laminin and collagens I and III, are upregulated during in vivo 
hypertrophy [92-94]. Also, several matricellular proteins in the ECM are 
upregulated during cardiac hypertrophy, such as osteopontin and tenascin 
[95,96]. The extent of ANP expression in rat cardiomyocyte cultures that were 
stimulated with an 1-adrenoceptor agonist appeared to be highly dependent of 
the ECM components present in the coating of the culture dishes, such as 
fibronectin and laminin [97].    
In hypertensive heart disease, fibrous tissue accumulation in the myocardium 
leads to myocardial dysfunction and heart failure. To assess efficacy of 
therapeutic strategies changes in myocardial collagen turnover should be 
monitored. To this purpose, the use of serological markers of collagen turnover, 
such as aminoterminal propeptide of type I procollagen (PINP), aminoterminal 
propeptide of type III procollagen (PIIINP) and carboxyterminal cross-linked 
telopeptide of type I collagen (CITP or ICTP), are extremely useful. The plasma 
level of PINP is significantly correlated to the collagen volume fraction in the 
myocardium of spontaneously hypertensive rats [98] and in the myocardium of 
hypertensive patients [99]. Treatment of spontaneously hypertensive rats with 
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quinapril [98] or losartan [100] led to (i) reduction of myocardial fibrosis, (ii) lower 
collagen volume fraction in the myocardium, (iii) lower plasma PINP 
concentrations, and (iv) a tendency to increased plasma ICTP concentrations. In 
hypertensive patients, treatment with losartan led to (i) lower collagen volume 
fraction in the myocardium, and (ii) lower plasma PINP concentrations [101].   
As normally collagen synthesis is in equilibrium with collagen degradation [102], 
situations that disturb this equilibrium, like long-standing hypertension, are 
associated with abnormalities in either plasma PINP or PIIINP levels and/or 
abnormalities in plasma ICTP and/or MMP levels, and/or TIMP levels. In patients 
with hypertrophic cardiomyopathy myocardial collagen turnover is enhanced 
compared with controls, as reflected by higher levels of PINP, ICTP, MMP2, 
MMP9, and TIMP-1 in plasma of patients compared to plasma of controls [103]. 
The higher the plasma PIIINP level, the smaller was the LV end-diastolic diameter 
[103]. Quality of LV diastolic function, represented by the difference in duration 
between transmitral forward wave (A) and pulmonary venous retrograde (Ar) 
wave, was (i) directly related to plasma MMP1 and MMP2 levels, and (ii) 
inversely related to plasma PINP levels [103]. Although increased levels of MMP1 
and MMP2 in plasma of patients with hypertrophic cardiomyopathy would 
compensate for increased plasma PINP and PIIINP levels, the increased plasma 
TIMP-1 level may explain why, in general, myocardial collagen turnover is 
enhanced in the patients associated with LV diastolic dysfunction.  
 
Integrins and Integrin Signaling 
In pressure-overload hypertrophy myocardial expression of integrins was 
increased markedly. The most abundantly expressed integrin in ventricular tissue, 
integrin β1D, was upregulated together with integrin α1, α5, and α7. ANP mRNA 
was increased 6-fold, and myocardial concentrations of phosphorylated FAK, 
ERK1 and ERK2 were elevated [104]. In rat cardiomyocytes in vitro α1-adrenergic 
stimulation resulted in cardiomyocyte hypertrophy, increased protein levels of 
integrin β1D by a factor of 3-4, and rapid and sustained phosphorylation of FAK 
[105]. Also β3-integrin plays a role in cardiac hypertrophy. In pressure-overloaded 
of rat RV β3-integrin, c-Src and FAK associate in a cytoskeleton-bound complex 
[106]. Stimulation of β3-integrin by Arg-Gly-Asp containing peptide in isolated 
adult cardiomyocytes triggers (i) activation of c-Src accompanied by binding to 
p130CAS and phosphorylation of FAK on Tyr925 [107] and (ii) activation of 
p70S6 kinase [108].  FAK has an important role in hypertrophic growth of 
cardiomyocytes. Upon pressure-overload myocardial FAK tyrosine 
phosphorylation is increased, associated with activation of c-Src and a number of 
downstream adapter and signaling proteins such as p130CAS, GRBS, PI3K and 
ERK1/2 [24,105,109-113]. Also mechanical stretch activates FAK and ERK1/2 
[110,114]. FAK signaling also plays a key role in cardiomyocyte hypertrophy 
induced by 1-adrenoceptor stimulation [105,111], endothelin-1 [112], and 
angiotensin II [115], all three being well known hypertrophic stimuli acting via G 
protein coupled receptors.  Phenylephrine-mediated ANP expression is 
attenuated by the dominant negative FAK mutant, FRNK [105] and by a dominant 
negative form of integrin β1D [97]. By overexpression of β1-integrin in rat 
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cardiomyocyte cultures that were stimulated with an 1-adrenoceptor agonist, 
protein synthesis and ANP expression increased 2-fold [97].       
In response to increased hemodynamic load, ligand binding of integrins in the 
cardiomyocytes leads to their clustering. To propagate integrin signaling, focal 
adhesion complexes enriched in adapter and signaling molecules are 
subsequently assembled, leading to activation of pathways that are known to be 
implicated in the hypertrophic response. Studies that have used myocardial 
hypertrophy-inducing stimuli, like stretch [110], endothelin-1 [112], and 
phenylephrine [111], implicate a prominent role for integrins, integrin-dependent 
FAK multicomponent signaling complex, and downstream Tyr-phosphorylation of 
signaling molecules. The responses to these stimuli appear to be dependent of 
the type of ECM protein and the type of integrin receptor. Cultured neonatal rat 
ventricular myocytes that were stretched on deformable silicone sheet coated with 
collagen caused activation of the prepro-B-type-natriuretic peptide (preproBNP) 
gene promotor that was dependent of the presence of the integrin subunits β1, β3 
and αvβ5 [116]. Stretch of cardiomyocytes can cause hypertrophy and induction of 
gene expression [117-120], as well as phosphorylation of FAK [121] and 
activation of the Ras/ERK1/2 pathway [119,122].  In pressure-overloaded rat 
heart, Franchini and coworkers observed a time-dendent increase in (i) FAK 
phosphorylation at Tyr397, (ii) c-Src phosphorylation at Tyr416, (iii) co-
immunoprecipitation of FAK with actin, and (iv) phosphorylation of ERK/2 and Akt 
[109].   
Overexpression of integrin β1D or FAK triggers hypertrophy in NRCMs [105].            
 
NO-Synthases and NO 
NOS3 
NOS3 normally generates NO, which can have antihypertrophic influences. 
However, pressure load results in NOS3 uncoupling associated with reduced 
tetrahydrobiopterin levels, transforming NOS3 activity to favor ROS generation 
[123]. In cardiomyocytes isolated from pressure-overloaded hearts NOS3 has 
reduced activity and expression [124]. Inhibition of endogenous NO formation 
induces myocardial hypertrophy [125]. Upon inhibition of NOS3-derived NO 
formation, adult rat ventricular cardiomyocytes showed an increase in protein 
synthesis and cell size [126], which confirms an earlier report demonstrating that 
NOS3-/- mice have hypertension and left ventricular hypertrophy [127]. In NOS3-/- 
mice pressure overload induced more severe left ventricular hypertrophy, LV 
dysfunction and myocardial fibrosis than in wild-type mice [128]. But if NOS3 was 
restored in the hearts of NOS3-/- mice, pressure overload by aortic constriction 
caused less LV hypertrophy and dysfunction than observed in NOS3-deficient 
mice [129]. Contradictory reports about the effects of NOS3 and NOS3-deficiency 
on pressure-overload LV hypertrophy and dysfunction have been published 
[123,130]. The former authors stipulated that NOS3 expression can have 
deleterious effects due to its uncoupling during pressure-overload, leading to 
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oxidant stress [123]. The latter authors stated that ANP production, associated 
with pressure overload, may prevent hypertrophy in NOS3-deficient mice [130].    
Cardiac-specific overexpression of NOS3 attenuates the LV hypertrophy induced 
by isoproterenol infusion [131] and the LV hypertrophy induced by coronary artery 
occlusion [132]. 
NOS1 




Mice with aortic constriction have induction of myocardial NOS2 expression and 
LV hypertrophy. NOS2-deficient mice demonstrated –upon aortic constriction– 
much less hypertrophy, dilatation, fibrosis and dysfunction, than wild-type mice 
with aortic constriction [134].     
 
III. Heart Failure 
Compensated hypertrophy is often seen to undergo a transition to heart failure 
[135]. Thus, although neurohumoral stimuli are accumulating to stimulate the 
heart to higher achievements, the heart is not able to do so leading to increased 
filling pressures and venous congestion. The failing heart has undergone many 
changes, the most prominent being changes in the calcium handling proteins 
[136]. The changing geometry, architecture and properties of the chamber are 
generally indicated as (adverse) chamber remodeling, in severe cases associated 
with atrioventricular valve insufficiency, dyssynchronous contractions of the 
chamber’s wall segments, and rhythm disturbances. An important mediator of 
ventricular remodeling is the neurohumoral activation of the heart by the 
sympathetic nervous system and the renin-angiotensin-aldosteron system 
(RAAS). Full recognition of their deleterious influences on the heart has led to the 
foundation of the cornerstones of heart failure therapy: β-blockers and ACE-
inhibitors (or angiotensin receptor type 1-blockers).   
In the myocardial tissue the ECM undergoes a series of changes due to (i) 
myocardial collagen accumulation, (ii) collagen fibril disruption, (iii) altered 
arrangement and reduced cross-linking between collagen fibers, and (iv) 
synthesis of proteins that are not present in the healthy myocardium. To the latter 
group of proteins belong tenascin-C [137], thrombospondin-2 [138], matrix Gla 
protein [139], and osteopontin [139]. The volume percentage of ECM in failing 
myocardial tissue is usually increased, which is often accompanied by increased 
serum levels of aminoterminal propeptide of type I procollagen (PINP) and 
aminoterminal propeptide of type III procollagen (PIIINP), two propeptides that are 
liberated from the tissue upon collagen type I and type III synthesis. At the same 
time serum levels of carboxyterminal cross-linked telopeptide of type I collagen 
(ICTP) are low, representing a low rate of collagen degradation [17]. These 
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changes in ECM composition are ascribed to the myocardial fibroblasts that are 
stimulated by high plasma levels of catecholamines, angiotensin-II and 
aldosteron.  High levels of collagen degrading enzymes, such as collagenases, 
may lead to increases in LV dimensions and subsequent cardiomyocyte slippage 
that may contribute to progressive LV remodelling [22]. In an animal model of 
hypertensive heart disease, increased expression of collagenases coincided with 
the transition from hypertrophy to heart failure [140].  
During cardiac overload, calcium homeostasis becomes disturbed leading to an 
increase of diastolic [Ca2+]i and a decrease of systolic [Ca
2+]i. One of the 
underlying mechanisms is a decreased activity of SERCA. Recently, also the 
changes in cardiac RyR (RyR2) function are becoming elucidated. RyR2 
comprises a tetramer composed of 4 RyR2 monomers, each binding 1 molecule 
of FKBP12.6 (also known as calstabin-2) [141]. Other proteins binding to the 
RyR2/FKBP12.6 complex are protein kinase A (PKA), the protein phosphatases 
PP1 and PP2A, and the anchoring protein mAKAP. In failing hearts 
phosphorylation of RyR2 by PKA causes dissociation of FKBP12.6 from the 
channel resulting in altered channel function manifested as an increased open 
probability (Po) of RyR2 [142]. Secondly, RyR2 may become S-nitrosylated by 
SR-associated NOS1, which may influence Po [47].  In failing cardiomyocytes an 
increased diastolic [Ca2+]i and an increased Na
+,Ca2+-exchanger (NCX)  may 
stimulate an electrogenic Na+ influx leading to early and delayed 
afterdepolarizations, underlying life-theatening arrhythmias. In this respect it is 
worthwhile mentioning that fish oils, such as EPA and DHA, protect against lethal 
arrhythmias and reduce Po of RyR [143]. Moreover, several mutations in the 
human RyR2 gene are associated with stress-induced ventricular tachycardia, 
leading to sudden cardiac death. In molecular and cellular studies these 
mutations exhibit gain-of-function Ca2+-release properties following cell 
stimulation [144].             
 
ECM Composition, Synthesis and Degradation 
The oxidative stress in the failing heart, in combination with high plasma levels of 
catecholamines, angiotensin-II, aldosteron, and endothelin-1, induces the 
synthesis of several MMPs and TIMPs, via transcription factor binding elements in 
their promoters, like binding sites for NF-κB, AP-1, Ets, and GATA. Also pro-
inflammatory cytokines may activate transcription factors, leading to induction of 
MMPs and TIMPs [145]. Besides transcriptional regulation, ROS can also post-
transcriptionally activate MMPs, e.g. by activating proMMPs. In failing hearts of 
patients with ischemic cardiomyopathy (ICM) or idiopathic dilated cardiomyopathy 
(DCM) protein and mRNA expression of TIMP1 and TIMP3 were reduced, but 
TIMP2 expression was unchanged [146]. These alterations were associated with 
increases in myocardial MMP1, MMP2, MMP9, MMP13 and MMP14 protein 
concentrations [147-151]. Right ventricular biopsies from hearts of patients with 
DCM demonstrated an inverse correlation between myocardial MMP2 and TIMP2 
levels and the LV ejection fraction [152]. In patients with progressive heart failure, 
myocardial MMP1 and TIMP1 concentrations were significantly elevated 
compared to donor hearts [153]. In myocardium of patients with hypertensive 
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heart disease TIMP1 levels correlated with extent of fibrosis. This inhibitive effect 
on collagenase activity was associated with increased rates of collagen synthesis 
[154].   
In myocardium of patients with heart failure several inflammatory cytokines, such 
as IL-1β, IL-6 and TNF are elevated [155]. These increased proinflammatory 
cytokines can directly decrease collagen synthesis and procollagen mRNA 
expression in cardiac fibroblasts, while increasing the mRNAs of several MMPs 
as well as increasing the activities of several MMPs [156]. Activation of MMP 
activities by proinflammatory cytokines is amplified by the decreased expression 
of TIMPs by these cytokines [157]. The stimulating effect of proinflammatory 
cytokines on MMPs are attenuated by NO [158].  
In myocardial biopsies from 20 patients with dilated cardiomyopathy (DCM), 5 
patients with hypertrophic obstructive cardiomyopathy (HOCM), and 5 nonfailing 
donor hearts (control) DCM was associated with increased concentrations of 
ADAM-10, -15 and -17, while HOCM was associated with increased 
concentrations of ADAM-12 and -17, as compared to their respective 
concentrations in control myocardium [159]. 
In LV myocardium of 19 patients with aortic stenosis (AS) who underwent aortic 
valve replacement EMMPRIN mRNA contents were significantly higher than in 
myocardial tissue of 12 nonused donor hearts with normal LV function [160].  
Plasma of patients with congestive heart failure (CHF) showed increased 
concentrations of tenascin-C and MMP9, that declined upon cardiac 
resynchronization therapy in patients who responded to this therapy by a 
decrease of LV end-systolic volume [137]. In addition, plasma of patients with 
CHF showed a 3-fold increase in MMP9/TIMP1 ratio and a 16-fold increase in 
MMP9/TIMP2 ratio, compared to plasma of a healthy reference population [161]. 
Another study reported higher circulating MMP2 in patients with severe CHF than 
in those with mild CHF, while in both groups circulating MMP2 levels were higher 
than in controls [162]. If MMP activities were inhibited with an MMP inhibitor, LV 
dilatation was attenuated in (i)  the infarcted mouse heart [163], (ii) an animal 
model of cardiac volume overload due to an arteriovenous fistula [164] and (iii) a 
rat model of progressive heart failure, the spontaneously hypertensive heart 
failure rat [165]. 
In the heart’s reaction to overload Janicki and coworkers recognized three 
phases. The intitial phase is characterized by an increased MMP activity 
associated with degradation of fibrillar collagen and development of progressive 
cardiomyocyte hypertrophy. In the following phase, the compensated phase, 
myocardial MMP activity and collagen concentration return to normal, while 
cardiomyocyte hypertrophy continues. The final phase, the decompensated 
phase, is attained once the compensatory mechanisms are exhausted and heart 
failure develops. This phase is characterized by elevated MMP activity, marked 
ventricular dilatation and prominent fibrosis [166]. During the decompensated 
phase, myocardial collagen content builds up despite elevated MMP activity due 
to massive collagen synthesis that is stimulated by multiple factors, including 
cytokines, angiotensin II, and high wall tension. The collagen synthesized may 
differ from that in the healthy heart with respect to type (e.g., type III instead of 
type I) and extent of collagen cross-linking.  
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These three phases were not observed in a porcine model of pacing-induced 
supraventricular tachycardia. In this model heart failure was induced that was 
progressive in the first 21 days after onset of pacing. During this period LV 
myocardial sections showed progressively lower collagen content and 
progressively higher activities of MMP1, MMP2 and MMP3, associated with 
progressively lower % fractional shortening of LV segments and progressively 
higher LV end-diastolic dimensions [167].  In patients with dilated cardiomyopathy 
the degree of diastolic dysfunction was associated with plasma PIIINP 
concentrations independently of LV volume and ejection fraction [168]. In these 
patients plasma PIIINP concentrations were correlated to (i) tissue collagen 
content [169], and (ii) poor outcome [170]. In patients with congestive heart failure 
resulting from LV systolic dysfunction event-free survival was predicted by plasma 
PIIINP level, LV ejection fraction and a restrictive mitral filling pattern [171].   
 
Integrins and Integrin Signaling 
As integrins trigger intracellular signaling pathways activating the cardiomyocyte 
hypertrophy program, mechanical signals and their integrin receptors likely 
contribute to transcriptional regulation of MMPs [172], expression of “fetal” genes, 
such as brain natriuretic peptide gene [173], and expression of genes encoding 
ECM proteins [174]. In a mouse model, cardiac-specific deletion of the integrin 1 
gene results in myocardial fibrosis and cardiac failure [175]. In myocardial 
biopsies taken from hearts of patients with ischemic cardiomyopathy there was a 
loss of integrin 1D by 36%, a loss of FAK by 54%, a loss of phosphorylated FAK 
by 49%, and a loss of phosphorylated AKT by 44%, compared to myocardial 
tissue from individuals without cardiac disease [176]. Apparently, these results 
are not specific for failing myocardium, since myocardial biopsies taken from 
hearts of patients with idiopathic dilated cardiomyopathy were not altered with 
respect to integrin 1D, FAK, FAK-P and AKT-P, as compared to myocardial 
tissue from individuals without cardiac disease [176]. In hearts of patients with 
ischemic cardiomyopathy the integrin 1 mRNA concentration was unchanged 
compared to control hearts. The possibility that integrin 1D has been shedded 
from the sarcolemma was tested and found to be unlikely as the observed loss of 
integrin 1D in hearts with ischemic cardiomyopathy was not associated with an 
increase of a 55-kD integrin fragment [176].           
 
NO-Synthases and NO 
Dysregulation of NO and increased oxidative and nitrosative stress are implicated 
in the pathogenesis of heart failure [177,178]. Peroxynitrite is a reactive oxidant 
that is produced from the reaction of NO with superoxide anion and impairs 
cardiovascular function through multiple mechanisms, including activation of 
MMPs and nuclear enzyme poly(ADP-ribose) polymerase (PARP).  
The induction of cytokines in the failing myocardium, such as IL6 and TNFα, 
induce the expression of NOS2 [37]. At the same time the production of reactive 
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oxygen species (ROS) is stimulated by NADPH oxidases, probably induced by 
increased angiotensinII levels [179].  
The combination of abundance of ROS, impaired antioxidant defense 
mechanisms (superoxide dismutase, catalase and glutathione peroxidase) and 
reduced concentrations of antioxidants (vitamin E, ascorbic acid, glutathione) 
contribute to a state of oxidative stress, that together with increased NO 
formation, leads to formation of peroxynitrite [180,181]. By a process called NOS 
uncoupling, a monomeric form of NOS may become a source for myocardial ROS 
rather than NO [182-184]. The generation of peroxynitrite has been demonstrated 
in various forms of acute heart failure and chronic heart failure in both animals 
and humans [185, Table 2 of ref. 177] and in neonatal rat ventricular 
cardiomyocytes in culture peroxynitrite had detrimental effects [38]. Rats with 
chronic renal failure demonstrated marked elevations of blood pressure, plasma 
malondialdehyde, plasma nitrotyrosine, and tissue nitrotyrosine abundance, 
associated with depressed vascular tissue NO production and reduced 
immunodetectable NOS proteins in the vascular, renal and cardiac tissues [186].   
Peroxynitrate has many effects [187], one of which being the induction of MMPs 
[188]. Overexpressing glutathione peroxidase [189] or administering 
tetrahydrobiopterin to decrease myocardial superoxide anion production [123] 
decreased myocardial MMP abundance. 
In isolated aortic rings from rats with infarction-induced heart failure acetylcholine-
induced vasodilatation was attenuated leading to a shift of the effect-dose curve 
to higher doses of acetylcholine [190].  
NOS3 
In cardiomyocytes isolated from canine hearts with hypertrophic cardiomyopathy 
NOS3 and caveolin have reduced expression [191]. Seddon and coworkers 
stated that “to date it remains unclear whether constitutive myocardial NOS3 
activity plays a role in regulating myocardial function in remodeled or failing 
hearts” [57]. Although several groups reported a reduction of myocardial NOS3 
expression and activity in failing myocardium of human hearts [192,193], other 
groups reported increased myocardial NOS3 expression and activity in failing 
myocardium of human hearts [194]. In biopsies taken from human failing hearts 
Fukuchi and coworkers demonstrated higher expression of NOS3 in 
cardiomyocytes of patients who were on β-blocker therapy than in 
cardiomyocytes of patients who were treated with β-adrenoceptor agonists [195]. 
Other groups found no change in LV NOS3 protein expression in infarcted mouse 
myocardium compared to sham-operated mouse myocardium [80], nor changes 
in myocardial NOS3 expression and activity in rats with volume overload-induced 
heart failure, compared to healthy rats [196].       
Transgenic upregulation of myocardial NOS3 expression in mice with myocardial 
infarction was associated with a beneficial effect on LV remodeling [132]. NOS3 
gene delivery protected mice with acute myocardial infarction against cardiac 
remodeling, myocardial fibrosis, apoptosis, and oxidative stress [197]. Apparently, 
NOS3 may counterbalance the deleterious effects of increased ROS in 
ischemia/reperfusion. Overexpression of human NOS3 in mice protected against 
myocardial infarction-induced congestive heart failure, including less pulmonary 
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edema and improved 1-month survival, compared to wild-type mice with 
myocardial infarction of equal size [198]. Correspondingly, NOS3 deletion had 
either detrimental effects (such as increased long-term mortality) or to have no 
significant impact on the development of LV failure in mice with myocardial 
infarction [199,200].  
Oxidant stress from NOS3 uncoupling was reported to be responsible for 
pressure-overload LV remodeling and failure [123].      
NOS2 
Cardiomyocytes from patients and experimental animals with CHF have 
increased expression of NOS2 [192,195,196,201-203].  However, Stein and 
coworkers found no NOS2 mRNA in 28 of 30 failing human hearts, nor any NOS2 
immunoreactivity in these hearts [194]. Only in failing hearts from patients with 
sepsis these investigators detected NOS2 protein expression [204]. NOS2 
expressed in failing hearts is considered to lead to nitrosative stress, a 
pathophysiologic situation characterized by accumulation of S-nitrosylated 
proteins to hazardous levels. In addition, abundant NOS2-derived NO serves as a 
source of myocardial reactive oxygen species (ROS) that contribute to LV 
hypertrophy and dilatation [134]. Thus, myocardial NOS2-derived NO contributes 
to a cardiomyopathy phenotype that may exhibit a lethal brady-arrhythmia [75]. In 
myocardial biopsies from 22 patients with end-stage heart failure (8 patients with 
dilated cardiomyopathy and 14 patients with ischemic heart disease) Vejlstrup 
and coworkers detected NOS2 predominantly in vascular endothelium and 
smooth muscle cells, regardless of the etiology. Only in 4 of 22 patients with end-
stage heart failure NOS2 was found in cardiomyocytes, associated with the 
sarcolemma [202]. In myocardial biopsies of 24 patients with end-stage heart 
failure NOS2 mRNA as well as NOS2 activity were increased. Myocardial NOS2 
activity was inversely correlated with the inotropic response to isoproterenol [192]. 
This attenuation of inotropic effects to isoproterenol was associated with an 
accelerated relaxation in the failing hearts.  The use of a general NOS inhibitor, L-
NMMA, enhanced the inotropic effects of the failing hearts to β-adrenergic 
stimulation. In LV endomyocardial biopsies taken from 20 patients with dilated 
cardiomyopathy NOS2 mRNA and NOS3 mRNA concentrations correlated 
linearly with LV stroke volume and LV stroke work [205]. An intracoronary infusion 
of substance P, which releases NO from the coronary endothelium, increased LV 
stroke volume and LV stroke work, and shifted the LV end-diastolic pressure-
volume relationship to the right, representing a concomitant increase in LV 
preload reserve [205].  Fukuchi and coworkers found that in biopsies of 28 failing 
human hearts increased NOS2 activity was mainly associated with infiltrated 
macrophages rather than with cardiomyocytes [195].      
In mice with myocardial infarction myocardial NOS2 expression is increased 
associated with higher NO production and higher nitrotyrosine levels, leading to 
myocardial dysfunction and increased mortality. NOS2-/- mice with myocardial 
infarction had better contractility and lower mortality than wild-type mice with 
acute myocardial infarction [206]. Other studies corroborated the deleterious 
effects of NOS2-derived NO on infarcted myocardium. Sam and coworkers found 
that in NOS2-deficient mice late after myocardial infarction contractile dysfunction 
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was attenuated and apoptotic cell death was reduced [207]. However, Jones and 
coworkers reported that in NOS2-deficient mice severe congestive heart failure 
was not attenuated compared to wild-type mice with myocardial infarction [208]. 
Liu and coworkers found that myocardial infarction-induced increase in LV 
chamber dimension and the decrease in LV ejection fraction were less severe in 
NOS2-/- mice compared to wild-type mice [209]. Also myocardial concentrations of 
nitrotyrosine and 4-hydroxy-2-nonenal, markers for ROS, were lower in infarcted 
NOS2-/- mice compared to wild-type mice with myocardial infarction, indicating 
reduced oxidative stress by lack of NOS2-derived NO.  
As mentioned before, induction of NOS2 by cytokines was found to cause 
cardiomyocyte apoptosis [74]. The increased expression of NOS2 in myocardium 
of animals and patients with heart failure [192,201-203] may be responsible for 
increased numbers of apoptotic cardiomyocytes observed in myocardium of 
animals and patients with heart failure [210,211].                
  
NOS1 
Myocardial NOS1 expression and activity have been reported to be increased 
following experimental myocardial infarction in rats [212,213], in mice [80], in 
human failing hearts [193], and in spontaneously hypertensive rats [191]. In failing 
LV myocardium NOS1 was found to be translocated from SR to the sarcolemma 
where NOS1 associates with caveolin-3 [193,212,213]. Irreversible activation of 
the RyR by oxidants leads to Ca2+ leak from SR, depressed calcium stores in the 
SR, and a heart failure phenotype [214].  
Increased activity of NOS1 in failing myocardium does not necessarily translate in 
higher NO production rates, particularly if tetrahydrobiopterin levels and other 
cofactors are falling short. Then NOS1 uncoupling may occur, leading to ROS 
generation. In plasma of patients with congestive heart failure elevated 
concentrations of biomarkers reflecting oxidative stress have been observed 
[215]. Plasma concentrations of lipid peroxides increased with increasing NYHA 
classes of heart failure [216] and  plasma concentrations of malondialdehyde-like 
material and plasma thiols correlated with LV ejection fraction negatively and 
positively, respectively [217].  
Upon translocation to the sarcolemma, NOS1 exerts NOS3-like effects, such as 
inhibition of β-adrenergic receptor-stimulated increase in inotropy [212].  
Inhibition of NOS1 enhanced the inotropic and lusitropic response to β-adrenergic 
stimulation in failing rat hearts but had no significant effect in sham-operated rats. 
Accordingly, myocardial NOS1 overexpression may contribute to the depressed 
β-adrenergic inotropic responsiveness observed in heart failure [213]. In NOS1-/- 
mice acute myocardial infarction caused more severe LV remodeling and 
impaired β-adrenergic reserve and increased mortality compared with wild-type 
mice with similar infarct size [80,218]. On the basis of these results Casadei 
suggested that NOS1-derived NO may delay the development of heart failure 
after myocardial infarction [219]. Since NOS1 suppresses xanthine 
oxidoreductase (XOD) activity under normal conditions, NOS1 deletion causes 
XOD activation and oxidative stress. In infarcted NOS-/- mice, oxidative stress is 
probably responsible for β-adrenergic hyporesponsiveness, depressed 
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myofilament responses to activator calcium, more intense hypertrophy of 
cardiomyocytes, adverse LV remodeling, and increased mortality [82,218,220].  
In failing LV myocardium NOS1 was found to be translocated from SR to the 
sarcolemma where NOS1 associates with caveolin-3 [193,212, 213]. Following 
ischemia/reperfusion female mice exhibited increased NOS1 in association with 
caveolin-3 and increased S-nitrosylation of the L-type Ca2+ channel. Functionally, 
this led to decreased L-type Ca2+ current with reduced Ca2+ entry into the cell, 
which in turn protected the cell from calcium overload injury [221]. Due to 
translocation of NOS1 from SR to the sarcolemma of failing cardiomyocytes, 
suppression of XOD activity is relieved, which contributes to oxidative stress. S-
nitrosylation of RyR2 is now considered to be beneficial for proper RyR2 function. 
In NOS1-/- mice cardiomyocytes were found to have higher diastolic Ca2+ 
concentrations compared to wild-type mice, suggesting diastolic Ca2+ leakage 
from SR. This Ca2+ leak from SR through RyR2 was associated with diminished 
S-nitrosylation and increased S-oxidation of RyR2 [222]. These authors 
concluded that the hyponitrosylation of RyR2 in NOS1-deficient mice is 
responsible for Ca2+ leakage from SR, leading to an arrhythmogenic phenotype.  
In infarcted NOS1-/- mice worse remodeling and survival occurred despite an 
increased NOS3 expression [218].  The finding that tissue NO production was not 
elevated in these mice may be explained by NOS3 uncoupling contributing to 
nitroso-redox imbalance [223].  
When both NOS1 and NOS3 genes are deleted, concentric hypertrophy is 
observed associated with interstitial fibrosis, impairment of LV diastolic properties, 
and high mortality [224]. 
Hearts of transgenic mice with cardiomyocyte-specific NOS1 overexpression 
subjected to pressure-overload by aortic constriction developed hypertrophy with 
thicker LV walls, less LV dilatation, and better preserved LV fractional shortening 
than hearts of wild-type mice with aortic constriction. Cardiomyocytes isolated 
from NOS1-overexpressing hearts with aortic constriction had higher amplitude of 
intracellular Ca2+ transients and higher SR Ca2+ load than cardiomyocytes 
isolated from hearts of wild-type mice with aortic constriction [225]. The negative 
effects of NOS1-knockout in conjunction with the positive effect of NOS1-
overexpression on cardiomyocyte function before and during overload stronly 
suggest that cardiomyocyte NOS1 plays an important role in cell protection, 
particularly during conditions of cardiac volume or pressure overload.  
 
IV. Experimental Models of Myocardial 
Hypertrophy and Heart Failure 
 
Neonatal Rat Ventricular Cardiomyocytes (NRVCs) in vitro 
The monolayer of NRVCs has proven to be a very useful cell preparation to study 
growth-promoting effects of conditions or substances on NRVCs in vitro. The 
capacity of pro-hypertrophic stimuli can be studied in terms of (i) increase in cell 
volume, (ii) expression of “fetal” genes, and (iii) sarcomeric organization. 
Simpson and colleagues have shown that 1-adrenoceptor stimulation has potent 
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pro-hypertrophic effects on NRVCs mediated by protein kinase C and 
downstream signaling proteins [226-229]. Other pro-hypertrophic conditions or 
substances that have been tested in NRVCs in vitro are endothelin-1 [230], 
angiotensin II [231,232], myotrophin [233], and stretch [118,234-236].  
 
Ventricular Pressure Overload in vivo     
By inducing an increased afterload on left or right ventricle, the myocardium will 
undergo hypertrophy, characterized by (i) increased size of cardiomyocytes 
[237,238], (ii) increased number of interstitial fibroblasts to keep the fibroblast 
density more or less constant [238,239], and (iii) expression of “fetal” genes, such 
as the genes encoding ANP,  skeletal -actin and -myosin heavy chain [240-
242]. Even animals born with hypertension, the spontaneously hypertensive rats 
(SHR), have cardiac hypertrophy.  
Due to multiple changes in gene expression a hypertrophic ventricle will undergo 
failure sooner or later [243], characterized by either ventricular dilatation, also 
referred to as ventricular remodeling, or myocardial fibrosis that opposes 
ventricular filling, also referred to as diastolic failure. Even SHRs will 
spontaneously develop heart failure at an age of 12-18 months [244]. 
Pressure overload of the RV is produced by either constriction of the pulmonary 
artery or induction of pulmonary artery hypertension (PAH).  
 
Monocrotaline-Induced Pulmonary Hypertension 
 
Mechanism and Pathology of Pulmonary Toxicity of 
Monocrotaline 
Monocrotaline (MCT), a pyrrolizidine alkaloid derived from Crotalaria spectabilis, 
causes a pulmonary vascular syndrome in rats characterized by proliferative 
pulmonary vasculitis, pulmonary artery hypertension (PAH), and cor pulmonale. 
Current lines of evidence of the pathogenesis of MCT-induced pneumotoxicity 
indicate that MCT is activated to one or more reactive metabolites in the liver, 
particularly a MCT pyrrole called dehydromonocrotaline [245-247], and is then 
transported by red blood cells to the lung [248], where it initiates endothelial injury 
[249,250]. The endothelial injury does not appear to be acute cell death but rather 
a delayed functional alteration that leads to smooth muscle cell proliferation in the 
media of pulmonary arteriolar walls by unknown mechanisms. The role of 
inflammation in the progression of MCT-induced pulmonary vascular disease is 
uncertain. Both perivascular inflammation and platelet activation have been 
proposed as processes contributing to the response of the vascular media [247]. 
MCT and dehydroMCT are known to be toxic to a variety of domestic and 
laboratory animals and to humans. Major pathological effects induced by MCT 
poisoning include hepatic cirrhosis and megalocytosis, venocclusive disease, 
PAH, and RV hypertrophy. There is a positive correlation between progressive 
PAH, thickening of the medial wall of small pulmonary arteries and arterioles, and 
RV hypertrophy as a function of time [251]. 
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Characterization of Right Ventricular Function during 
Monocrotaline-induced Pulmonary Hypertension in the Intact 
Rat 
Besides RV hypertrophy, the primary response to MCT treatment is RV dilatation, 
i.e. increases of RV end-systolic and end-diastolic volumes and, consequently, a 
decrease of RV ejection fraction. The dose-dependent RV hypertrophy strongly 
correlates with MCT-induced pressure overload, but, despite this increased 
muscle mass, RV wall stress gradually increases, ultimately leading to RV 
decompensation [252]. Interestingly, RV end-systolic elastance and end-diastolic 
stiffness did not change significantly, even when corrected for myocardial muscle 
mass, suggesting that intrinsic myocardial function was not importantly altered. 
The unchanged RV diastolic stiffness was consistent with the absence of changes 
in fibrosis and the fact that filling pressures remained relatively normal. However, 
end-systolic and end-diastolic pressure-volume relationships showed a tendency 
to be shifted toward larger volumes, suggesting myocyte slippage as a potential 
mechanism for dilatation. In addition, early active relaxation, as reflected by , was 
severely depressed in the group of rats treated with 80 mg MCT/kg body weight,  
consistent with severe RV hypertrophy [252]. Using an orthogonal three-lead 
system, Henkens and coworkers recorded ECGs from rats with MCT-induced 
PAH at baseline, and 14 and 25 days after MCT administration [253]. Baseline 
ECGs of controls and MCT rats were similar, and ECGs of controls did not 
change over time. In MCT rats, ECG changes were already present on day 14 but 
more explicit on day 25: increased RV electromotive forces decreased mean 
QRS-vector magnitude and changed QRS-axis orientation. Important changes in 
action potential duration distribution and repolarization sequence were reflected 
by a decreased spatial ventricular gradient magnitude and increased QRS-T 
spatial angle. On day 25, RV hypertrophy was found, but not on day 14. They 
concluded that developing PAH was characterized by early ECG changes 
preceding RV hypertrophy, whereas severe PAH was marked by profound ECG 
changes associated with anatomical and functional changes in the RV. Three-




V. Purpose of the Study 
We hypothesized that pressure overload is “felt” by the myocardium through 
stretch-like effects imposed on integrins, the receptor by which cardiomyocytes 
are attached to the ECM. In the cell model of NRVCs in vitro, we activate the 
integrins by administration of a Arg-Gly-Asp (RGD) containing pentapeptide to 
test whether integrin stimulation leads to NRVC hypertrophy. Any pro-
hypertrophic effect of RGD-containing pentapeptide on NRVCs is compared with 
the well-known pro-hypertrophic effects of 1-adrenoceptor stimulation with 
phenylephrine (chapter 2). 
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Ventricular failure is associated with a disturbed myocardial collagen turnover. In 
patients with heart failure, myocardial collagen turnover can be assessed by 
plasma concentrations of PINP, PIIINP, and ICTP that either represent measures 
of collagen synthesis (PINP, PIIINP) or collagen degradation (ICTP). We set out 
to investigate the effects of cardiac resynchronization therapy (CRT) on 
myocardial collagen turnover in patients with heart failure by comparing PINP, 
PIIINP and ICTP concentrations in plasma obtained at baseline and after 6 
months of CRT (chapter 3). 
  
As it is known for some time that MCT-induced PAH and RV failure were 
associated with activation of MMPs in RV myocardium, we first set out to 
investigate whether NO plays any role in PAH-induced RV hypertrophy and 
failure. To that purpose, two doses of MCT were used that produced RV 
hypertrophy only and RV hypertrophy and subsequent RV failure, respectively 
(chapter 4). 
  
Which experimental treatments of PAH have been described? In chapter 5 we 
review the novel approaches to treat pulmonary artery hypertension, particularly 
in experimental animals. 
 
PAH is a life-threatening disease with an important pulmonary component that 
may provide a target to direct therapy. We set out to investigate whether MCT-
induced PAH and subsequent RV failure can be treated with bone marrow-
derived mesenchymal stem cells (MSCs) obtained from donor rats with PAH 
caused by injection of MCT 28 days earlier. At day 14 after MCT injection, 
recipient rats are treated with i.v. administration of MSCs from rats that had a 
MCT injection 28 days earlier (chapters 6 and 7).  
In chapter 6 the effects of stem cell therapy to rats with PAH on pulmonary 
pathology, incl. hypertension, are examined. In chapter 7 the effects of stem cell 
therapy to rats with PAH on RV function and stucture are examined, including 
changes in myocardial extracellular matrix composition. 
  
Cardiomyocytes isolated from RV myocardium of rats with and without PAH have 
been investigated electrophysiologically to explore PAH-related changes in 
excitability. In chapter 8 we report on cardiomyocyte excitability properties 
dependent on Kv-channel expression, because these channels have been 
proposed to play an important role in PAH-related arrhythmias. We define the 
control excitability properties of RV cardiomyocytes from rats without PAH and 
make a provisional comparison with myocytes from PAH-rats in the discussion of 
this study. 
 
By using in vitro cell preparations, rat hearts in vivo and ex vivo, and human 
plasma samples our goal is to characterize (i) the signaling pathways that are 
activated by pro-hypertrophic stimuli, (ii) changes in the ECM that are typical for 
heart failure, and (iii) the effects of cell therapy with MSCs on RV function, RV 
myocardial structure, and RV cardiomyocyte electrophysiology of rat hearts with 
MCT-induced PAH.  
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Background: Prolonged myocardial stretch typically leads to hypertrophy of 
cardiomyocytes. As integrins are cellular receptors of stretch, we hypothesize that 
integrin stimulation induces cardiomyocyte hypertrophy. 
 
Methods: Integrins of neonatal rat cardiomyocytes (NRCMs) were stimulated with 
a peptide containing the Arg-Gly-Asp (RGD) sequence for 24 h. For comparison, 
α1-adrenergic stimulation by phenylephrine (PE) for 24 h was applied. Saline-
treated NRCMs were used as control. The hypertrophic response was quantified 
by measuring cell surface area (CSA). Phosphorylation of NO-synthase-1 (NOS1) 
was assessed by immunocytochemistry.  
 
Results: CSA was increased by 38% (IQR 31-44%) with RGD and by 68% (IQR 
64-84%) with PE vs. control (both p<0.001). NOS-1 phosphorylation was 
increased by 61% with RGD and by 21% with PE vs. control (both p<0.01). A 
general NOS inhibitor (L-NAME) inhibited RGD-induced hypertrophy completely, 
but had no significant effect on PE-induced hypertrophy. Administration of NO-
donor to NRCMs co-incubated with RGD + L-NAME partly restored hypertrophy 
(to 62% of the hypertrophic effect of RGD alone), but had no effect if incubated 
with PE + L-NAME. Ryanodine and BAPTA-AM inhibited RGD-induced 
hypertrophy completely, but not that induced by PE.  
 
Conclusions: Integrin stimulation of NRCMs by RGD leads to hypertrophy, likely 
by activation of NOS-1. Abrogation of RGD-induced hypertrophic response upon 
NOS-inhibition and rescue of this hypertrophic effect by NO-donor suggest that 
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methyl ester; SMTC, S-methyl-L-thiocitrulline; PKC, protein kinase C; BAPTA-AM, 
1,2-bis(2-aminophenoxy)ethane-N,N,N’,N’-tetraacetic acid tetrakis-acetoxymethyl 








The primary stimulus for cardiac hypertrophy in response to hemodynamic 
overload is mechanical stretch itself. Upon mechanical stretch in vitro, protein 
synthesis in cardiomyocytes is stimulated associated with expression of 
“immediate-early” (IE) genes and re-expression of fetal genes [1-6]. As to the 
mechanosensors involved in stretch-induced protein synthesis of cardiomyocytes, 
the integrins are likely candidates as they take a central position between the 
extracellular matrix (ECM) of the tissue on which the stretch is applied and the 
cellular cytoskeleton through which the cell becomes deformed in response to 
stretch [7,8]. When ECM proteins interact with integrins, signals are transmitted 
by integrins to the cell cytoplasm through “outside-in signaling” [7]. Transmission 
of intracellular signals after integrin ligation is carried by, among others, focal 
adhesion kinase (FAK), a key cytoplasmic tyrosine kinase [9,10]. FAK associates 
with several different signaling proteins such as Src-family protein-tyrosine 
kinases, p130Cas, Shc, Grb2, and paxillin [11-14].  
Earlier we have shown that short-term integrin stimulation of neonatal rat 
cardiomyocytes (NRCMs) using a pentapeptide containing the Arg-Gly-Asp 
(RGD) sequence resulted in elevations of intracellular Ca2+ and NO 
concentrations [15]. The latter was considered the result of an increased 
concentration of the phosphorylated form of NO-synthase-1 (NOS1) [15].              
In the present study we compared integrin stimulation-induced cardiomyocyte 
hypertrophy with a well-established cell model of hypertrophy, PE-induced 
cardiomyocyte hypertrophy [16], with respect to components of the intracellular 
signaling cascade [17]. Specifically, NRCMs were exposed to integrin stimulation 
by RGD or PE for 24 h, followed by assessment of the state of phosphorylation of 
several candidate signaling molecules, and quantification of the hypertrophic 
response. The specific roles in the hypertrophic process of NOS1, NO, Ca2+, 
ryanodine receptor, protein kinase C, and ERK1/2 were studied using inhibitors 
and an NO donor, sodium nitroprusside.  
 
 
Materials and Methods 
  
Cardiomyocyte cultures 
Neonatal (2-day-old) rat ventricular cardiomyocytes (NRMCs) were prepared as 
described before [18]. Briefly, ventricular myocardium was dissociated with 
collagenase (Worthington, USA) and preplated in plastic dishes (Falcon primaria, 
Becton-Dickinson, USA) to allow preferential attachment of non-cardiomyocytes. 
Then, 1 h later, non-adherent cells were transferred to Petri dishes (ø 35 mm), 
each containing a glass cover-slip (ø 25 mm) coated with rat-tail collagen (20 
μg/mL; Sigma, USA) The culture medium consisted of Ham’s F10 supplemented 
with 10% heat-inactivated fetal bovine serum (FBS), 10% heat-inactivated horse 
serum (HS), 100 U/mL penicillin and 0.1 g/L streptomycin, all from Invitrogen (the 
Netherlands). The culture medium was replaced 24 h after seeding by a medium 
containing Ham’s F10 and DMEM (Invitrogen)(1:1, v/v), 5% HS, antibiotics, and 
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100 μmol/L 5-bromo-2’-deoxyuridine (Sigma) to inhibit cardiac fibroblast 
proliferation. The cultures of NRCMs were grown in a humidified incubator at 
37oC and 5% CO2. The medium was replaced 48 h after seeding by a medium 
containing Ham’s F10 and DMEM (1:1, v/v), 2.5% HS and antibiotics. The 
experiments had the approval of the Animal Experiments Committee of the 
Leiden University Medical Center.  
 
Experimental protocol 
Seventy-two hours after seeding the NRCMs, PE (100 μmol/L, Sigma), the 
pentapeptide Gly-Arg-Gly-Asp-Ser (RGD, 300 μg/mL, Sigma), or PBS (control) 
were added to the culture medium. Twenty-four hours later, spontaneously 
beating NRCMs were lysed with ice-cold lysis buffer containing 0.1 mol/L Tris-
HCl, 0.1% Tween-20 and 0.5 mmol/L sodium orthovanadate (Sigma), pH 7.5. 
After freezing and thawing for three times, the cell extracts were sonified two 
times for 30 s each, at 60% output using the microtip (Branson Ultrasonics, USA). 
Cell extracts were stored at -20oC before assay.  
In separate series of experiments, spontaneously beating NRCMs were incubated 
with several drugs and agents, added to the culture medium 30 min before adding 
RGD, PE or PBS for a total duration of 24 h. These drugs and agents were (i) the 
general NOS-inhibitor Nω-nitro-L-arginine methyl ester (L-NAME, 100 μmol/L, 
Sigma); (ii) the specific NOS1-inhibitor S-methyl-L-thiocitrulline (SMTC, 0.1 
μmol/L, Sigma); (iii) the MAP kinase inhibitors apigenin (10 μmol/L, Calbiochem, 
USA) and PD98059 (100 μmol/L, Calbiochem); (iv) the protein kinase C inhibitors 
chelerythrine (10 μmol/L, Sigma) and bisindolylmaleimide (50 μmol/L, Sigma); (v) 
an NO-donor (sodium nitroprusside (SNP), 10 μg/mL, pharmacy of LUMC); (vi) 
an inhibitor of the Ca2+ release channel of the sarcoplasmic reticulum ryanodine 
(100 μmol/L, Sigma); (vii) the intracellular Ca2+ chelator BAPTA-AM (50 μmol/L, 
Invitrogen); (viii), and the sarcolemmal L-type Ca2+ channel blocker verapamil 
(100 μmol/L, Sigma). 
 
Protein assay 
Protein concentration was determined by the bicinchoninic acid (BCA) protein 




Ten μg of protein was loaded per well and run on SDS-PAGE, using NuPage 12% 
Bis-Tris gels (Invitrogen) and electro-transferred to polyvinylidene difluoride filter 
(PVDF) membrane (Hybond-P, GE Healthcare, the Netherlands). To reduce non-
specific binding, the PVDF membrane was blocked for 1 h at room temperature 
with blocking buffer (ECL Advance blocking agent, GE Healthcare) in TBST 
solution composed of 10 mmol/L Tris-HCl, 0.05% Tween-20, 150 mmol/L NaCl, 
pH 8.0. Thereafter, the PVDF membrane was incubated with primary antibodies 
diluted 1:50,000 in blocking buffer at room temperature for 60 min, washed four 
times in TBST solution, and incubated with horseradish peroxidase-conjugated 
secondary antibodies diluted 1:35,000 in blocking buffer at room temperature for 
60 min.  
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For ANP and GAPDH, the PVDF membrane was incubated with both anti-ANP 
and anti-GAPDH primary antibodies at the same time. For ERK1-P/ERK1 and 
ERK2-P/ERK2, the PVDF membrane was incubated with anti-phospho ERK1 and 
anti-phospho ERK2 antibody followed by incubation with anti-ERK1 or anti-ERK2  
antibody, respectively, after stripping the membrane. 
Bands were visualized with the enhanced chemiluminescence detection system 
(ECL Advance western blotting detection kit, GE Healthcare), exposed to X-ray 
film (GE Healthcare), and analysed using a densitometer (Ultrascan XL, LKB, 
Sweden).   
Primary antibodies used were: rabbit polyclonal anti-ANP antibody (Chemicon), 
mouse monoclonal anti-GAPDH antibody (Chemicon), and mouse monoclonal 
anti-phospho ERK1 and anti-phospho ERK2 antibodies (Cell Signaling 
Technology, USA). Secondary antibodies used were goat anti-mouse IgG 
conjugated to HRP (Santa Cruz Biotechnology, USA) and goat anti-rabbit IgG 
conjugated to HRP (Santa Cruz Biotechnology).  
 
Immunofluorescence microscopy 
Cultures of NRCMs were processed as described earlier [15]. Primary antibodies 
used were: mouse monoclonal anti-sarcomeric α-actinin antibody (Sigma), rabbit 
anti-phospho (Tyr397) FAK antibody (Upstate, USA), and rabbit anti-phospho 
NOS1 antibody (Upstate). The primary antibodies were diluted 1:200 in PBS 
containing 1% FBS. Secondary antibodies were goat anti-rabbit IgG conjugated to 
FITC (Sigma), goat anti-mouse IgG conjugated to FITC (Sigma), goat anti-rabbit 
IgG conjugated to Alexa-568 (Molecular Probes, USA) and rabbit anti-mouse IgG 
conjugated to Alexa-568 (Molecular Probes, USA). The secondary antibodies 
were diluted 1:150 in PBS containing 1% FBS. Immunofluorescence images were 
produced using a fluorescence microscope (Eclipse, Nikon, Japan) equipped with 
a digital camera (DXM1200, Nikon). Images were analysed quantitatively using 
Image Pro Plus software (Media Cybernetics, USA) providing pixel intensity 
distributions of blue, green and red fluorescence. 
Cell surface areas were measured by morphometric analysis of α-actinin stained 
NRCMs using Image Pro Plus software (Media Cybernetics). Surface areas of 




Results are expressed as median with interquartile range (IQR), unless stated 
otherwise. The significance of differences between means was calculated by 
Student’s t-test and one-way analysis of variance (ANOVA) followed by 
Bonferroni's post hoc test wherever appropriate. Correlations were determined 
using a parametric test (Pearson). Differences were considered significant at 
p<0.05. SPSS12 for Windows (SPSS Inc., USA) was used for statistical analysis. 
Experimental data were always compared with data collected in control 
experiments performed at the same day. 




Effects of RGD and PE on hypertrophy 
Cardiomyocytes incubated with RGD-peptide (300 μg/mL) or PE (100 µmol/L) for 
24 h showed a median increase in cell surface area by 38% (IQR 31-44%; 
p<0.001 vs. control) or by 68% (IQR 64-84%; p<0.001 vs. control) compared with 
the cells treated with PBS (Fig.1a). The left panel of fig.1a shows the medians, 
interquartile ranges and ranges of the cell areas in the three groups of one 
representative experiment, indicating that the large variability of cell surface area 
data per group represents a true variation in cell surface area within a particular 
NRCM culture. In the right panel of fig.1a the medians, interquartile ranges and 
ranges of 8 median values of cell areas obtained from 8 independent experiments 
are presented. Unlike the large variation of cell areas within a treatment group of 
one experiment (variation coefficient of 30%), the between-experiment variation 
in the groups with the same treatment is much lower (variation coefficient of 
10%).  
After treatment with RGD for 24 h we found an increase in average (±SD) 
ANP/GAPDH ratio by 49±9% compared with PBS (p<0.05) (Fig. 1b).  After 
treatment with PE for 24 h we found an increase in average (±SD)  ANP/GAPDH 
ratio by 111±27% compared with PBS (p<0.05) (Fig. 1b).  
 
      

















































Figure 1A. LEFT  Box and whisker plots of cell areas of three groups of NRCMs grown in 
the presence of phenylephrine (PE, 100 μmol/L), RGD-containing pentapeptide (RGD, 300 
μg/mL), or control (PBS) for 24 h. Cell areas are expressed as percentage of the mean 
value of cell areas of the control culture. The boxes show median, 1st and 3rd quartiles, and 
the whiskers show the range. Data shown originate from one representative experiment. 
Per group n=77. RIGHT  Box and whisker plots of median values of cell areas obtained 
from 8 independent experiments with NRCMs grown in the presence of phenylephrine (PE, 
100 μmol/L), RGD-containing pentapeptide (RGD, 300 μg/mL), or control (PBS) for 24 h.   
 # p<0.001 vs. control (PBS), by ANOVA and Bonferroni correction 
 * p<0.001 PE vs. RGD, by ANOVA and Bonferroni correction 



































Figure 1B. ANP/GAPDH protein ratio in NRCMs treated with PBS (control), RGD (300 
µg/mL), and PE (100 µmol/L) for 24 h. Values are mean  SD. n=3 cultures per bar. 




Effects of RGD and PE on activation of FAK, NOS1, ERK1/2 and 
PKC 
After 24 h incubation, RGD had caused an average (±SD) increase in FAK 
phosphorylation by 34±27% compared with PBS (p<0.05). Incubation with PE for 
24 h had caused an average (±SD) increase in FAK phosphorylation by 111±17% 
compared with PBS (p<0.001) (Table). 
NOS1 phosphorylation was increased by 61±29% (mean±SD) by incubation with 
RGD for 24 h compared to PBS (p<0.01), whereas PE had caused an increase in 






















Signaling Control        +RGD  +PE                 P  
molecule           (RGD vs. PE) 
 
FAK-P  10046       13427#        21117###           <0.001 
NOS1-P  10029       16129###     12111                <0.01 
ERK1-P  1009         16318##        7414                <0.001 
ERK2-P  1005         1524#          10140                <0.05 
 




Table. Quantification of phosphorylated forms of signaling molecules such as focal 
adhesion kinase (FAK), nitric oxide synthase-1 (NOS1), and extracellular related kinases-1 
and -2 (ERK1 and ERK2, respectively) after 24 h incubation of NRCMs in control medium 
(Control), medium containing RGD peptide (+RGD, 300 µg/mL), phenylephrine (+PE, 100 
µmol/L). Phosphorylated forms of FAK and NOS1 were quantified by immunofluorescence 
microscopy. Number of independent observations is 5 per group. Phosphorylated forms of 









Figure 2 shows representative immunofluorescent images of NRCMs stained for 
phosphorylated FAK and NOS1 before and after stimulation with PE (100 μmol/L) 
or RGD (300 μg/mL).    
In NRCMs incubated with RGD for 24 h phosphorylated forms of ERK1 and ERK2 
had increased by, on average (±SD), 63±18% and 52±4%, compared with PBS, 
respectively (both p<0.05). Incubation with PE for 24 h had no significant effects 
on ERK1/2 phosphorylation (Table). However, phosphorylation of ERK1/2 had 
already peaked during the first hour of incubation with PE, whereas their 
phosphorylation was still rising at the end of first hour incubation with RGD (data 



















Figure 2a. Immunofluorescence images of phosphorylated FAK in NRCMs treated with 









Figure 2b. Immunofluorescence images of phosphorylated NOS1 in NRCMs treated with 
PBS (control, A), RGD (300 µg/mL, B) PE (100 μmol/L, C).   In panels A, B, and C the 
secondary antibody used was goat anti-rabbit IgG conjugated to Alexa-568 (red). All 





Cells pre-treated with MAP kinase inhibitor apigenin in the presence of RGD 
showed a complete inhibition of hypertrophy (p<0.001 vs. RGD). Cells pre-treated 
with MAP kinase inhibitor PD98059 or with the combination of apigenin and 
PD98059 also showed complete inhibition of RGD-induced hypertrophy (p<0.001 
vs. RGD)(Fig. 3a). Cells pre-treated with apigenin in the presence of PE showed 
no significant change in CSA compared with cells treated with the “PE only” 
group. Likewise, cells pre-treated with PD98059 or with the combination of 
apigenin and PD98059 did not show a significant change in CSA compared with 
the “PE only” group (Fig. 3a). 
Addition of the protein kinase C inhibitors bisindolylmaleimide (50 μmol/L) and 
chelerythrine (10 μmol/L) reduced the PE-induced hypertrophy by 41% (p<0.001 
vs. “PE only”), whereas the RGD-induced hypertrophy was not significantly 
influenced by these agents compared to “RGD only” (Fig. 3b).  
 
A B C 
A B C 
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A. Effect of RGD (300 µg/mL) on cell surface area without and with pre-treatment with the 
MAP kinase inhibitors apigenin (Api, 10 μmol/L), PD98059 (PD, 100 μmol/L), and the 
combination of these two inhibitors and the effect of PE (100 µmol/L) on cell surface area 
without and with pre-treatment of apigenin (10 μmol/L), PD98059 (100 μmol/L), and the 
combination of these two inhibitors.  
In all series of experiments, the incubations lasted 24 h.  
Columns show median values with 1st and 3rd quartiles. N= 36-83 cells per bar. 
# p<0.05 vs. PBS 
* p<0.05 vs. “RGD only” 
B. Effect of RGD (300 µg/mL) on cell surface area without and with pre-treatment with 
protein kinase C inhibitors (PKCi, being 50 µmol/L bisindolylmaleimide and 10 µmol/L 
chelerythrine) and the effect of PE (100 µmol/L) on cell surface area without and with pre-
treatment with these protein kinase C inhibitors.   
In all series of experiments, the incubations lasted 24 h. Columns show median values with 
1st and 3rd quartiles. N= 20-59 cells per bar. 
# p<0.05 vs. PBS 
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Effect of intracellular NO on RGD- and PE-induced hypertrophy         
NRCMs pre-treated with a general NOS-inhibitor L-NAME (100 μmol/L) in the 
presence of RGD showed a complete inhibition of hypertrophy (p<0.001 vs. RGD) 
(Fig. 4a). Cells pre-treated with the specific NOS1-inhibitor SMTC (0.1 μmol/L) in 
the presence of RGD also showed a complete inhibition of hypertrophy (p<0.001 
vs. RGD)(data not shown). 
Cells pre-treated with L-NAME (100 μmol/L) in the presence of PE showed no 
significant change in CSA compared with the “PE only” group (Fig. 4a). Cells pre-
treated with SMTC (0.1 μmol/L) in the presence of PE showed a 55% inhibition of 
hypertrophy compared with the “PE only” group (p<0.05 vs. PE)(data not shown). 
Addition of SNP (10 µg/mL) to NRCMs incubated with RGD + L-NAME for 24 h 
partially restored the hypertrophic capacity of RGD to 132% (p<0.001 vs. RGD+L-
NAME) which is 62% of the full effect by “RGD only”. SNP added to NRCMs 
incubated with PE + L-NAME had no significant effect (Fig. 4a).  
 
 
Effect of intracellular Ca2+ on RGD- and PE-induced 
hypertrophy     
Pretreatment of NRCMs by BAPTA (50 µmol/L) inhibited the hypertrophic effect of 
RGD completely (p<0.001 vs “RGD only”). Likewise, blockade of the ryanodine 
receptor by ryanodine (100 μmol/L) caused a complete inhibition of RGD-induced 
hypertrophy. Verapamil (100 μmol/L) had no significant effect on RGD-induced 
hypertrophy (Fig. 4b). So, Ca2+ release from the sarcoplasmic reticulum appears 
to be a prerequisite for the hypertrophic capacity of RGD.  
In PE-incubated NRCMs, BAPTA, nor ryanodine, nor verapamil had any effect on 
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Figure 4 A. Effect of RGD (300 µg/mL) on cell surface area without and with pre-treatment 
with L-NAME (100 µmol/L) and L-NAME + SNP (10 μg/mL) and the effect of PE (100 
µmol/L) on cell surface area without and with pre-treatment with L-NAME (100 µmol/L) and 
L-NAME + SNP (10 μg/mL). Columns show median values with 1st and 3rd quartiles. N= 
72-80 cells per bar. 
# p<0.05 vs. PBS 
* p<0.05 vs. “RGD only” 
&p<0.05 vs. RGD + L-NAME 
B. Effect of RGD (300 µg/mL) on cell surface area without and with pre-treatment with 
BAPTA (50 µmol/L), ryanodine (100 µmol/L) and verapamil (100 µmol/L), and the effect of 
PE (100 µmol/L) on cell surface area without and with pre- 
treatment with BAPTA (50 µmol/L), ryanodine (100 µmol/L) and verapamil (100 µmol/L). In 
all series of experiments, the incubations lasted 24 h. Columns show median values with 
1st and 3rd quartiles. N= 48-90 cells per bar. 
#  p<0.05 vs. PBS 








The present study shows that integrin stimulation with a pentapeptide containing 
the Arg-Gly-Asp (RGD) sequence for 24 h leads to NRCM hypertrophy in vitro via 
an NO-dependent mechanism. In comparison to the frequently used model of 
cellular hypertrophy by α1-adrenergic stimulation using PE, the intracellular 
signaling cascades of the two models differed in a number of aspects including 
dependence upon NO, intracellular Ca2+, and protein kinase C.  
Cardiac hypertrophy is a fundamental process of adaptation to an increased 
workload. During development of cardiac hypertrophy, cardiomyocytes undergo 
specific changes, such as rapid induction of immediate-early genes, quantitative 
and qualitative changes in gene expression and increased rate of protein 
synthesis [6]. The primary stimulus for cardiac hypertrophy is mechanical stress 
and/or an accompanying increase in neurohumoral factors [1-5]. Mechanical 
stretch of cardiomyocytes in vitro produces effects that are generally similar to 
those observed in the heart exposed to hemodynamic overload [1-5], including 
activation of MAP kinases [3,19,20].  
The cardiomyocyte’s mechanosensors are the integrins, being transmembrane 
proteins that link the extracellular matrix (ECM) to the cellular cytoskeleton at 
places called focal adhesion sites [21]. The cytoplasmic domain forms links with 
cytoskeletal proteins and intracellular signaling molecules such as focal adhesion 
kinase (FAK) [21,22]. Integrins can function as signal transducers that regulate 
gene expression and cellular growth [7,23]. Integrins also influence the 
hypertrophic response in cardiomyocytes [24]. Overexpression of β1-integrin in 
the cardiomyocyte increases ANP expression and protein synthesis without 
affecting DNA synthesis [24]. In addition, Kuppuswamy et al. have shown an 
association of β3–integrin and two non-receptor kinases, FAK and c-Src, with the 
cytoskeleton in hypertrophic cat hearts [25]. Upon integrin-induced 
phosphorylation of these kinases, they become activated, may recruit Grb2/Sos 
and then initiate the Ras/ERK signal transduction pathway [11,26-30]. We found 
an increase in FAK phosphorylation in both integrin-stimulated as well as PE-
stimulated NRCMs after 24 h, although significantly more with PE than with 
integrin stimulation. Pham et al. have shown that α1-adrenergic receptor 
stimulation induced a rapid and sustained phosphorylation of FAK, which 
appeared to be a prerequisite for a hypertrophic response of α1-adrenoceptor 
agonists, as FAK-mutants had a blunted α1-adrenoceptor-induced hypertrophic 
response [31].  
PE, like several other agonists of G-protein coupled receptors, stimulates 
sarcomeric organization, induces ANP and produces hypertrophy in NRCMs. 
Moreover, PE stimulates a rapid increase in tyrosine phosphorylation of focal 
adhesion proteins including FAK, paxillin, and p130Crk-associated substrate and 
subsequent formation of peripheral focal complexes [32]. α1-adrenergic receptor-
stimulated signaling implies phosphorylation of p90RSK [33]. Eukaryotic 
elongation factor 2 kinase (eEF2K) is a known p90RSK target. eEF2K 
phosphorylation was significantly reduced by the protein kinase C inhibitor 
bisindolylmaleimide [34]. In the nucleus p90RSK phosphorylates transcription 
factors, including c-Fos, Nur77 and CREB [35,36]. In the present study, inhibition 
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of protein kinase C reduced PE-induced hypertrophy by 41%, but had no effect on 
RGD-induced hypertrophy.  
Although ERK signaling has been shown to be involved in effective PE-induced 
cardiomyocyte hypertrophy [37-39], other studies including the present study 
have shown that the MEK1 inhibitor PD98059 did not block PE-induced 
cardiomyocyte hypertrophy to a significant extent [40-42]. In the present study, 
the MAP kinase inhibitors apigenin and PD98059 inhibited hypertrophy 
considerably in RGD-treated NRCMs, and hardly in PE-treated NRCMs.     
The present study has been conducted with NRCMs that upon stimulation of 
integrins with RGD-peptide revealed increased intracellular concentrations of NO 
and Ca2+, in combination with markedly increased concentrations of 
phosphorylated NOS1 [15].  Accordingly, the NOS inhibitors L-NAME and SMTC 
prevented the RGD-induced hypertrophy of NRCMs, but had little effect on PE-
induced hypertrophy of NRCMs. However, the pro-hypertrophic effect of NO and 
the anti-hypertrophic effect of NO inhibitors have to be considered in association 
with integrin stimulation. In the literature we can find studies reporting that NO has 
pro-hypertrophic effects [43-46] and studies reporting that NO has anti-
hypertrophic effects [47-49]. These apparently contradictory observations are 
explained by taking into account the fact that in the cardiomyocyte NOS3 and 
NOS1 are localized at sarcolemma and sarcoplasmic reticulum, respectively, 
leading to NO formation that is confined to particular compartments with different 
consequences. This is illustrated by the finding that in NOS3-deficient mice, blood 
pressure is ≈30% higher than in wild-type mice and associated with LV 
hypertrophy [49], whereas in NOS1-deficient mice blood pressure is similar to that 
in wild-type mice when awake, and hypotensive under anaesthesia [50,51]. Other 
factors that may explain why NO may have pro- and anti-hypertrophic effects are 
(i) the formation of other vasoactive compounds, such as ANP and angiotensin-II, 
(ii) the formation of superoxide anion due to “uncoupling” of the NOS isoenzyme, 
thereby causing oxidative stress, (iii) the reaction of NO with superoxide anion to 
form peroxynitrite, and (iv) direct effects of NO on proteins by means of S-
nitrosylation, or indirect effects via stimulation of guanylate cyclase and cGMP 
formation. 
The present study has clearly demonstrated the calcium dependence of the 
integrin stimulation-induced hypertrophy. This dependence was demonstrated 
particularly by inhibiting RyR function and by chelating intracellular Ca2+ ions, 
whereas blockade of Ca2+ influx via L-type Ca2+ channels by verapamil was 
without any effect.  Ca2+ release from the SR appears necessary for integrin 
stimulation-induced hypertrophy. NO controls RyR2 function probably by NO-
induced nitrosylation of RyR2, leading to increased conductance of RyR2 and 
increased Ca2+ concentration [52-55]. 
As to the limitations of our study, we note (i) the use of collagen as an ECM 
substrate to culture the NRCMs; we did not investigate the effects of other ECM 
components such as fibronectin, laminin and gelatin on NRCM hypertrophy; (ii) 
the use of neonatal rat cardiomyocytes in vitro; we did not investigate whether 
adult rat cardiomyocytes were behaving similarly, as in our hands adult rat 
cardiomyocytes loose vitality within 24 h; (iii) the time window of 24 h which 
represents acute rather than chronic events. 




The present study demonstrates that although integrin stimulation and α1-
adrenergic receptor stimulation both lead to hypertrophy of NRCMs in vitro, 
intracellular signaling cascades differ between the two models. In Fig. 5 a 
hypothetical scheme of both signal transduction pathways is presented, showing 
that the PE-stimulated signaling cascade is protein kinase C-dependent and that 
the RGD-stimulated signaling cascade contains both release of Ca2+ ions from the 
SR and production of NO. In the latter pathway, we have clearly demonstrated 
that exogenous NO (donated by nitroprusside) was able to bypass the L-NAME-
induced blockade of the signaling pathway.  Absence of a hypertrophic response 
by NOS-inhibition suggests that integrin stimulation-induced hypertrophy is NO-
dependent, whereas stimulation by PE appears largely NO-independent.  
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A hypothetical scheme of signaling events leading to hypertrophy induced by α1-adrenergic 
receptor stimulation using phenylephrine and by integrin stimulation using RGD peptide.  
Abbreviations: GPCR, G-protein coupled receptor; PLCγ, phospholipase-γ; Gq, G-protein q; 
DAG, diacylglycerol; PKC, protein kinase C; p90RSK, p90 ribosomal S6 kinase; FAK, focal 
adhesion kinase; NOS1, nitric oxide synthase-1; L-NAME, Nω-nitro-L-arginine methyl 
ester; SMTC, S-methyl-L-thiocitrulline; NO, nitric oxide; RyR2, ryanodine receptor-2; 
BAPTA-AM, 1,2-bis(2-aminophenoxy)ethane-N,N,N’,N’-tetraacetic acid tetrakis-
acetoxymethyl ester; MEK1/2, MAP kinase kinase 1/2; ERK1/2, p44 and p42 MAP kinase  
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Background: In patients with heart failure cardiac resynchronization therapy 
(CRT) leads to reverse ventricular remodelling.  
 
Aim: To evaluate whether myocardial collagen metabolism in patients with heart 
failure is implicated in adverse ventricular remodelling and response to CRT. 
 
Methods: Collagen synthesis and degradation were assessed from the 
concentrations of aminoterminal propeptides of type I and type III collagen (PINP 
and PIIINP) and carboxyterminal telopeptide of type I collagen (ICTP), 
respectively, in serum of 64 patients with heart failure before and after 6 months 
of CRT. The pro-form of matrix metalloproteinase-1 (proMMP1) and tissue 
inhibitor of metalloproteinase-1 (TIMP1) were also assayed at these time points. 
Forty-six patients (72%) showed a >10% reduction in LV end-systolic volume at 
follow-up and were classified as responders to CRT, the other 18 patients (28%) 
were classified as non-responders. 
 
Results: Responders demonstrated a mean (±SEM) increase of serum PINP and 
PIIINP during follow-up, from 32.9±2.2 to 46.7±4.0 μg/L (p<0.001) and from 
4.59±0.24 to 5.13±0.36 μg/L (p<0.05), respectively. In non-responders, serum 
PINP and PIIINP remained unchanged during follow-up. At baseline, responders 
had significantly lower serum PINP than non-responders (32.9±2.2 vs. 41.8±4.3 
μg/L; p<0.05). ICTP levels of responders at baseline tended to be higher than in 
non-responders (3.54±0.56 vs. 2.08±0.37 μg/L, p=ns), and in both groups ICTP 
levels did not change upon CRT. 
 
Conclusion: Reverse LV remodelling following CRT is associated with increased 





Key words: Heart failure, cardiac resynchronisation therapy, PINP, PIIINP, ICTP 




In addition to myocardial hypertrophy, overloaded hearts frequently demonstrate 
a reactive fibrosis due to alterations in collagen synthesis and degradation. 
Accumulation of interstitial collagen type I and type III increases myocardial 
stiffness resulting in changes in diastolic properties of the left ventricle (LV) [1]. 
Collagen type I and type III are secreted by interstitial fibroblasts as procollagens 
followed by splitting off of propeptides by endopeptidases and the release of their 
aminoterminal propeptides, PINP and PIIINP, and carboxyterminal propeptides, 
PICP and PIIICP, into the circulation. During degradation of type I collagen fibrils 
the carboxyterminal telopeptide of type I collagen (ICTP) is formed, which is a 12 
kD peptide [2].   
Extracellular matrix components, like collagen type I and type III, are continuously 
synthesized and degraded. With respect to degradation, matrix 
metalloproteinase-1 (MMP1), a collagenase, and MMP2 and MMP9, two 
gelatinases, can be upregulated at the mRNA level [3], can be activated at the 
protein level, for instance by MT1-MMP (or MMP14)[4], and can be stimulated by 
lowered concentrations of MMP inhibitors like tissue inhibitor of 
metalloproteinases (TIMPs) [5].  
The myocardial extracellular matrix is implicated in a number of conditions and 
diseases, such as hypertensive heart disease, dilated cardiomyopathy, and 
cardiac remodelling. In failing hearts myocardial MMP1 and MMP2 concentrations 
have been shown to be elevated, while TIMP1 levels were depressed or 
unchanged [6]. Rapid myocardial collagen synthesis rate and slow collagen 
degradation rate impair diastolic function and promote LV adverse remodelling, 
probably due to cardiomyocyte slippage secondary to increased LV diastolic 
pressures [7]. 
In the present study, the biochemical markers of collagen synthesis rate (PINP 
and PIIINP) and collagen degradation rate (ICTP), including proMMP1 and 
TIMP1, were assayed in patients with heart failure before and after 6 months of 
cardiac resynchronisation therapy (CRT), to evaluate whether responders and 
non-responders to CRT differ with regard to serum markers of collagen 
metabolism at those two time points and whether serum markers of collagen 









Sixty-four patients with heart failure, scheduled for implantation of a CRT device, 
were included in the study. Baseline characteristics of these patients have been 
reported in an earlier study evaluating the levels of circulating biomarkers of 
extracellular matrix metabolism [8].  The group had a mean age 64±1.2 years and 
consisted of 52 men (81%) and 12 women (19%). Ischaemic aetiology of heart 
failure was present in 45 patients (70%) and non-ischaemic aetiology in 19 
patients (30%). Selection criteria for CRT were New York Heart Association 
(NYHA) functional class III-IV, LV ejection fraction ≤35%, and QRS duration 
>120ms. Patients with decompensated heart failure and patients with a recent 
myocardial infarction (<3 months) were excluded. LV dyssynchrony was 
quantified at baseline. Clinical status was assessed before CRT implantation 
(baseline) and at 6 months follow-up. At both time points, 2-dimensional 




At baseline and at 6 months follow-up clinical status was evaluated by (i) 
assessment of NYHA functional class, (ii) determination of quality-of-life score 
using the Minnesota Living with Heart Failure questionnaire, and (iii) assessment 
of exercise capacity using the distance of a 6-minute hall walk test.  
 
Echocardiography 
Echocardiography was performed as described previously [8,9]. A commercially 
available system (Vingmed system Seven, General Electric-Vingmed, Milwaukee, 
Wisconsin, USA) was used to acquire conventional apical 2- and 4-chamber 
images, which allow calculation of LV end-systolic and end-diastolic volumes 
(LVESV and LVEDV) and LV ejection fraction, using the biplane Simpson’s 
technique [10] and commercial software (Echopac version 5.0.1, General Electric 
– Vingmed). Echocardiographic data were analyzed by two independent 
observers who were blinded to all other patient data. Inter- and intra-observer 
variabilities for assessment of LV ejection fraction and LV volumes were 90% and 
96%, respectively [11]. Based on recent data [12], patients with a reduction of  
>10% in LVESV at 6 months follow-up were classified as responders to CRT, 
whereas patients with a reduction of ≤10% in LVESV or an increased LVESV at 6 
months follow-up, were classified as non-responders. For the assessment of LV 
dyssynchrony, two regions of interest were selected in the basal portions of the 
septum and the LV lateral wall allowing calculation of the septal-to-lateral delay in 
time-to-peak systolic myocardial velocity [9]. A septal-to-lateral delay of ≥ 65 ms 
was considered to represent significant LV dyssynchrony [13]. Additionally, wall 
motion score index (WMSI) was assessed in all subjects. The LV was divided into 
16 segments. A semi quantitative scoring system (1, normal; 2, hypokinesia; 3, 
akinesia; 4, dyskinesia) was used to analyze each study. Global WMSI was 
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calculated by the standard formula: sum of the segment scores divided by the 
number of segments scored [14].               
 
Pacemaker implantation 
The LV pacing lead was inserted via the subclavian vein. After a coronary sinus 
venogram was obtained, the LV pacing lead was introduced into the coronary 
sinus and placed as far as possible in the venous system, preferably in a 
(postero-) lateral vein. The right atrial and right ventricular leads were positioned 
according to standard procedures. Implantation of leads and CRT device was 
accomplished in all patients without major complications.  
 
Biochemical analysis 
Blood samples were obtained before CRT and after 6 months follow-up. Serum 
and EDTA-plasma samples were stored at -80°C prior to assay.  
Serum levels of carboxyterminal cross-linked telopeptide of type I collagen (ICTP) 
were assayed by a competitive ELISA (Orion Diagnostica, Espoo, Finland) which 
has a measurement range of 1.0-50 μg/L [15]. Inter-assay variations were 6% 
both at high (28 μg/L) and low (3 μg/L) ICTP concentrations. Detection limit of the 
assay was 0.3 μg/L. Intra-assay variability was 11% at low ICTP concentrations, 
and 7% at high ICTP concentrations. Reference ranges of human serum ICTP 
concentrations were 1.6-4.2 μg/L for women and 1.5-4.3 μg/L for men.  
To measure of rates of synthesis of collagen type I and type III, we chose to use 
serum levels of aminoterminal propeptides of type I collagen (PINP) and of type III 
collagen (PIIINP). We acknowledge that there is ample experience with the use of 
the carboxyterminal propeptide of collagen I (PICP) (see for instance [16]); 
however, the commercial availability of assays for both PINP and PIIINP and the 
fact that there is a 1:1:1 stoichiometric relationship between the aminoterminal 
propeptide, the carboxyterminal propeptide and the collagen molecule formed for 
either collagen type, influenced our decision to use the assays to quantify PINP 
and PIIINP. Serum levels of PINP were assayed by radioimmunoassay (Orion 
Diagnostica) which has a measurement range of 5-250 μg/L [17]. Inter-assay 
variations were 6% both at high (167 μg/L) and 9.8% at low (12 μg/L) PINP 
concentrations. Detection limit of the assay was 2 μg/L. Intra-assay variability was 
9.8% at low PINP concentrations (12 μg/L) and 10.2% at high (173 μg/L) PINP 
concentrations. Reference ranges of human serum PINP concentrations were 19-
83 μg/L for women and 22-87 μg/L for men.  
Serum levels of PIIINP were assayed by radioimmunoassay (Orion Diagnostica) 
which has a measurement range of 1.0-50 μg/L [18]. Inter-assay variations were 
7.2 % at high (12.2 μg/L) and 6.5 % at low (2.7 μg/L) PIIINP concentrations. 
Detection limit of the assay was 0.3 μg/L. Intra-assay variability was 3.0 % at low 
PIIINP concentrations (2.8 μg/L) and 4.1% at high (11.9 μg/L) PIIINP 
concentrations. Reference ranges of adult human serum PIIINP concentrations 
were 2.3-6.4 μg/L.  
The tissue inhibitor of metalloproteinases-1 (TIMP1) was assayed in EDTA-
plasma by ELISA (GE Healthcare, Little Chalfont, Buckinghamshire, UK) which 
has a measurement range of 3-50 μg/L. Inter-assay variations were 15% at low 
(12.5 μg/L) and 13% at high (47.3 μg/L) TIMP1 concentrations. Intra-assay 
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variability was 11% at low (10.3 μg/L) and 9% at high (39.4 μg/L) TIMP1 
concentrations. Reference range of adult human EDTA-plasma TIMP1 
concentrations was 49 – 183  μg/L [19].  
Serum levels of pro-matrix metalloproteinase-1 (proMMP-1) were assayed by 
ELISA (Quantikine, R&D Systems, Abingdon Science Park, Abingdon, UK) which 
has a measurement range of  0.15 – 10 μg/L. Inter-assay variations were 10.4% 
at low (0.74 μg/L) and 6.7% at high (4.66 μg/L) proMMP-1 concentrations. Intra-
assay variability was 5.6% at low (0.70 μg/L) and 5.4% at high (4.43 μg/L) 
proMMP-1 concentrations. Detection limit of the assay was 0.02 μg/L. According 
to the manufacturer, average value of healthy adult human serum proMMP-1 
concentration was 3.45 μg/L, with a range of 0.91 – 9.34 μg/L. Mean reference 





Data were expressed as mean ±SEM unless stated otherwise. Differences 
between the two groups (responders and non-responders) were tested with two-
tailed Student’s t-test for paired or unpaired data when appropriate. Univariable 
and multivariable logistic regression analyses were performed to characterize 
predictors of good response to CRT. Continuous variables included baseline 
values of NYHA functional class, quality-of-life score, 6-minute hall walk distance, 
LVESV, LVEDV, LV ejection fraction, NT-proBNP, PINP, PIIINP, ICTP, TIMP1 
and proMMP1. All variables with p<0.25 entered the multivariable regression 
analysis that was performed by stepwise backward deletion. All variables with 
p<0.25 remained in the final model. All statistical tests were performed with SPSS 
12.1 software (SPSS Inc, Chicago, IL, USA). For all tests, a probability value 





None of the patients died during the 6 months follow-up period. CRT was 
successful in reducing LVESV by >10% in the first 6 months in 46 (72%) patients 
(responders), whereas in 18 (28%) patients LVESV was reduced by <10% or was 
even increased (non-responders). The clinical and echocardiographic variables at 
baseline and after 6 months of CRT in responders and non-responders have 
been presented previously [8]. At baseline, responders (1) were older (65.5±1.4 
yrs vs. 59.5±2.6 yrs, p=0.03), (2) had more dyssynchrony (100±8 ms vs. 71±11 
ms, p=0.05), and (3) had longer QRS duration (165±3 ms vs. 135±8 ms, 
p<0.001), compared to non-responders. There was no difference in baseline 
WMSI between responders and non-responders (2.30±0.27 vs. 2.18±0.20, n.s.). 
In responders, NYHA class improved from 3.1±0.1 to 2.0±0.1 (p<0.001), the 6-
minute hall walk distance improved from 333±18 m to 427±17 m (p<0.001), and 
quality-of-life score improved from 35±3 to 17±3 (p<0.001). 
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Responders had a lower serum PINP level at baseline (32.9±2.2 μg/L vs. 
41.9±4.3 μg/L, p=0.04) than non-responders. During follow-up, responders 
demonstrated an increase in serum PINP level from 32.9±2.2 μg/L to 46.7±4.0 
μg/L (p<0.001), whereas non-responders demonstrated no significant change 
(see Figure). At baseline, plasma levels of PIIINP in responders did not differ from 
those of nonresponders. In responders, plasma PIIINP levels increased during 
follow-up (from 4.590.24 to 5.13±0.36 μg/L, p<0.05), whereas in non-responders 




















































Figure 1. Levels of aminoterminal propeptide of type I procollagen (PINP), aminoterminal 
propeptide of type III procollagen (PIIINP), and carboxyterminal cross-linked telopeptide of 
type I collagen (ICTP) measured in serum of 64 patients with congestive heart failure at 
baseline (□) and at 6 months follow-up (■), divided in a group of patients who were 
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Serum ICTP levels tended to be higher in responders at baseline and at 6 months 
follow-up than in non-responders at corresponding time points (see Figure). 
Plasma levels of proMMP1, TIMP1 and proMMP1/TIMP1 did not differ between 






Table 1.  TIMP1 and proMMP1 concentrations in plasma of 64 patients with heart failure 
determined before CRT (baseline) and at 6 months follow-up, divided according to 
response to CRT. (mean values ± SEM). 
---------------------------------------------------------------------------------------------------     
            Responders          Non-responders           p-value 
                 n=46          n=18 
------------------------------------------------------------------------------------------------------------------------- 
    
TIMP1 (baseline) (µg/L)  124±5.2         111±7.1  0.16 
TIMP1 (6 months follow-up) (µg/L) 129±5.8         112±7.7               0.11 
    
proMMP1 (baseline) (µg/L) 7.55±0.72        8.04±1.12               0.71 
proMMP1 (6 mo follow-up) (µg/L) 7.89±0.85        8.08±1.11               0.90 
 
proMMP1/TIMP1 (baseline) 0.063±0.006        0.080±0.015               0.20 
proMMP1/TIMP1 (6 mo f-u) 0.064±0.007        0.083±0.017               0.21 
    
---------------------------------------------------------------------------------------------------------------- 
 
Abbreviations: CRT, cardiac resynchronisation therapy; TIMP1, tissue inhibitor of 







Univariable correlation of the following baseline parameters, NYHA functional 
class, quality-of-life score, 6-minute hall walk distance, LVESV, LVEDV, LV 
ejection fraction, NT-proBNP, PINP, ICTP, PIIINP, TIMP1 and proMMP1, with 
good response to CRT demonstrated that PINP scored best (Table 2).  
Multivariable correlation of all variables that had an univariable probability value 
<0.25 demonstrated that PINP, PIIINP and LVEDV at baseline were correlated 
with good response to CRT, but only PINP to a significant extent (Table 2). 
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Table 2. Univariable and multivariable correlation of baseline parameters with good 
response to CRT (reduction of LVESV by >10%). 
------------------------------------------------------------------------------------------------   
                Univariable analysis        Multivariable analysis 
                                           ---------------------------------------                 ------------------------------------------- 
                    OR        CI        p-value                   OR            CI            p-value 
------------------------------------------------------------------------------------------------------------------------------------ 
NYHA functional class 0.74 0.28-1.96   0.55    
Quality-of-life score  0.99 0.96-1.01   0.45    
6-min hall walk distance 1.00 0.99-1.00   0.76    
LVESV   1.00 0.99-1.01   0.15    
LVEDV   1.00 0.99-1.01   0.20  1.00 0.99-1.01    0.14 
LV ejection fraction  0.94 0.88-1.02   0.15    
NT-proBNP  1.00 1.00-1.00   0.22    
PINP   0.99 0.93-1.00   0.05  0.96 0.93-0.99    0.03 
ICTP   1.24 0.93-1.66   0.13    
PIIINP   1.23 0.86-1.76   0.23  1.35 0.94-1.93    0.10 
TIMP1   1.01 0.99-1.03   0.16    
proMMP1  0.97 0.87-1.09   0.71    
-----------------------------------------------------------------------------------------------------------------------------------                                
 
Abbreviations: OR, odds ratio; CI, 95% confidence limits; CRT, cardiac resynchronisation 
therapy; NYHA, New York Heart Association; LVESV, left ventricular end-systolic volume; 
LVEDV, left ventricular end-diastolic volume; NT-proBNP, N-terminal pro B-type natriuretic 
peptide; PINP, aminoterminal propeptide of type I procollagen; ICTP, carboxyterminal 
cross-linked telopeptide of type I collagen; PIIINP,  aminoterminal propeptide of type III 










The present study demonstrated that patients with heart failure who were 
successfully treated with CRT had relatively low serum levels of PINP at baseline, 
a measure of collagen synthesis rate, and relatively high serum levels of ICTP at 
baseline, a measure of collagen degradation rate. After 6 months of CRT, serum 
PINP and PIIINP levels had increased significantly, whereas serum ICTP had 
hardly changed. Accordingly, a high serum level of PINP at baseline is associated 
with failure to respond to CRT, which is in line with reports showing that high 
levels of markers of collagen synthesis in serum of patients with heart failure are 
associated with poor outcome [16, 22-24].   
In patients with hypertension and LV hypertrophy, elevated PINP levels in serum 
at baseline are associated with an increased myocardial collagen volume fraction 
(a measure of myocardial fibrosis) [25], low plasma levels of total and free MMP1, 
and high plasma levels of total and free TIMP1 [26]. Myocardial fibrosis is often 
associated with abnormal myocardial stiffness [27], diastolic abnormalities, and a 
decline in myocardial elastance during contraction, a measure of systolic 
dysfunction [28]. Perivascular accumulation of collagen may impair the 
vasodilator capacity of intramyocardial coronary arteries and contribute to the 
decrease in coronary reserve [29]. In patients with hypertrophic cardiomyopathy, 
high serum levels of PINP were associated with reduced diastolic function [30]. In 
patients with essential hypertension, serum levels of PINP and PIIINP were 
elevated compared to normotensives. In hypertensives, serum PIIINP levels were 
inversely correlated to diastolic (dys)function, whereas serum PINP levels were 
correlated positively to LV mass index [24]. In patients with dilated 
cardiomyopathy, the presence of a restrictive mitral pattern was associated with 
highest serum levels of PIIINP and high serum levels of PIIINP were related to 
poor outcome [31]. In patients with dilated cardiomyopathy, serum PIIINP levels 
were significantly elevated compared to corresponding levels in controls, these 
serum PIIINP levels were correlated to NYHA functional class, daily diuretics 
dosage, and mean right atrial pressure, and were inversely correlated to cardiac 
output [24]. 
In the present study, the responders to CRT tended to have higher serum ICTP 
levels than non-responders. Six months therapy with CRT had no significant 
effect on serum ICTP in responders, nor in non-responders. However, serum 
levels of proMMP1, a collagenase, did not differ between baseline and follow-up, 
nor did they differ between responders and non-responders at these two time 
points. 
Previously it has been demonstrated that patients with dilated cardiomyopathy 
had higher serum levels of MMP1 than controls, which was associated with higher 
MMP1/TIMP1 ratio, and serum free MMP1 as well as MMP1/TIMP1 ratio which 
correlated positively with LV end-diastolic volume and negatively with cardiac 
index [21]. In failing hearts supported by a LV assist device myocardial MMP1 
levels decreased, whereas TIMP1 and TIMP3 levels increased [32].  
High serum levels of ICTP have also been observed in patients with dilated 
cardiomyopathy [21] and in patients with hypertrophic cardiomyopathy [30].  
Klappacher et al. found that serum ICTP levels beyond a cut-off level of 7.6 μg/L 
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in patients with dilated cardiomyopathy were associated with increased risk of 
advanced clinical stage, increased risk of poor haemodynamic condition, 
increased risk of hyponatraemia (<138 mmol/L), and increased risk of heart 
transplantation [24].  
The increase of serum PINP in responders to CRT (the patients demonstrating 
reverse LV remodelling) in the present study, is interpreted as an increased 
myocardial collagen synthesis in responders to CRT during 6 months follow-up. 
This increased myocardial collagen synthesis in responders may be a reaction of 
the myocardium induced by improved loading conditions (due to improved 
synchronicity of segmental wall motion); and thus LVESV and LVEDV were 
decreased by biochemical forces within the tissue that provide “passive tissue 
contraction”.   
The responders were the group of patients with the lowest collagen synthesis at 
baseline, which according to the above explanation, associates with adverse LV 
remodelling by weakening the myocardial structure, thereby allowing progressive 
LV dilatation. In a study using myocardial biopsies from patients with end-stage 
heart failure taken before and after 100-600 days of left ventricular assist device 
(LVAD) implantation, Bruggink and co-workers observed an increase in ECM 
volume in the first 200 days after LVAD implantation, followed by a gradual 
decrease of ECM volume in the following 200 days to a level that was still higher 
than that observed pre-LVAD [33]. Plasma PINP levels increased considerably 
(≈3-fold) in the first month after LVAD implantation, and remained increased in the 
first 6 months after LVAD implantation. Thus, reverse LV remodelling induced by 
LV unloading was associated with increased collagen synthesis and expanded 
ECM space. Although in our study the tertiles of plasma PINP levels at baseline 
showed a tendency to associate with response to CRT (lowest tertile: 17/21 
responders, 81%; middle tertile: 16/22 responders, 73%; highest tertile 13/21 
responders, 62%), our study population was probably too small to find a 
significant association. 
One or more patients with systemic diseases that would induce abnormalities in 
collagen metabolism may have been included in the study; however, signs and 
symptoms of such diseases were absent. Furthermore, echocardiography-derived 
backscatter data indicative of myocardial fibrosis were not available in this study.  
In conclusion, elevated collagen synthesis rate at baseline is unfavourable in 
terms of therapeutic success of CRT. Reverse LV remodelling upon CRT is 
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Abstract 
Background: Pulmonary hypertension induces right ventricular (RV) overload 
that is transmitted to cardiomyocytes via integrins that activate intracellular 
messengers, including focal adhesion kinase (FAK) and neuronal nitric oxide 
synthase (NOS1). We investigated whether RV hypertrophy (RVH) and RV failure 
(RVF) were associated with activation of FAK, NOS1 and matrix 
metalloproteinases (MMPs). 
 
Methods: Rats were treated without (RVC) or with monocrotaline in low dose (30 
mg/kg) to induce RVH and in high dose (80 mg/kg) to induce RVF. After ≈30 
days, RV function was determined using combined pressure-conductance 
catheter. After sacrifice, FAK, NOS1, their phosphorylated forms (FAK-P and 
NOS1-P), MMP-2 and MMP-9 were quantified in RV myocardium by 
immunohistochemistry.     
 
Results: In RVH and RVF, RV weight/ body weight increased by 36% and 109%, 
whereas RV ejection fraction decreased by 23% and 57% vs. RVC, respectively. 
FAK-P and FAK-P/FAK were highest in RVH (2.87±0.12 and 2.52±0.23 fold 
compared to RVC, respectively) and slightly elevated in RVF (1.76±0.17 and 
1.15±0.13 fold compared to RVC, resp.). NOS1-P and NOS1-P/NOS1 were 
increased in RVH (1.63±0.12 and 3.06±0.80 fold compared to RVC, resp.) and 
RVF (2.16±0.03 and 3.30±0.38 fold compared to RVC, resp.). MMP-2 was highest 
in RVH and intermediate in RVF (3.50±0.12 and 1.84±0.22 fold compared to 
RVC, resp.). MMP-9 was elevated in RVH and RVF (2.39±0.35 and 2.92±0.68 
fold compared to RVC, resp.).  
 
Conclusions: Activation of FAK in RVH points to an integrin-dependent 
hypertrophic response of the myocardium. Activation of NOS1 in failing RV 
suggests a role of excessive NO in development of failure and activation of MMPs 






Hypertrophy; heart failure; focal adhesion kinase; neuronal nitric oxide synthase; 
matrix metalloproteinase 
 
Abbreviations: FAK, focal adhesion kinase; nNOS, neuronal nitric oxide 
synthase; NOS1, neuronal nitric oxide synthase; NO; nitric oxide; MMP, matrix 
metalloproteinase; ECM, extracellular matrix; SR, sarcoplasmic reticulum; RyR, 
ryanodine receptor; MCT, monocrotaline; ROS, reactive oxygen species; CHF, 
congestive heart failure; RV, right ventricle; LV, left ventricle; IVS, interventricular 
septum; RVC, right ventricular control; RVH, right ventricular hypertrophy; RVF, 
right ventricular failure; PBS, phosphate-buffered saline; LVH, left ventricular 
hypertrophy; LVEF, left ventricular ejection fraction; LVESV, left ventricular end 
systolic volume; SNP, Sodium nitroprusside. 




Pulmonary hypertension is a condition that causes overloading of the right 
ventricle (RV). The forces of overload are transferred to the cardiomyocytes via 
integrins, a family of transmembrane adhesion receptors. Integrin signaling 
occurs via a large array of intracellular messenger systems, including focal 
adhesion kinase (FAK) [25, 26]. FAK is a cytoplasmic tyrosine kinase that 
discretely localizes to membrane regions that attach to the extracellular matrix 
(ECM), called focal adhesions. FAK transmits signals from the ECM via integrins 
to the cytoskeleton and particular cytoplasmic proteins. Stimulation of integrins 
and FAK leads to a hypertrophic response in cardiomyocytes [17].   
Earlier we have shown that integrin stimulation was associated with immediate 
FAK phosphorylation and delayed phosphorylation of neuronal nitric oxide 
synthase (nNOS, NOS1) [32, 33]. NOS1 is located on the sarcoplasmic reticulum 
(SR) of cardiomyocytes, and is considered to modify SR function via nitrosylation 
of the ryanodine receptor (RyR) which is the calcium release site of the SR [3, 19, 
29, 34, 38]. NO and reactive oxygen species (ROS) produce peroxynitrite, known 
to activate matrix metalloproteinases (MMPs) [20, 35] that are involved in 
ventricular remodeling [27].  The exact role of the NO formed in the failing 
myocardium is not yet fully elucidated. We hypothesize that signaling pathways 
involved in myocardial hypertrophy and failure are NO-dependent, including NO-
dependent MMP activation leading to ventricular remodeling. 
A frequently used model to study functional, structural and molecular changes 
associated with compensated RV hypertrophy (RVH) and RV failure (RVF) is the 
rat treated with monocrotaline (MCT), a pyrrolizidine alkaloid [13, 16]. MCT 
selectively injures the vascular endothelium of the lung and induces pulmonary 
vasculitis [37]. Muscularization and hypertrophy of media of pulmonary arteries 
lead to increased vascular resistance and increased pulmonary arterial pressure 
[8, 22]. MCT-induced pulmonary hypertension is associated with the development 
of compensated RVH progressing to RVF within weeks, depending on the dose of 
MCT and the age of the rats [7, 15, 36]. Previous studies have shown selective 
induction of either RVH or RVF after 4 weeks of treatment with a low dose (30 
mg/kg body weight) or a high dose (80 mg/kg body weight) of MCT, respectively 
[7, 14].  
In the rat model of MCT-induced pulmonary hypertension, we determined 
activation of FAK, NOS1, immunoreactive MMP-2 and MMP-9 in RV myocardium 
to compare differences with respect to their activation patterns between controls, 
RVH and RVF. To test whether NO stimulates expression of MMP-2 and MMP-9, 
neonatal rat ventricular cardiomyocyte cultures were treated without and with the 
NO-donor sodium-nitroprusside for 24 h, followed by quantitative determination of  
immunoreactive MMP-2 and MMP-9.   
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Materials and Methods 
 
Animal model 
All animals were treated in accordance with the national guidelines and with the 
approval of the Animals Experiments Committee of the Leiden University Medical 
Center. A total of 14 male Wistar rats (Harlan, Zeist, the Netherlands) weighing 
200-250 g were randomly assigned to three groups. Animals received a single 
subcutaneous injection of MCT (Sigma-Aldrich, Zwijndrecht, the Netherlands) 
diluted in phosphate-buffered saline (PBS) in a low dose (30 mg/kg body weight, 
n=5; RVH group) or in a high dose (80 mg/kg body weight, n=5, RVF group). 
Control rats (RVC, n=4) were injected with an equal volume of PBS. 
 
Hemodynamics 
After 4 weeks of MCT administration RV pressure and volume signals were 
recorded by combined pressure-conductance catheter. To that purpose rats were 
sedated by inhalation of a mixture of isoflurane (4%) and oxygen. General 
anesthesia was administered by intraperitoneal (i.p.) injection of a fentanyl-
fluanison-midazolam mixture in a dose of 0.25 mL/100 g body weight. The 
mixture consisted of 2 parts Hypnorm® (0.315 mg/mL fentanyl + 10 mg/mL 
fluanison, VitalPharma, Maarheeze, the Netherlands), 1 part Dormicum® (5 
mg/mL midazolam, Roche, Mijdrecht, the Netherlands) and 1 part saline. After 
tracheotomy the animals were ventilated mechanically using a pressure-
controlled respirator and a mixture of air and oxygen.   
After midsternal thoracotomy a combined pressure-conductance catheter (SPR-
878, Millar Instruments, Houston, TX, USA) was introduced via the apex into the 
RV and positioned along the long axis of the RV. The catheter was connected to 
a Sigma-SA signal processor (CD Leycom, Zoetermeer, the Netherlands) and RV 
pressures and volumes were recorded digitally. All data were acquired using 
Conduct-NT software (CD Leycom) at a sample rate of 2000 Hz and analysed off-
line by custom-made software. The volume signal was calibrated using an 
ultrasonic flow probe (Transonic Systems, Maastricht, the Netherlands) around 
the ascending aorta, essentially as described by Hessel et al. [14]..  
Heart rate, RV stroke volume, cardiac output, RV end-diastolic volume, RV end-
systolic volume, RV ejection fraction, RV end-diastolic pressure, RV peak systolic 
pressure and RV end-systolic pressure were determined from pressure-volume 
loops. 
    
Tissue preparation 
Immediately after hemodynamic measurements, hearts were rapidly dissected 
and weighed. The RV, left ventricle (LV) and interventricular septum (IVS) were 
cut free, weighed, fixed in 4% formaline for more than 24 h, and embedded in 
paraffin. Subsequently, 4 μm thick sections of the RV tissue were cut and 
deparafinized in Ultraclear®  (Klinipath, Duiven, the Netherlands) for 5 min. 
Sections were rehydrated in decreasing graded alcohols (100-25%) followed by 
two 5-min washes in distilled water and TBS (10 mmol/L Tris-HCl, 150 mmol/L 
NaCl, pH 8.0). 
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Immunohistochemistry 
Sections cut from RV myocardium of RVC, RVH and RVF groups were stained for 
FAK, FAK-P, NOS1, NOS1-P, MMP-2 and MMP-9. Rabbit anti-FAK and anti-FAK-
P antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Rabbit 
anti-NOS1 and anti-NOS1-P antibodies were from Upstate (Charlottesville, VA, 
USA). Mouse anti-MMP-2 antibody and mouse anti-MMP-9 antibody were from 
Chemicon International (Temecula, CA, USA).  
Secondary antibodies used were donkey anti-rabbit IgG conjugated to Texas Red 
(Santa Cruz), goat anti-rabbit IgG conjugated to FITC (Sigma-Aldrich), goat anti-
mouse IgG conjugated to FITC (Sigma-Aldrich), and donkey anti-mouse IgG 
conjugated to Cy3 (Jackson Immuno Research Labs, West Grove, PA, USA). 
Sections were incubated in a solution of 0.1% sodium citrate and 0.5% Triton X-
100 at room temperature for 3 min. After washing with distilled water and TBS 
solution, sections were incubated for 20 min in 10% serum derived from the same 
animal species in which the secondary antibody was raised, in TBSB (TBS 
containing 0.05 mg/mL baseral). After removal of blocking serum, the sections 
were incubated overnight at 4oC with the primary antibody diluted in TBSB.  After 
removal of the primary antibody and washing three times with TBS, sections were 
incubated with secondary antibody diluted in TBSB for 1 h at room temperature in 
the dark. Subsequently, sections were washed three times with TBS, and 
counterstained with 0.01 mg/mL Hoechst 33342 (Molecular Probes, Eugene, OR, 
USA) for 10 min at room temperature in the dark. Sections were washed three 
times with TBS and mounted on microscope glass using Vectashield (Vector 
Laboratories, Burlingame, CA, USA). Sections were photographed in a 
fluorescence microscope (Nikon Eclipse, Nikon Europe, Badhoevedorp, the 
Netherlands) equipped with a 100x oil-immersion objective and a digital camera 
(Nikon DXM 1800). Images were analyzed using Image-Pro Plus software (Media 
Cybernetics, Silver Spring, MD, USA) that allows quantification of blue, green and 
red separately. Per section 5 images were acquired and analyzed to compensate 
for variations within a section.  
 
Preparation of neonatal rat ventricular cardiomyocytes and 
immunocytochemistry of cellular MMP2 and MMP9 
Neonatal (2-day-old) rat ventricular cardiomyocytes were prepared as described 
before [24]. Cells were plated in 6-well plates containing per well a collagen-
coated glass cover-slip and were grown in growth medium consisting of DMEM 
and Ham’s F10 (1:1, v/v), 2.5% horse serum, 100 U/mL penicillin and 100 µg/mL 
streptomycin (all from Invitrogen, Breda, the Netherlands). Three days after 
isolation, the cardiomyocytes were used for experiments. At termination of the 
experiment, the cover-slips were prepared for immunofluorescence microscopy 
according to a protocol described before [33]. Briefly the cover-slip was washed, 
incubated with PBS containing 1% formalin for 30 min, washed, incubated with 
PBS containing 0.1% Triton X-100 for 10 min, washed, and incubated overnight 
with first antibody (200x diluted in PBS + 1% FBS) at 4oC. Primary antibodies 
raised against MMP2 and MMP9 were the same as used with the myocardial 
tissue sections. After washing, the cells were incubated with secondary rabbit 
anti-mouse Alexa568-conjugated antibody (Molecular Probes; 400x diluted in 
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PBS + 1% FBS) for 1 h. After washing, the cultures were incubated with 10 µg/mL 
Hoechst 33342 for 10 min. After washing, cells were mounted on microscope 
slides using Vectashield. Microscope and camera were the same as used with the 




Data are expressed as mean ± SD.  The effect of treatment (RVC, RVH and RVF) 
was evaluated by one-way analysis of variance (ANOVA) followed by Bonferroni's 
post hoc test. Correlations were determined using a parametric test (Pearson). 
Differences were considered significant at p<0.05. SPSS12 for Windows (SPSS 
Inc, Chicago, IL, USA) was used for statistical analysis.  
 




Body and heart weights 
Table 1 summarizes characteristics of the animals at the day they were sacrificed. 
Immediately after hemodynamic measurements, hearts were rapidly dissected 
and weighed. Body weight of RVF rats was significantly lower than that of RVC 
and RVH rats (p<0.05 vs. RVC and RVH). RV weight of RVF animals was 
significantly higher than that of RVC and RVH rats (p<0.05 vs. RVC and RVH). 
The degree of RV hypertrophy was determined as the ratio of RV weight over the 
body weight. This hypertrophy parameter was increased (by +36%) in RVH 
(p<0.05 vs. RVC) and was significantly higher in RVF (+109% compared to RVC, 
+53% compared to RVH, both p<0.05). Furthermore, weight of RV as a fraction of 
total ventricular weight was significantly increased in RVH (+27% compared to 
RVC) and in RVF (+54% compared to RVC, +21% compared to RVH, both 
p<0.05) confirming RV hypertrophy in both MCT-treated groups. Conversely, 
there was no significant increase in the ratios of (LV+IVS) weight over body 
weight and (LV+IVS) weight over total ventricular weight in RVH and RVF 
compared with RVC (Table 1). 
 
 
Table 1. General and cardiac characteristics of RVC, RVH and RVF animals 
 
  






Body weight (g) 370 ± 24.71 365.2 ± 26.52 319.8 ± 24.04*# 
RV weight (g) 0.24 ± 0.03 0.33 ± 0.03* 0.44 ± 0.08*# 
(LV+IVS) weight (g) 0.85±0.1 0.84±0.08 0.85±0.06 
VW (RV+LV+IVS) (g) 1.09 ± 0.12 1.17 ± 0.11 1.29 ± 0.12* 
RV/BW (mg.g-1) 0.66±0.08 0.90±0.05* 1.38±0.3* 




VW/BW (mg.g-1) 2.94 ± 0.13 3.2 ± 0.16* 4.05 ± 0.47*# 
(LV+IVS)/BW (mg.g-1) 2.28± 0.12 2.3± 0.13 2.67± 0.19 
(LV+IVS)/VW 0.77±0.02 0.72±0.01 0.66±0.04 
 
* p<0.05 vs. RVC 
# p<0.05 vs. RVH 
abbreviations: RVC, RV control; RVH, RV hypertrophy; RVF, RV failure; RV, right ventricle; 




                                                                                                           Chapter 4 
 86 
Right ventricular function 
Results of combined pressure-conductance catheter measurements are 
summarized in Table 2. 
RV ejection fraction (RVEF) was 53.2±5.7 % in RVC, 40.9±9.6 % in RVH and 
22.7±6.9 % in RVF (p<0.05 vs. RVC) while RV end-diastolic pressure was 
1.4±0.4 mmHg in RVC, 3.6±0.4 mmHg in RVH and 8.0±1.5 mmHg in RVF 
(p<0.05 vs. RVC and RVH) confirming RV failure in the RVF group. Furthermore, 
in RVH rats, cardiac output (CO) and stroke volume (SV) were maintained, 
indicating a compensatory state at the expense of increased RV end-diastolic and 
end-systolic volumes and increased RV filling pressure (all p<0.05 vs. RVC).  
 
 
Table 2. Cardiac and right ventricular function of RVC, RVH and RVF animals 
 
 






Heart rate (min-1) 407 ± 24 397 ± 22  259 ± 77 
Stroke volume (μL) 145 ± 11.4 162 ± 13.1 177 ± 26.5 
Cardiac output (mL.min-1) 58.3 ± 1.2 64.0 ± 5.3 41.8 ± 7.3 
RV end-systolic volume (μL) 134 ± 29.2 265 ± 52.1 690 ± 186* 
RV end-diastolic volume (μL) 276 ± 40.7 409 ± 47.2 833 ± 197* 
RV ejection fraction (%) 53.2 ± 5.7 40.9 ± 9.6 22.7 ± 6.9* 
RV end-systolic pressure (mmHg) 25.9 ±  4.1 28.6 ± 3.7 46.7 ± 10.9 
RV end-diastolic pressure (mmHg)  1.4 ± 0.4 3.6 ± 0.4 8.0 ± 1.5*# 
 
*  p<0.05 vs. RVC 
# p<0.05 vs. RVH 





FAK is involved in the hypertrophic response of cardiomyocytes and undergoes 
autophosphorylation on integrin stimulation. To assess the activation of FAK in 
our RV hypertrophy and failure model, we quantified its phosphorylation and FAK-
P/FAK ratio by immunohistochemical techniques (Fig. 1). Myocardial FAK-P 
concentration was highest in RVH (2.87±0.12 fold higher than the corresponding 
value in RVC, p<0.05 vs. RVC) and less elevated in RVF (1.76±0.17 fold higher 
than the corresponding value in RVC, p<0.05 vs. RVC) (Fig. 1b). The ratio of 
FAK-P/FAK was also found to be the highest in RVH (2.52±0.23 fold higher than 
the corresponding value in RVC, p<0.05 vs. RVC) and hardly elevated in RVF 
group (1.15±0.13 fold higher than the corresponding value in RVC) (Fig. 1c). 
Hence there was an increase in phosphorylation of FAK as well as FAK-P/FAK 
ratio in RV hypertrophy group. 














Figure 1a. Immunofluorescence images of phosphorylated FAK in RVC (A), RVH (B) and 
RVF (C) using an FITC labeled secondary antibody. All images were taken at 20x 
magnification. . Immunofluorescence images of total FAK in RVC (D), RVH (E) and RVF 



















NOS1 is another signaling protein thought to be involved in integrin stimulation. 
We assessed NOS1 phosphorylation by quantification of immunofluorescence 
(Fig. 2a). Myocardial NOS1-P concentration was found to be increased in RVH 
(1.63±0.21 fold higher than the the corresponding value in RVC, p<0.05 vs. RVC) 
and RVF (2.16±0.03 fold higher than the corresponding value in RVC, p<0.05 vs. 
RVC and RVH) (Fig. 2b).The ratio of NOS1-P/NOS1 was markedly elevated in 
RVH (3.06±0.80 fold higher than the corresponding value in RVC, p<0.05 vs. 
RVC) and RVF (3.30±0.38 fold higher than the corresponding value in RVC, 
p<0.05 vs. RVC) (Fig. 2c), showing elevated NOS1 phosphorylation state with RV 
hypertrophy and failure.  
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Figure 1b. Relative fluorescence of FAK-P in  
RVC, RVH and RVF.  



















Figure 1c. Ratios of the relative fluorescence of 
phosphorylated FAK/ total FAK (FAK-P/FAK) in  
RVC, RVH and RVF.  
(* p< 0.05 vs. RVC; # p<0.05 vs. RVH) 















Figure 2a. Immunofluorescence images of phosphorylated NOS1 in RVC (A), RVH (B) and 
RVF (C) using an FITC labeled secondary antibody. All images were taken at 20x 
magnification. Immunofluorescence images of total NOS1 in RVC (D), RVH (E) and RVF 





















Activation of MMP-2 and MMP-9 by exogenous NO 
Neonatal rat ventricular cardiomyocytes were incubated with 10 μg/mL sodium-
nitroprusside (SNP) for 24 h and subsequently analysed for cellular MMP2 and 
MMP9 immunoreactivity by immunofluorescence microscopy. This dose of NO-
donor caused an increase of MMP2 by 222% (p<0.001) and an increase of MMP9 
by 72% (p<0.001) in 24 h (Figure 3), indicating that NO stimulates MMP2 and 
MMP9 expression.      
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Figure 2b. Relative fluorescence of NOS1-P  
in RVC, RVH and RVF.  



















Figure 2c. Ratios of the relative fluorescence  
of phosphorylated NOS1/ total NOS1  
(NOS1-P/NOS1) in RVC, RVH and RVF.  
(* p< 0.05 vs. RVC) 

































Activation of MMP-2 and MMP-9 in hypertrophied and failing RV 
MMP-2 and MMP-9 are the most commonly implied MMPs in ventricular failure 
and remodeling. We assessed the activation of RV myocardial immunoreactive 
MMP-2 and MMP-9 in our rat model of heart failure by immunohistochemical 
methods. We found that myocardial MMP-2 concentration (Fig. 4b) was the 
highest in RVH (3.50±0.12 fold higher than the corresponding value in RVC, 
p<0.05 vs. RVC) and intermediate in RVF (1.84±0.22 fold higher than the 



























Figure 3a. Immunofluorescence images of 
MMP2 in rat ventricular cardiomyocytes 
incubated  without (SNP 0, A) and with 10 
µg/mL sodium-nitroprusside (SNP 10, B)  for 
24 h. Quantitative analysis of signal 
intensities is presented.  
(# p<0.001 vs. SNP0) 
A B 





















Figure 3b. Immunofluorescence images of 
MMP9 in rat ventricular cardiomyocytes 
incubated  without (SNP 0, A) and with 10 
µg/mL sodium-nitroprusside (SNP 10, B)  for 
24 h. Quantitative analysis of signal 
intensities is presented.  
(# p<0.001 vs. SNP0) 






























Myocardial MMP-9 concentration was significantly increased both in RVH and 
RVF (2.39±0.35 and 2.92±0.68 fold higher than the corresponding values in RVC, 
respectively, both p<0.05 vs. RVC) (Fig 5b). Hence we found an activation of both 
































Figure 4a. Immunofluorescence images of 
immunoreactive MMP-2 in RVC (A), RVH (B) and RVF 
(C) using an FITC labeled secondary antibody. All images 
were taken at 20x magnification.  
Figure 4b. Relative fluorescence of 
MMP-2 in RVC, RVH and RVF.  
(* p< 0.05 vs. RVC; # p<0.05 vs. RVH)
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Figure 5a. Immunofluorescence images of 
immunoreactive MMP-9 in RVC (A), RVH (B) and RVF (C) 
using an FITC labeled secondary antibody. All images 
were taken at 20x magnification.  
Figure 5b. Relative fluorescence of 
MMP-9 in RVC, RVH and RVF.  
(* p< 0.05 vs. RVC) 




In the present study we showed that in a rat model of pulmonary hypertension, 
there is an activation of signaling proteins FAK and NOS1 with concurrent 
activation of matrix metalloproteinases MMP-2 and MMP-9 in the RV 
myocardium. In rat cardiomyocyte cultures, exogenous NO was found to activate 
cellular MMP-2 and MMP-9. In the rat model of pulmonary hypertension, we 
found a dose-dependent effect of the toxin, monocrotaline, on the pulmonary 
vasculature, leading to compensated RV hypertrophy in RVH group and RV 
failure in RVF group.  
For the RV, pulmonary hypertension means increased afterload. The forces 
associated with increased afterload are transferred to the cardiomyocytes of the 
RV myocardium via integrins, a family of transmembrane adhesion receptors. 
Integrins couple the proteins of the extracellular matrix to the cellular cytoskeleton 
and other specific proteins, like FAK. Stimulation of integrins elicits cellular 
signaling pathways via a large array of cellular messenger systems, including 
autophosphorylation of FAK. Stimulation of integrins and FAK leads to a 
hypertrophic response in cardiomyocytes [17]. Integrin-mediated signaling 
activates protein tyrosine kinases such as FAK and Src, and results in the 
activation of the ERK2 and JNK1 pathways which in turn activate transcription 
factors relevant to MMP transcriptional regulation [23, 18].  
Bayer et al. [4] have shown that FAK levels increased during established phase of 
compensatory left ventricular hypertrophy (LVH) and the transition from 
compensated LVH to heart failure in a rat model of LVF induced by abdominal 
aortic coarctation. Furthermore, phosphorylated FAK levels also increased during 
established phase of compensatory LVH and transition from compensated LVH to 
heart failure. FAK undergoes tyrosine phosphorylation in response to growth 
factor stimulation in both cardiomyocytes and smooth muscle cells, and FAK 
phosphorylation is necessary for activation of downstream signaling cascades 
leading to cytoskeletal reorganization and cellular growth. Increased FAK 
expression occurred in both cardiomyocytes and cardiac fibroblast [4]. 
Earlier we have shown selective induction of either RVH or RVF after 4 weeks of 
treatment with a low dose (30 mg/kg body weight) or a high dose (80 mg/kg body 
weight) of MCT, respectively [14]. Here we show that phosphorylation of FAK is 
significantly increased in MCT-induced RV hypertrophy (RVH) and failure groups 
(RVF) compared with the control RVC (p<0.05 vs. RVC), while the ratio of 
phosphorylated FAK to total FAK is significantly increased in RVH only (p<0.05 
vs. RVC). 
NO synthase (NOS) is expressed constitutively as two isoforms: endothelial 
(eNOS) and neuronal (nNOS, NOS1) [30]. Earlier we showed that neuronal nitric 
oxide synthase (NOS1) is activated by integrin stimulation [32, 33]. NOS1 is 
located on the SR of cardiomyocytes, and is considered to modify SR function via 
nitrosylation of the ryanodine receptor which is the calcium release site of the SR 
[3, 19, 29, 34, 38]. 
The protein level and the activity of NOS1 have been shown to be enhanced in 
the LV myocardium of chronically infarcted animals and in failing human hearts [5, 
9, 11], suggesting that NOS1 may play a part in the myocardial response to 
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stress. Furthermore, under these conditions, NOS1 seems to be preferentially 
localized to the sarcolemmal membrane (rather than to the SR), where it 
colocalizes with caveolin-3. Bendall et al. [5] have shed some light on the 
functional significance of these findings by showing that under basal conditions 
NOS1 inhibition increased basal LV inotropy and prolonged the time constant of 
isovolumic relaxation in sham operated rat hearts, whereas in failing hearts these 
effects were significantly reduced. In contrast, inhibition of NOS1 enhanced the 
inotropic and lusitropic response to β-adrenergic stimulation in failing hearts but 
had no significant effect in sham-operated rats. 
In the present study we show that phosphorylated NOS1 as well as the ratio of 
phosphorylated NOS1 to total NOS1 are significantly increased in MCT-induced 
RV hypertrophy (RVH) and failure groups (RVF) compared with the control RVC 
(p<0.05 vs. RVC). 
Nitric oxide (NO) and reactive oxygen species produce peroxynitrite, known to 
activate matrix metalloproteinases (MMPs) [20, 35] that are involved in ventricular 
remodeling [27]. The stimulating effect of NO on expression of MMP2 and MMP9 
has been confirmed in neonatal rat ventricular cardiomyocytes, suggesting that 
NOS1 activation may be responsible for increased immunoreactivity of MMP-2 
and MMP-9. MMPs comprise a family of endopeptidases encompassing more 
than 25 members able to degrade numerous extracellular matrix components and 
several intracellular proteins. MMPs are involved in many pathological conditions, 
including inflammation and different stages of heart failure [6, 28]. In the present 
study we analysed whether pulmonary hypertension-induced RV failure in rats is 
associated with an activation of MMP-2 and MMP-9 in RV myocardium.  
The structural basis for the development of congestive heart failure (CHF) is a 
maladaptive myocardial remodeling process which occurs secondarily to post-
myocardial infarction (MI), hypertension-induced LV hypertrophy, or 
cardiomyopathy. Both cellular and extracellular factors are involved in the 
remodeling process and it is the combined action of these factors giving rise to 
changes in myocardial structure which eventually affects function. One 
component in this remodeling process is the MMPs. Many bioactive molecules 
such as cytokines/chemokines, bioactive peptides, and neurohormones which are 
operative in CHF likely contribute to the induction of MMPs. For example, a 
specific cassette of transcription factors is likely induced with extracellular stimuli 
in the context of CHF which in turn induces MMPs and contributes to the 
maladaptive remodeling process [12]. 
MMP-2 and MMP-9 have been shown to be increased in the plasma of patients 
with heart failure [1]. A study conducted by Banfi et al. [2] also demonstrated that 
plasma levels of both MMP-2 and MMP-9 were elevated in patients with idiopathic 
and ischemic dilated cardiomyopathy. In another recently conducted study, 
elevated plasma MMP-9 levels correlated with lower LVEF and higher LVESV 
[39]. These findings suggest that monitoring of plasma markers of myocardial 
remodeling may provide important prognostic information with respect to ongoing 
adverse LV remodeling in patients with heart failure. A study by Tyagi et al. [31] 
also showed an induction of MMP-2 and MMP-9 in ventricular tissues from human 
heart end-stage failure secondary to ischemic cardiomyopathy. Focusing on the 
RV myocardium, we found an activation of immunoreactive MMP-2 and MMP-9 in 
the remodeled RV myocardium of rats with pulmonary hypertension induced RV 
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failure, suggesting that these MMPs are implicated in RV remodeling. The lower 
value of MMP-2 immunoreactivity in RV myocardium of rats with RV failure 
compared to RV myocardium of rats with RV hypertrophy may be due to the 
release of MMP-2 from the tissue into the circulation, as was reported for MMP-2 
concentration in serum of patients with CHF [1,2].  
A recent study by Morita et al. [21] has shown that selective MMP inhibition 
attenuates progression of LV dysfunction and remodeling in dogs with CHF.  
In conclusion, tyrosine phosphorylation of FAK was most pronounced in 
hypertrophic RV myocardium whereas phosphorylation of NOS1 was most 
pronounced in failing RV myocardium, which may point to a role of excessive NO 
formation in development of failure and an activation of MMPs leading to 
ventricular remodeling. The exact role of the NO formed in the failing myocardium 
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Objective: Pulmonary arterial hypertension (PAH) is a life-threatening disease 
characterized by an increase in pulmonary artery pressure leading to right 
ventricular (RV) hypertrophy, RV failure and, ultimately, (sudden) cardiac death. 
Current treatments can improve symptoms and reduce the severity of the 
hemodynamic disorder in patients with PAH but frequently gradual deterioration in 
the patient’s condition necessitates a lung transplant. In this review we discuss 
the treatment options tested so far in experimental models of PAH. 
  
Data sources: PubMed. 
 
Study selection: These treatment options include a spectrum of pharmacologic 
agents ranging from elastase inhibitors, endothelin receptor antagonists, 
phosphodiesterase inhibitors and phytoestrogens to Rho-kinase inhibitors, 
serotonin receptor antagonists and statins. In addition, we discuss the emerging 
trends of using gene and cell therapy for the treatment of PAH. Finally, we 
discuss the possible applications of experimentally tested interventions for 
therapeutic purposes in humans with PAH. 
  
Conclusions: Several of these therapeutic options have been shown to be 
effective also in PAH patients leading to improved life expectations and a better 
quality of life. However, many patients remain symptomatic despite therapy. Cell 
therapy is a novel treatment option, but more animal data should be collected to 
investigate optimal cell type, in vitro cell transduction, route of cell administration, 
and number of cells to inject. Autologous MSC therapy is expected to be a safe 
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Pulmonary Arterial Hypertension 
 
Pulmonary arterial hypertension (PAH) is a progressive condition characterized 
by elevated pulmonary arterial pressures leading to RV failure. PAH is primarily a 
lung disorder which is associated with increased pulmonary vascular resistance, 
pulmonary vascular pathology, medial hypertrophy of arterioles, and inflammation 
of the lungs. Causes of PAH are many fold, including idiopathic PAH, familial 
PAH, chronic hypoxia-induced PAH, congenital heart disease associated PAH, 
infections and HIV-associated PAH, PAH due to inflammation and collagen 
vascular disease, and drugs- and toxins-induced PAH.  
Current therapeutic strategies may improve symptoms and reduce the severity of 
the hemodynamic abnormality, but deterioration of pulmonary and cardiac 
functions in many cases ultimately necessitates a lung transplant. Novel 
approaches in treating PAH include reversing the advanced occlusive structural 
changes in the pulmonary circulation causing PAH and regeneration of damaged 
pulmonary tissue using stem cells. These approaches have been tested using (i) 
pharmacotherapy, (ii) gene therapy, and (iii) cell therapy. 
 
Animal Models of Pulmonary Arterial Hypertension 
 
Various experimental models have been proposed for induction of PAH in 
animals. These models include: 
1. Monocrotaline-induced pulmonary hypertension with or without aortocaval 
shunt 
2. Pulmonary artery banding-induced pulmonary hypertension  
3. Chronic hypoxia-induced pulmonary hypertension 
4. Chronic embolism-induced pulmonary hypertension  
5. Ligation of ductus arteriosus 
6. Genetically modified animal models 
In the past 10 years most experimental studies on therapy of PAH have employed 
the monocrotaline-induced PAH model. 
 
Monocrotaline-induced Pulmonary Arterial Hypertension 
Mechanism and Pathology of Pulmonary Toxicity of 
Monocrotaline 
 
Monocrotaline (MCT), a pyrrolizidine alkaloid derived from Crotalaria spectabilis, 
causes a pulmonary vascular syndrome in rats characterized by proliferative 
pulmonary vasculitis, pulmonary artery hypertension (PAH), and cor pulmonale. 
Current lines of evidence of the pathogenesis of MCT-induced pneumotoxicity 
indicate that MCT is activated to one or more reactive metabolites in the liver, 
particularly a MCT pyrrole called dehydromonocrotaline [1-3], and is then 
transported by red blood cells to the lung [4], where it initiates endothelial injury 
[5, 6]. The endothelial injury does not appear to be acute cell death but rather a 
delayed functional alteration that leads to smooth muscle cell (SMC) proliferation 
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in the media of pulmonary arteriolar walls by unknown mechanisms. The role of 
inflammation in the progression of MCT-induced pulmonary vascular disease is 
uncertain. Both perivascular inflammation and platelet activation have been 
proposed as processes contributing to the response of the vascular media [3]. 
MCT and dehydroMCT are known to be toxic to a variety of domestic and 
laboratory animals and to humans. Major pathological effects induced by MCT 
poisoning include hepatic cirrhosis and megalocytosis, venocclusive disease, 
PAH, and RV hypertrophy. There is a positive correlation between progressive 
PAH, thickening of the medial wall of small pulmonary arteries and arterioles, and 
RV hypertrophy as a function of time [7]. 
 
 
Treatment Options for Experimental Pulmonary 
Arterial Hypertension 
 
1. Pharmacological interventions 
Several pharmacologic agents have been used either alone or in combination to 
treat MCT-induced pulmonary hypertension. These agents are discussed below. 
 
1.1 Serine elastase inhibitors 
Progression of PAH is associated with increased serine elastase activity and the 
proteinase-dependent deposition of the extracellular matrix protein tenascin-C. 
Tenascin-C amplifies the response SMCs to growth factors, which are also 
liberated through matrix proteolysis. Recent organ culture studies using 
hypertrophied rat pulmonary arteries have shown that elastase inhibitors 
suppress tenascin-C and induce apoptosis of SMCs [8, 9]. This initiates complete 
regression of the hypertrophied vessel wall by a coordinated loss of cellularity and 
extracellular matrix. Elastase inhibitors can reverse advanced pulmonary vascular 
disease produced in rats by injecting MCT. If the peptidyl trifluoromethylketone 
serine elastase inhibitors M249314 or ZD0892 were orally administered from 21 
days after injection of MCT onwards, survival after 1 week was 92%, compared 
with only 39% survival in untreated or vehicle-treated rats. Pulmonary artery 
pressure and muscularization were reduced by cardiomyocyte apoptosis and loss 
of extracellular matrix, specifically elastin and tenascin-C. After 2 weeks, 
pulmonary artery pressure and structure normalized, and survival was 86%, 
compared with 0% in untreated or vehicle-treated rats [10]. 
 
1.2 Platelet-derived growth factor inhibition 
Progression of PAH is associated with increased proliferation and migration of 
pulmonary vascular SMCs. Platelet-derived growth factor (PDGF) is a potent 
mitogen and is involved in this process. It was reported that the PDGF receptor 
antagonist STI571 (imatinib) reversed advanced pulmonary vascular disease in 
two animal models of PAH. If in rats with MCT-induced PAH daily administration 
of STI571 was started 28 days after induction of the disease, there was 100% 
survival in the first 2 weeks, compared with only 50% in sham-treated rats. PAH 
and RV hypertrophy were reversed to near-normal levels. Similar results were 
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obtained in chronically hypoxic mice, which were treated with STI571 after full 
establishment of PAH. Moreover, expression of the PDGF receptor was found to 
be significantly increased in lung tissue from patients with PAH compared with 
healthy donor lung tissue. In conclusion, STI571 reversed vascular remodeling 
and cor pulmonale in severe experimental PAH regardless of the initiating 
stimulus. This regimen offers a unique novel approach for anti-remodeling therapy 
in progressed PAH [11]. 
 
1.3 Prostacyclin therapy 
Male Wistar rats with flow-associated PAH due to an aortocaval shunt, in addition 
to MCT-induced PAH, were treated with low-dose aspirin (25 mg/kg/day) or 
iloprost (72 μg/kg/day), a prostacyclin analogue. Ninety % of the untreated rats 
with PAH developed dyspnea and pleural fluid, whereas this was seen in 50% 
and 10% of the aspirin and iloprost-treated rats, respectively. This could not be 
attributed to changes in pulmonary artery pressure, wall to lumen ratio of the 
pulmonary arterioles, or RV hypertrophy. However, both therapies restored the 
reduced RV capillary to cardiomyocyte ratio in rats with PAH (0.95±0.10 in MCT-
treated rats vs. 1.38±0.18 in healthy rats, 1.32±0.11 in aspirin-treated MCT rats 
and 1.29±0.90 in iloprost-treated MCT rats) which was associated with improved 
RV contractility. Thus, interventions in the prostacyclin–thromboxane metabolism 
improve outcome in rats with flow-associated PAH. However, these effects may 
be attributed to effects on cardiac rather than on pulmonary vascular remodeling 
[12]. 
Subcutaneous administration of a novel prostacyclin agonist (ONO-1301) 
markedly attenuated MCT-induced PAH and improved survival in rats. The 
beneficial effects of ONO-1301 occurred through its long-lasting stimulation of 
cAMP and inhibition of thromboxane synthase [13]. 
Although prostacyclin is recognized as a therapeutic breakthrough for pulmonary 
hypertension, it needs continuous infusion because of its short half-life in plasma. 
Therefore, Obata et al. developed a new drug delivery system for prostacyclin by 
preparing ONO-1301MS, a novel sustained-release prostacyclin analogue 
polymerized with poly(D,L-lactic-co-glycolic acid) (PLGA) microspheres. A single 
injection of ONO-1301MS resulted in sustained activity for 3 weeks, and 
attenuated PAH, partly through its antiproliferative effect on vascular SMCs via 
inhibition of ERK phosphorylation [14]. The inhalation of iloprost has been shown 
to reverse PAH and vascular structural remodeling in MCT-treated rats. This 
regimen demonstrated the feasibility of a reverse remodeling therapy in PAH [15]. 
 
1.4 Combined prostacyclin and phosphodiestersae inhibition 
Combination therapy with oral sildenafil, a phosphodiesterase inhibitor, and 
beraprost, an oral prostacyclin analogue, attenuated the development of MCT-
induced PAH compared with treatment with either drug alone [16]. The combined 
administration of iloprost, a long-acting prostacyclin analogue, and a dual-
selective phosphodiesterase 3/4 inhibitor, tolafentrine, reversed the development 
of PAH and cor pulmonale in response to MCT in rats [17]. 
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1.5 Rho-kinase inhibition 
Long-term treatment with a Rho-kinase inhibitor fasudil improved the mortality 
rate of MCT-induced PAH in rats [18], as well as ameliorated hypoxia-induced 
PAH in mice, partially by activation of endothelial nitric oxide synthase (eNOS) 
[19]. Fasudil exerts effective and selective vasodilatation of pulmonary arteries in 
rats with MCT-induced PAH, which explains its usefulness for the treatment of 
this fatal disorder [20]. Nagaoka et al. found in chronically hypoxic rats that 
inhalation of Rho-kinase inhibitors nearly normalized PAH, but had no pulmonary 
vascular selectivity [21]. 
 
1.6 Combined Rho-kinase inhibitor and prostacyclin therapy  
Combination therapy has been advocated based on the potential for additive or 
synergistic effects. Long-term inhibition of Rho-kinase, an effector of the small 
GTPase Rho, ameliorated MCT-induced PAH in rats and hypoxia-induced PAH in 
mice. It was reported that prostacyclin and its oral analogue beraprost may lack 
direct inhibitory effect on Rho-kinase in vitro, suggesting that combination therapy 
with a Rho-kinase inhibitor and beraprost is effective for the treatment of PAH. 
Male Sprague-Dawley rats were given a subcutaneous injection of MCT (60 
mg/kg), and subsequently treated without or with a Rho-kinase inhibitor (fasudil, 
30 mg/kg/day), beraprost (200 mg/kg/day), or a combination of both drugs for 3 
weeks. The combination therapy, when compared with each monotherapy, 
showed significantly more improvement in PAH, RV hypertrophy, and pulmonary 
medial thickness without any adverse effects. Plasma concentrations of fasudil 
were not affected by beraprost. These results demonstrated that combination 
therapy with a Rho-kinase inhibitor and a prostacyclin analogue exerts further 
beneficial effects on PAH [22]. 
 
1.7 Endothelin receptor antagonists 
Endothelin-1 (ET-1), a potent vasoactive and mitogenic peptide, has been 
implicated in the pathogenesis of several forms of PAH. Hill et al. have shown that 
a nonspecific endothelin-receptor antagonist, bosentan, blunts MCT-induced PAH 
in rats [23].  
The antagonism of the ETA receptor was shown to be essential for the protection 
from MCT-induced PAH, irrespective of the presence of the ETB receptors, 
although a protective role of ETB receptor-mediated action in the pathogenesis of 
this disease model could not be ruled out [24]. 
Furthermore, in another study from the same group, the functional roles of 
endothelin ETA and ETB receptors in the development of MCT-induced PAH were 
investigated using MCT-treated rats in the absence or presence of a daily 
administration of A-192621, a selective ETB receptor antagonist, ABT-627, a 
selective ETA receptor antagonist, or a combination of both drugs. The results 
demonstrated that ETA receptor-mediated action contributed exclusively to the 
pathogenesis of MCT-induced PAH [25]. 
 
1.8 Combined endothelin-A receptor antagonist and prostacyclin 
therapy 
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Rats with MCT-induced PAH were treated with oral ETA receptor antagonist TA-
0201 and/or the oral prostacyclin analogue beraprost for 19 days. The PAH-
associated RV systolic pressure elevation was significantly depressed by TA-
0201 and beraprost, and most strongly by TA-0201+beraprost. The indexes of RV 
hypertrophy showed the same tendency as the increase in RV systolic pressure 
in the groups MCT, MCT+TA-0201, MCT+beraprost and MCT+TA-
0201+beraprost. The expression of the “fetal” gene β-myosin heavy chain was 
markedly upregulated in the “MCT only” group, and less upregulated in the 
MCT+TA-0201 and MCT+beraprost groups, and least upregulated in the 
MCT+TA-0201+beraprost groups. The same was true for medial wall thickness of 
the pulmonary artery, being most pronounced in “MCT only” group and least 
increased in the MCT+TA-0201+beraprost group. The combination of an oral ETA 
receptor antagonist and an oral prostacyclin analogue appeared to be superior to 
the use of each drug alone in inhibiting the progression of PAH and its 
consequences to RV myocardium [26]. 
 
1.9 Serotonin transporter inhibition 
Progression of PAH is associated with increased pulmonary expression of the 
serotonin transporter (5-HTT), which leads to hyperplasia of the pulmonary artery 
smooth muscle cells (PA-SMCs). Given the fact that overexpression of the 5-HTT 
gene in PA-SMCs leads to PAH [27], it was investigated whether the highly 
selective 5-HTT inhibitor fluoxetine prevented and/or reversed PAH in MCT-
treated rats. Selective antagonists to the 5-HT1B/1D receptor, 5-HT2A receptor and 
5-HT2B receptor were used for comparative testing. MCT injection (60 mg/kg s.c.) 
was followed by an early peak in lung 5-HTT expression on day 1, which 
preceded the onset of PAH. Established PAH on day 15 was associated with a 
sustained 5-HTT increase. Continued fluoxetine treatment completely prevented 
PA-SMC proliferation and PAH development, and also suppressed the late 5-HTT 
increase, without affecting the early peak. The 5-HT receptor antagonists did not 
affect PAH. Oral fluoxetine (10 mg/kg/day) started 3 weeks after MCT injection 
completely reversed established PAH, normalizing pulmonary artery pressure and 
structure. MCT-induced PAH was also associated with increased expression of 
various cytokines, but only interleukin-1β and monocyte chemotactic protein-1 
increased at the early phase and stimulated 5-HTT expression by cultured PA-
SMCs. Complete reversal of established PAH by inhibiting 5-HTT provides a 
rationale for new therapeutic strategies in human PAH [28]. 
Furthermore, a selective serotonin re-uptake inhibitor (SSRI), sertraline, protects 
against MCT-induced PAH by decreasing pulmonary artery pressure, RV index, 
and pulmonary artery remodeling, probably related to a reduction in serotonin 
transporter mRNA [29]. 
A serotonin receptor antagonist, MCI-9042, attenuated the development of MCT-
induced PAH, suggesting a pivotal role of serotonin in the development of PAH 
induced by MCT [30]. 
Specific 5-HT2A receptor blockade with sarpogrelate, a 5-HT2A receptor 
antagonist, immediately after MCT administration, inhibited PAH and prolonged 
survival in rats. These effects were accompanied by anti-inflammatory and anti-
                                                                                                          Chapter 5 
 106
proliferative effects in the lung tissue and marked improvement of pulmonary 
vascular endothelial dysfunction and activation [31]. 
 
1.10 Phosphodiesterase inhibition 
Phosphodiesterase (PDE) inhibitors for treatment of PAH have been studied 
extensively. Oral sildenafil prevented (in a study in which sildenafil was given 1 
day after MCT) and reversed (in a study in which sildenafil was given 3 weeks 
after MCT) the development of PAH in MCT-treated rats, associated with a 
reduction in the ETA-receptor density in SMCs of pulmonary small arteries 
(diameter < 100 μm) [32]. The effects of oral pumafentrine, a mixed-selective 
PDE3/4 inhibitor, have been investigated in rats with MCT-induced PAH. When 
chronically administered in weeks 4 to 6 after a single injection of MCT (60 
mg/kg), pumafentrine (10 mg/kg daily) partially reversed PAH and RV hypertrophy 
in rats [33]. In addition, small pulmonary arterial muscularization, medial 
hypertrophy and decrease in lumen area were largely reversed. Inhibition of PA-
SMC proliferation by pumafentrine was demonstrated in vivo. Pumafentrine also 
had a pro-apoptotic effect on vascular cells in vitro. Moreover, pumafentrine dose-
dependently increased cAMP levels and inhibited proliferation of cultured PA-
SMCs. Thus, oral pumafentrine partially reverses MCT-induced PAH, pulmonary 
vascular remodeling, and RV hypertrophy in rats [33].  
Schermuly et al. investigated chronic effects of sildenafil, a PDE5 inhibitor, in 
MCT-induced PAH in rats. Four weeks after a single subcutaneous injection of 
MCT, the animals displayed nearly threefold elevated pulmonary artery pressure 
and vascular resistance values, with a concomitant decline in central venous 
oxygen saturation and arterial oxygenation. Marked RV hypertrophy was evident, 
and massive thickening of the arteriolar SMC layer was histologically apparent. 
Sildenafil, administered from day 14 to day 28, significantly increased plasma 
cGMP and inhibited the development of PAH and RV hypertrophy, with 
improvement of central venous oxygen saturation and arterial oxygenation. A 
corresponding efficacy profile was also noted for treatment with sildenafil started 
at day 28 till day 42. Moreover, the death rate significantly decreased in those 
animals treated with sildenafil [34]. 
Pullamsetti et al. demonstrated for the first time that inhalation of combined 
PDE3/4 inhibitor tolafentrine reversed PAH that occurred in response to MCT in 
rats. This "reverse remodeling" effect included structural changes in the lung 
vascular wall and key molecular pathways of matrix regulation, concomitant with 
60% normalization of hemodynamics [35]. 
 
1.11 Combination of phosphodiesterase and endothelin receptor 
inhibition 
Clozel et al. evaluated the effects of bosentan, a nonspecific endothelin receptor 
antagonist, sildenafil, and their combination in rats with MCT-induced PAH [36]. A 
first group consisted of control rats without MCT injection. Four other groups of 
rats received MCT subcutaneously and were assigned to receive no treatment, 
300 mg/kg/day bosentan in the food, 100 mg/kg/day sildenafil in drinking water, or 
their combination for 4 weeks. The doses of bosentan and sildenafil were the 
maximally effective doses based on a dose-range–finding study. Mortality was 
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0%, 53%, 11%, 11%, and 0%, respectively, in the five different groups. Bosentan 
and sildenafil significantly attenuated the increase in mean pulmonary arterial 
pressure, and the combination had an additional effect [36]. 
 
1.12 Caveolin-1 peptide 
Caveolins, the principal structural proteins of caveolar microdomains, have been 
implicated in the development of PAH. Mice with homozygous deletion of the 
caveolin-1 (Cav-1) gene develop PAH and RV hypertrophy. In several animal 
models of PAH and in patients with severe PAH, reductions in pulmonary Cav-1 
expression were apparent.  
Whether in vivo modulation of Cav-1 expression could affect the development of 
PAH and RV hypertrophy was studied by Jasmin et al. [37].Thirty minutes after 
injection of saline or MCT, rats were assigned to receive a daily injection of saline, 
a peptide corresponding to the homeodomain of the Drosophila transcription 
factor antennapedia (AP; 2.5 mg/kg/day), or a peptide consisting of the Cav-1–
scaffolding domain coupled to AP (AP-Cav; 2.5 mg/kg/day) for 2 weeks. MCT and 
MCT+AP rats developed PAH with RV systolic pressures of 40.2±1.5 and 
39.6±1.5 mmHg, respectively. Administration of AP-Cav to MCT rats significantly 
reduced the RV systolic pressure to 30.1±1.3 mm Hg. MCT and MCT+AP rats 
also developed pulmonary artery medial hypertrophy and RV hypertrophy, which 
was normalized by administration of AP-Cav. Mechanistically, the development of 
PAH was associated with reduced expression of pulmonary Cav-1 and Cav-2, 
hyperactivation of the STAT3 signaling cascade, and upregulation of cyclin D1 
and D3 protein levels, all of which were prevented by administration of AP-Cav. 
Thus, short-term administration of a Cav-based cell-permeable peptide to MCT 
rats prevented the development of pulmonary artery medial hypertrophy, PAH, 
and RV hypertrophy [37]. 
 
1.13 Estradiol 
Daily supplementation of genistein, a phytoestrogen, potently attenuated MCT-
induced PAH, RV hypertrophy, and pulmonary vascular remodeling in rats [38]. 
Also 2-methoxyestradiol (2ME), a non-estrogenic estradiol metabolite, prevented 
the development and retarded the progression of MCT-induced PAH [39]. 2ME 
significantly attenuated RV hypertrophy and pulmonary arterial medial 
hypertrophy, and reduced proliferative and inflammatory responses in the lungs. 
Furthermore, in diseased animals, 2ME (given from day 14 to 28) significantly 
decreased RV peak systolic pressure and RV hypertrophy, and reduced mortality. 
Thus, 2ME, a major non-estrogenic, non-carcinogenic metabolite of estradiol, 
prevented the development and retarded the progression of MCT-induced PAH 
[39, 40]. 
Recently, Tofovic et al. provided the first evidence that 2-ethoxyestradiol strongly 
inhibited vascular remodeling in PAH and suggested that anti-proliferative agents, 
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Various statins have been shown to be effective in treating experimental PAH. 
Simvastatin attenuated MCT-induced pulmonary vascular remodeling, PAH, and 
RV hypertrophy in rats [42]. Pravastatin reduced the development of MCT-
induced PAH and improved endothelium-dependent pulmonary artery relaxation 
through reduced apoptosis and a restored eNOS expression of endothelial cells 
[43]. Rosuvastatin provided protection against the development of PAH and RV 
hypertrophy [44]. These studies demonstrate that the targeted preservation of 
coronary endothelial function and vasoactivity provides a novel approach to 
protect against cardiac remodeling.  
 
1.15 Miscellaneous therapeutic agents 
1.15.1 Amlodipine, a third-generation calcium channel blocker, inhibited the 
development of PAH and improved survival in rats independent of its effect on 
lowering blood pressure. These effects were associated with marked inhibition of 
the downregulation of eNOS and improvement of pulmonary vascular endothelial 
activation, as well as anti-inflammatory, antiproliferative and antifibrotic effects in 
the lung tissue. However, amlodipine failed to reverse established PAH [45]. 
 
1.15.2 Nicorandil, an ATP-sensitive potassium (KATP) channel opener with a 
nitrate-like action, inhibited development of MCT-induced PAH but failed to 
reverse it. These effects were associated with marked up-regulation of diminished 
lung eNOS concentration along with improvement of pulmonary vascular 
endothelial activation and anti-inflammatory and anti-proliferative effects in the 
lung tissue [46]. 
 
1.15.3 Infusion of C-type natriuretic peptide (CNP), the third member of the 
natriuretic peptide family, attenuated MCT-induced PAH and improved survival. 
The beneficial effects were mediated by regeneration of pulmonary endothelium, 
inhibition of endothelial cell apoptosis, prevention of monocyte/macrophage 
infiltration, and restoration of fibrinolytic activity [47]. 
 
1.15.4 Repeated inhalation of adrenomedullin, a potent vasodilator peptide that 
was originally isolated from human pheochromocytoma, has been shown to inhibit 
MCT-induced PAH without systemic hypotension, and thereby improving survival 
in MCT rats [48]. 
 
1.15.5  Zhou et al. have shown that heme oxygenase-1 was critical for the 
antiproliferative and vascular protective effects of rapamycin, an 
immunosuppressive agent with antiproliferative activity not only against 
lymphocytes but also against vascular cells, in vitro and in vivo in MCT-induced 
PAH [49]. 
 
1.15.6 Granulocyte colony-stimulating factor (G-CSF) inhibited the 
progression of PAH in a rat model, possibly by stimulating pulmonary endothelial 
cells to proliferate at sites of impaired lung vasculature [50]. 
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1.15.7 The NF-κB nuclear localization and vascular cell adhesion molecule 
(VCAM-1) expression are temporally and spatially associated with the 
development of MCT-induced PAH in rats. Administration of a NF-κB inhibitor, 
pyrrolidine dithiocarbamate (PDTC), reversed the MCT-induced development of 
PAH in rats [51]. 
 
1.15.8 In rats with MCT-induced PAH treatment with an interleukin-1 receptor 
antagonist started at the same time as MCT administration and continued for the 
first 2 weeks prevented the development of PAH and RV hypertrophy as 
assessed 3 weeks after MCT injection [52]. 
  
1.15.9 In rats with MCT-induced PAH treatment with antibodies to monocyte 
chemotactic and activating factor/monocyte chemoattractant protein-1 
started at the same time as MCT administration, or at day 3.5, 7 or 14 after MCT 
administration. Antibody therapy started together with MCT administration was 
the most effective in alleviating RV hypertrophy, as compared to later starts [53]. 
Antibody therapy started together with MCT administration did not prevent 
development of pulmonary hypertension, but right ventricular peak systolic 
pressure was significantly lower than observed in rats treated with MCT only (50 
mmHg and 70 mmHg, respectively). 
  
1.15.10 Rats were, 1 day after MCT administration (60 mg/kg), treated without or 
with a specific inhibitor of p38 mitogen-activated protein kinase, FR167653, 
for 27 days. Four weeks after MCT administration pulmonary artery pressure and 
RV weight had hardly increased, compared to rats that received only MCT. The 
beneficial effects of FR167653 were ascribed to attenuated expression of 
inflammatory cytokines, thereby preventing the progression of pulmonary 
hypertension [54]. 
        
1.15.11 PAH is associated with endothelial injury [55] and with NO-dependent 
endothelial dysfunction [56].  Rats treated with daily i.p. doses of L-arginine (500 
mg/kg), started 3 days before MCT administration, and continuing till sacrifice of 
the animals at day 17 after MCT injection, prevented the development of PAH, 
RVH, and pulmonary vascular disease [57]. 
     
1.15.12 Rats were, 2 day before MCT administration (60 mg/kg), treated without 
or with an inhibitor of lipoxygenase pathways, diethylcarbamazine, for 23 days. 
Three weeks after MCT administration, therapy with diethylcarbamazine 
appeared to have blocked the development of pulmonary hypertension and RVH, 
associated with inhibition of influx of polymorphonuclear cells and alveolar 
macrophages into the alveoli and the activation of these cells by lipoxygenase-
related products [58].                           
 
  
2. Gene therapy 
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2.1 There is ample evidence that oxidative stress contributes to the pathogenesis 
and/or development of PAH. Intratracheal gene transfer of human extracellular 
superoxide dismutase (EC-SOD) was studied in rats with MCT–induced PAH 
[59]. MCT-injected rats were intratracheally administered either vehicle (MCT 
group) or an adenovirus encoding β-galactosidase (Adβgal group), or human EC-
SOD (AdEC-SOD group). After intratracheal gene transfer, EC-SOD was 
successfully expressed in lung tissue, bronchoalveolar lavage fluid, and plasma. 
Twenty-eight days after MCT injection, RV systolic pressure and the weight ratio 
of the RV to the LV plus septum were significantly lower in the AdEC-SOD group 
(42.5 ± 1.4 mmHg and 0.45 ± 0.02, respectively) than in the MCT group (59.8 ± 
1.6 mmHg and 0.63 ± 0.02, respectively) and the Adβgal group (61.5 ± 2.1mmHg 
and 0.65 ± 0.03, respectively). Moreover, vascular remodeling and proliferation of 
vascular smooth muscle cells in pulmonary arteries were markedly suppressed in 
the AdEC-SOD group [59]. Thus EC-SOD acts as an antioxidant in PAH, and 
apparently increased oxidative stress plays an important role in the pathogenesis 
of MCT-induced PAH. 
 
2.2 Ikeda et al. have suggested that monocyte/macrophage chemoattractant 
protein-1 (MCP-1), a potent chemoattractant chemokine and an activator for 
mononuclear cells, may play a role in the initiation and/or progression of PAH 
[60]. They found that anti-MCP-1 gene therapy attenuated PAH in rats. Hence an 
anti-inflammatory strategy via blockade of the MCP-1 signal pathway may be an 
alternative approach to treat subjects with PAH. 
 
2.3 Prostacyclin is a potent vasodilator that also inhibits platelet adhesion and cell 
growth. Intratracheal transfer of the human prostacyclin synthase (PGIS) gene 
to rats with MCT-induced PAH augmented pulmonary prostacyclin synthesis, 
ameliorated MCT-induced PAH, and improved survival in MCT rats [61]. An 
intramuscular injection of adeno-associated virus (AAV) vector harboring the 
PGIS gene (AAV-PGIS) also prevented MCT-induced PAH in rats. This approach 
provides an attractive therapeutic alternative for preventing PAH in humans [62]. 
 
2.4 Cell-based gene transfer with angiopoietin-1 (Ang-1), a newly discovered 
ligand of the endothelial-specific tyrosine kinase receptor Tie-2, has been shown 
to improve survival and pulmonary hemodynamics in experimental PAH by a 
mechanism involving the inhibition of apoptosis and protection of the pulmonary 
microvasculature [63]. 
 
2.5 In another study, Zhao et al. demonstrated that cell-based endothelial NO 
synthase (eNOS) gene transfer was more effective than vascular endothelial 
growth factor A (VEGF) in reversing established PAH, associated with evidence 
of regeneration of pulmonary microcirculation [64]. 
 
2.6 Interleukin (IL)-10 is a pleiotropic anti-inflammatory cytokine with 
vasculoprotective properties. After rats were injected intramuscularly with an AAV 
serotype 1 vector expressing IL-10, followed by MCT injection, it was 
demonstrated that IL-10 expression prevented MCT-induced PAH in rats [65]. 
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3. Cell therapy 
 
3.1 Intratracheal mesenchymal stem cell therapy 
Baber et al. studied the effect of intratracheal administration of rat bone marrow 
derived mesenchymal stem cells (rMSCs) on MCT-induced PAH and impaired 
endothelium-dependent responses in the rat [66]. rMSCs had been transfected 
with the lacZ gene before intratracheal administration. The intratracheal 
administration of 3 x 106 rMSCs 2 weeks after administration of MCT attenuated 
the rise in pulmonary arterial pressure and pulmonary vascular resistance, and 
restored pulmonary responses to acetylcholine toward values measured in control 
rats. Treatment with rMSCs decreased RV hypertrophy induced by PAH. 
Immunohistochemical studies showed widespread distribution of lacZ-labeled 
rMSCs in lung parenchym surrounding airways in MCT-treated rats. These 
rMSCs retained expression of von Willebrand factor and α-smooth muscle-actin, 
being markers specific for endothelial cell and SMC phenotypes, respectively. 
However, lacZ expressing rMSCs were not detected in the wall of pulmonary 
vessels. These data suggest that the decrease in pulmonary vascular resistance 
and improved responses to acetylcholine in PAH rats treated with MSCs were the 
result of paracrine effects of transplanted rMSCs in lung parenchym on vascular 
endothelial function in the injured lungs [66]. 
 
3.2 Intravenous administration of pulmonary artery smooth muscle cells 
Primary cultures of PA-SMCs from Fisher 344 rats were labeled with a 
fluorescent, membrane-impermeable dye chloromethyl-trimethyl-rhodamine or 
transfected with the β-galactosidase (βGal) reporter gene under the control of the 
cytomegalovirus (CMV) promoter (pCMV-β) [67]. Transfected or labeled SMCs (5 
x 105 cells/animal) were delivered to syngeneic recipient rats by injection into the 
jugular vein. The animals were killed at intervals between 15 min and 2 weeks, 
and the lungs, spleen, kidneys, and skeletal muscle were excised and examined. 
At 15 min after transplantation, injected cells were detected mainly in the lumen of 
small pulmonary arteries and arterioles, often in groups of three or more cells. 
After 24 h, labeled SMCs were found incorporated into the vascular wall of 
pulmonary arterioles, and transgene expression persisted in situ for 14 d with no 
evidence of any immune response. Approximately 57±5% of the labeled cells 
injected into the venous circulation were recovered in the lungs after 15 min, 
34±7% at 48 h, 16±3% at 1 week, and 15±5% at 2 weeks. Similar results were 
observed using cells transfected with the LacZ gene. To determine whether this 
method of gene transfer is effective in inhibiting the development of pulmonary 
vascular disease, PA-SMCs were transfected in vitro with either the full-length 
coding sequence of the eNOS gene or with the control vector (pcDNA3.1) and 
injected simultaneously with MCT. At 28 d after injection the RV systolic pressure 
was 50±4 mmHg in animals injected with the null-transfected SMCs, and 33±3 
mmHg in animals injected with the eNOS-transfected SMCs (p<0.01). These 
results indicate that a cell-based strategy of ex vivo transfection provides an 
effective nonviral approach for the selective delivery of foreign transgenes to 
pulmonary microvessels in the treatment of pulmonary vascular disease [67]. 
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Campbell et al. prepared primary cultures of PA-SMCs and transfected these 
cells with vascular endothelial growth factor (VEGF)-A [68]. These cells were 
administered i.v. into Fisher 344 rats with MCT-induced PAH. Four weeks after 
MCT and i.v. SMC administration, PAH, RV hypertrophy and medial hypertrophy 
of pulmonary arterioles were significantly less in the VEGF-treated animals 
compared to MCT-treated animals that did not receive cell therapy. Four weeks 
after gene transfer, the VEGF mRNA was still detectable in the pulmonary tissue 
of animals injected with VEGF-transfected cells, demonstrating survival of 
transfected cells and persistent transgene expression. If cell-based gene transfer 
using VEGF-expressing PA-SMCs was delayed till PAH had developed, also a 
significant decrease in the progression of PAH and RV hypertrophy was 
documented [68]. These results indicate that cell-based VEGF gene transfer is 
effective in preventing the development and progression of PAH in the MCT 
model. Thus, a therapeutic role for angiogenic factors in the therapy of PAH is 
very likely. 
    
3.3 Intravenous administration of endothelial progenitor cells 
PAH is characterized by a progressive increase in pulmonary vascular resistance 
caused by narrowing and loss of pulmonary microvasculature, which in its late 
stages becomes refractory to traditional therapies. Zhao et al. isolated bone 
marrow–derived endothelial progenitor cells (EPCs) from Fisher-344 rats, cultured 
them for 7 to 10 days in endothelial growth medium and injected them 
intravenously in syngeneic MCT-treated rats [69]. The EPCs engrafted at the level 
of the distal pulmonary arterioles and incorporated into the endothelial lining of 
the MCT-injured lung. The administration of EPCs 3 days after MCT 
administration nearly completely prevented the increase in RV systolic pressure 
observed at 3 weeks with MCT alone (31±1 versus 48±3 mmHg, respectively; 
p<0.001), whereas i.v. administration of skin fibroblasts had no protective effect 
(51±5 mmHg). Delayed administration of EPCs 3 weeks after MCT prevented the 
further progression of PAH 2 weeks later, whereas animals receiving EPCs 
transfected with the human eNOS gene exhibited significant regression of 
established disease at day 35 (31±2 mmHg, p<0.005) compared with day 21 
(50±3 mmHg). Fluorescent microangiography revealed widespread occlusion of 
pulmonary arterioles 3 weeks after MCT, whereas arteriolar-capillary continuity 
and microvascular architecture were preserved if syngeneic EPCs had been 
administered. Moreover, the delivery of EPCs to rats with established PAH 
resulted in marked improvement in survival, which was greatest in the group 
receiving eNOS-transduced EPCs [69]. Thus bone marrow–derived EPCs can 
engraft and repair the MCT-damaged lung, restoring structure and function of 
pulmonary microvasculature. Therefore, the regeneration of lung vascular 
endothelium by injection of EPCs, and in particular eNOS-transduced EPCs, may 
represent a novel treatment for patients with PAH. 
 
3.4 Intravenous administration of bone marrow-derived cells 
Recent evidence suggests that bone marrow–derived cells may differentiate into 
vascular cells that participate in arterial repair and/or lesion formation [70]. 
However, it remains uncertain whether bone marrow-derived cells can also 
participate in vascular remodeling associated with PAH. The bone marrow of 
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Sprague-Dawley rats was reconstituted with that of green fluorescent protein 
(GFP)–transgenic rats. The bone marrow-chimeric rats were injected 
intraperitoneally with 60 mg/kg MCT after unilateral pneumonectomy, and 
concurrently underwent wire-mediated endovascular injury in one femoral artery. 
After 28 days, they had elevated RV systolic pressure (58.8±5.4 versus 20.4±2.4 
mmHg in sham-control; p<0.01) [71]. The pulmonary arterioles were markedly 
thickened, with an infiltration of GFP–positive macrophages into the perivascular 
areas. The endothelium of pulmonary arterioles contained only a few GFP–
positive cells, and GFP–positive cells were seldomly detected in the media of 
thickened pulmonary arterioles. In contrast, bone marrow-derived smooth 
muscle–like cells could be readily detected in the thickened neointima and media 
of the wire-injured femoral artery. Moreover, intravenous injection of 108 
unfractionated bone marrow-derived cells from young rats had no beneficial 
effects on PAH, pulmonary arterial remodeling, and survival in the aged rats 
treated with MCT plus unilateral pneumonectomy. No injected bone marrow-
derived cell was identified as an endothelial cell or a vascular SMC [71]. These 
results suggest that bone marrow-derived cells can participate in arterial 
neointimal formation after mechanical injury, whereas they do not contribute 
substantially to pulmonary arterial remodeling associated with MCT-induced PAH 
in pneumonectomized rats. 
Raoul et al. investigated the effect of bone marrow-derived cells on PAH induced 
by either MCT or exposure to chronic hypoxia in mice [72]. Intravenous 
administration of the active MCT metabolite (monocrotaline pyrrole, MCTp) to 
C57BL/6 mice induced PAH within 15 days, due to remodeling of small pulmonary 
arterioles. Three days after MCTp injection, the mice were injected with bone 
marrow-derived cells harvested from femurs and tibias of donor mice treated with 
5-fluorouracil (3.5 mg i.p./animal) to deplete mature cells and to allow proliferation 
of progenitor cells. Bone marrow-derived cells significantly attenuated PAH as 
assessed by reductions in RV systolic pressure (20 ± 1 mmHg vs. 27 ± 1 mmHg, 
p≤0.01), weight ratio of RV to the LV plus septum (0.29 ± 0.02 vs. 0.36 ± 0.01, 
p≤0.03), and percentage of muscularized pulmonary arterioles (26.4% vs. 33.5%, 
p≤0.05), compared to irradiated bone marrow-derived cells administered to 
MCTp-treated animals. Tracking cells from constitutive GFP-expressing male 
donor mice with anti-GFP antibodies or chromosome Y quantification by real-time 
PCR demonstrated the presence of bone marrow-derived cells in the lung. In 
contrast, chronically hypoxic mice subjected to the same procedure failed to show 
improvement in PAH [72]. These results demonstrate bone marrow-derived cells 
limit pulmonary vascular remodeling induced by vascular injury but not pulmonary 
vascular remodeling induced by hypoxia. 
       
3.5 Intravenous administration of mesenchymal stem cells overexpressing 
endothelial nitric oxide synthase (eNOS) 
Bone marrow-derived cell transplantation is reported to reduce the development 
of PAH by increasing or repairing vascular beds in the pulmonary circulation, and 
upregulated eNOS expression enforces this therapeutic effect. Kanki-Horimoto et 
al. have studied the efficacy of intravenous administration of eNOS-transfected, 
bone marrow-derived MSCs (MSCs/eNOS) in rats with MCT-induced PAH [73]. 
One week after MCT administration, the rats received 3 different treatments: 
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MSCs (MSC group), MSCs/eNOS, (MSC/eNOS group), or no treatment (PAH 
group). As the negative control, rats received saline instead of MCT (control 
group). RV systolic pressures in the MSC and MSC/eNOS groups were 
significantly lower than in the PAH group, and RV systolic pressure in the 
MSC/eNOS group was significantly lower than in the MSC group. Similar results 
were obtained with regard to RV hypertrophy in the 3 groups. The survival time of 
rats receiving MSCs/eNOS was significantly longer than survival time of PAH rats 
without treatment [73]. Hence, intravenous administration of MSCs/eNOS offers 
therapeutic effects on MCT-induced PAH, RV hypertrophy, and mortality. 
 
3.6 Transplantation of endothelial progenitor cells into the lung 
EPCs have been shown to promote neovascularization. Takahashi et al. have 
examined the effects of EPC transplantation into the lungs of dogs with 
dehydromonocrotaline-induced PAH [74]. The lung parenchym of dogs with PAH 
was injected with ex vivo-expanded, autologous EPCs using a bronchoscope. 
EPC transplantation resulted in significant improvements in mean pulmonary 
artery pressure, pulmonary vascular resistance and cardiac output. Histological 
evaluation revealed improvement in the medial thickness of the small pulmonary 
arteries and neovascularization of lung tissue [74]. These results indicate that 
EPC transplantation into the lung is effective at preventing the progression of 
dehydromonocrotaline-induced PAH in dogs, and may provide a new therapeutic 
option for patients with PAH. 
 
3.7 Intravenous administration of MSCs from rats suffering with PAH 
Recently, we completed a study in which rats with MCT-induced PAH were, 14 
days after MCT injection, treated with a single i.v. MSC injection (106 cells/rat) 
obtained from from bone marrow of rats with MCT-induced PAH, or a single 
injection with PBS. Another 2 weeks later RV pressures were measured, the rats 
were sacrificed and heart and lungs were dissected. The PBS-treated MCT rats 
developed PAH as expected. In the MSC-treated MCT rats the RV pressures 
were significantly lower compared to the PBS-treated MCT rats. Accordingly, RV 
hypertrophy in the MSC-treated MCT rats was significantly lower compared to the 
PBS-treated MCT rats. In this study we have demonstrated that bone marrow-
derived MSCs obtained from donor rats suffering from PAH when administered to 




Cell Therapy for PAH: from Experimental Models to 
Clinical Disease 
Cell therapy is a promising novel therapeutic option, and several cell types have 
been tested in experimental models of PAH. Endothelial progenitor cells have 
recently been explored as a potential source for neovascularization of the 
diseased pulmonary circulation in patients with PAH. A randomized trial by Wang 
et al. has indicated that intravenous infusion of autologous EPCs to patients with 
idiopathic PAH appears to be feasible and safe, and has beneficial effects on 
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exercise capacity and pulmonary hemodynamics in patients with idiopathic PAH 
[75]. 
Also MSC is a cell type that can improve the pulmonary pathology of PAH by 
either differentiating into other cell types leading to regeneration of the diseased 
vasculature or secreting an array of substances, the “pro-survival factors” 
including various growth factors and cytokines, leading to improvement in lung 
pathology by paracrine mechanisms. Autologous bone marrow-derived MSC 
therapy has a practical advantage over other types of cell therapies, as the mode 




In conclusion, a wealth of therapeutic modalities including pharmacotherapy, 
gene therapy and cell therapy has been tested in several animal models of PAH 
including MCT-induced PAH. Several of these therapeutic options have been 
shown to be effective also in PAH patients leading to improved life expectations 
and a better quality of life. However, many patients remain symptomatic despite 
therapy. Cell therapy is a novel treatment option, but more animal data should be 
collected to investigate optimal cell type, in vitro cell transduction, route of cell 
administration, and number of cells to inject. Autologous MSC therapy is expected 
to be a safe and efficacious option to treat patients with PAH. 
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Table. Classification of published therapies of experimental pulmonary hypertension 
 
Anti-mitogenic (particularly towards PA-SMCs)                                (ref) 
PDGF inhibitors                     (11) 
Endothelin receptor blockers                    (23-26,36) 
Prostacyclin                    (12-17,22,26) 
Serotonin transporter inhibitors                   (28) 
Serotonin receptor blockers                    (30,31) 
Serotonic re-uptake inhibitor                    (29) 
PDE 4/5 and 3/4 inhibitors                    (16,17,32-36) 
Caveolin-1 blockers                    (37) 
Estradiol (derivatives)                    (38-41) 
Amlodipine                     (45) 
Rapamycin                     (49) 
Endothelial NO synthase gene                   (64)  
Prostacyclin synthase gene                    (61,62) 
NF-κB inhibitor                     (51) 
Pro-endothelial function, vasodilatation and pro-angiogenesis 
Rho-kinase inhibitors                    (18-22) 
Statins                      (43,44) 
Nicorandil                     (46) 
Granulocyte-colony stimulating factor                    (50) 
L-arginine                     (57) 
Prostacyclin                     (12-17,22,26) 
Endothelin receptor blockers                    (23-26,36) 
PDE 4/5 and 3/4 inhibitors                    (16,17,32-36) 
Adrenomedullin                     (48) 
Prostacyclin synthase gene                    (61,62)                 
Angiopoietin-1 gene                    (63) 
Cell therapy using EPCs and MSCs                   (66,69,73-75) 
Cell therapy using differentiated cells transduced with eNOS gene       (67,69,73) 
Cell therapy using differentiated cells transduced with VEGF gene       (68) 
Anti-inflammatory and anti-oxidative  
Serotonin receptor blockers                     (30,31) 
Amlodipine                     (45) 
Nicorandil                     (46) 
Statins                      (43,44) 
C-type natriuretic factor                    (47) 
Interleukin-1 receptor antagonist                   (52) 
Antibodies to monocyte chemotactic and activating factor/MCP1          (53) 
Inhibitor of p38 mitogen-activated protein kinase                  (54) 
Inhibitor of lipoxygenase pathways                   (58) 
Anti-monocyte chemoattractant protein-1 gene                  (60) 
Interleukin-10 gene                    (65) 
Extracellular superoxide dismutase gene                  (59) 
Pro-apoptosis of PA-SMCs 
Serine-elastase inhibitors                    (10) 
PDE 4/5 and 3/4 inhibitors                    (16,17,32-36) 
 
 
Abbreviations: PA-SMCs, pulmonary artery-derived smooth muscle cells; PDGF, platelet-derived 
growth factor; PDE, phosphodiesterase; NO, nitric oxide; EPC, endothelial progenitor cells; MSC, 
mesenchymal stem cells; eNOS, endothelial NO-synthase; VEGF, vascular endothelial growth factor; 
MCP1, monocyte chemoattractant protein-1.  
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Background: Pulmonary arterial hypertension (PAH) is a chronic lung disease 
characterized by increased pulmonary artery pressure, pulmonary vascular 
damage and medial hypertrophy of pulmonary arterioles. Stem cell therapy may 
improve pulmonary damage in patients with PAH.  
Purpose: To test the effects of treatment with bone marrow-derived 
mesenchymal stem cells (MSCs) obtained from donor rats with monocrotaline 
(MCT)-induced PAH to recipient rats with MCT-induced PAH on (i) pulmonary 
artery pressure, (ii) lung histology, (iii) pulmonary arteriolar diameters, and (iv) 
right ventricular (RV) hypertrophy. This model was chosen to mimic autologous 
stem cell therapy.  
Methods: Female Wistar rats were divided in 4 groups, receiving either PBS 
(control, n=10), MCT (60 mg/kg, n=10), MCT (60 mg/kg) 14 days later followed by 
administration of 106 MSCs per rat i.v. (n=10), or 106 skin fibroblasts (SFs) per rat 
i.v. (n=10). MSCs were obtained from bone-marrow of PAH rats treated with MCT 
(60 mg/kg) for 28 days. SFs were obtained from healthy rats. At 28 days after 
MCT (or PBS) administration, the animal was sacrificed, lungs and heart were 
excised, weighed, fixed and examined by histology.  
Results: At 28 days after MCT-treatment, rats had PAH (RV peak systolic 
pressure of 42±17 vs. 27±5 mmHg in control; p<0.02), and increased lung weight 
(1.66±0.32 vs. 0.96±0.15 g in control; p<0.05). Lung histology demonstrated 
severe narrowing of precapillary arterioles, thickening of arteriolar walls (3.4 times 
increased vs. control; p<0.001), thickening of alveolar septa (3.5 times increased 
vs. control; p<0.001), and increased RV mass (by 63%; p<0.01). Treatment with 
MSCs for 14 days attenuated PAH (31±4 mmHg; n.s. vs. MCT60; n.s. vs. control), 
and almost normalized lung weight (1.16±0.24 g; p<0.05 vs. MCT60), wall 
thickness of arterioles (p<0.01 vs. MCT60), thickness of alveolar septa (p<0.01 
vs. MCT60), and RV hypertrophy (p<0.01 vs. MCT60). In MCT-treated rats i.v. 
therapy with SFs from healthy rats had less beneficial effects than i.v. therapy 
with MSCs from PAH rats.  
Conclusions:  Intravenous administration of MSCs from donor rats with PAH to 
recipient rats with PAH decreased RV peak systolic pressure, pulmonary 
arteriolar narrowing, alveolar septum thickening, and RV hypertrophy. These 
results suggest that autologous stem cell therapy may help to alleviate cardiac 














Pulmonary arterial hypertension (PAH) is a chronic lung disease characterized by 
increased pulmonary artery pressure, pulmonary vascular damage and medial 
hypertrophy of pulmonary arterioles. In the current study we use a well-
established model of experimental PAH induction in rats by a single injection of 
monocrotaline (MCT). MCT, a pyrrolizidine alkaloid derived from Crotalaria 
spectabilis, causes a pulmonary vascular syndrome in rats characterized by 
proliferative pulmonary vasculitis, PAH, and cor pulmonale. Current lines of 
evidence of the pathogenesis of MCT-induced pneumotoxicity indicate that MCT 
is activated to one or more reactive metabolites in the liver, particularly a MCT 
pyrrole called dehydromonocrotaline [1-3], and is then transported by red blood 
cells to the lung [4], where it initiates endothelial injury [5,6]. The endothelial injury 
does not appear to be acute cell death but rather a pathological condition that 
leads to smooth muscle cell proliferation in the media of pulmonary arteriolar 
walls by unknown mechanisms. The role of inflammation in the progression of 
MCT-induced pulmonary vascular disease is uncertain. Both perivascular 
inflammation and platelet activation have been proposed as processes 
contributing to the response of the vascular media [3]. The resulting lung lesions 
mimic the changes observed in lungs of the patients with PAH. There is a positive 
correlation between progressive PAH, thickening of the medial wall of small 
pulmonary arteries and arterioles, and RV hypertrophy as a function of time [7]. 
PAH is a difficult disease to treat and has been shown to be refractory to most of 
the conventional therapies. Many treatment modalities have been employed for 
treating PAH ranging from calcium channel blockers [8], phosphodiesterase 
inhibitors [9], endothelin receptor antagonists [10] to prostacyclin analogues [11], 
but still a standard treatment is lacking. Combination therapy has also been 
employed more recently [12], but still no definitive results have been obtained.  
Stem cell therapy may constitute a new treatment modality for patients with PAH. 
Different modes of administration of stem cells including intravenous [13], 
intratracheal [14], and direct implantation of cells into the lungs [15] have been 
used. We have used the intravenous route of administration being a safe and 
feasible method of cell injection.  
We hypothesize that when administered intravenously, the mesenchymal stem 
cells (MSCs) filter through the lungs and have a chance to engraft at the sites of 
lung parenchymal or vascular damage. Once these cells reside in damaged 
tissue, they start secreting ‘pro-survival factors’ such as growth factors or 
cytokines, hence helping improve the tissue’s condition by paracrine mechanisms 
[16] or possibly by differentiating into endothelial or smooth muscle cells [17] and 
help to ameliorate pulmonary damage.  
Although i.v. administration of bone marrow-derived MSCs to treat PAH has been 
studied already [13], our purpose was to treat recipient rats with MCT-induced 
PAH with bone marrow-derived MSCs obtained from donor rats with MCT-
induced PAH, to mimic autologous stem cell transplantation. In this study we 
demonstrate that treatment of rats with PAH with MSCs from donor rats with PAH 
results in (i) lower pulmonary artery pressure, (ii) lower lung weight, (iii) less 
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abnormalities of pulmonary architecture, and (iv) less RV hypertrophy, compared 




Materials and Methods 
 
Animals 
All animals were treated in accordance with the national guidelines and with 
permission of the Animal Experiments Committee of the Leiden University 
Medical Center. Eight-week-old female Wistar rats weighing 200-250 g (Harlan, 
Zeist, The Netherlands) were treated with MCT (Sigma-Aldrich, Zwijndrecht, The 
Netherlands) to produce pulmonary hypertension. Rats were randomly assigned 
to four groups. The animals received a single subcutaneous injection of MCT 
diluted in phosphate-buffered saline (PBS) (MCT60, 60 mg/kg body wt, n =10) or 
the same dose of MCT followed 14 days later by intravenous injection into the 
jugular vein of 106 DiI-labeled mesenchymal stem cells  (MCT+MSC, n = 10), 
or106 DiI-labeled skin fibroblasts (MCT+SF, n=10). Control (Cont) rats (n =10) 
were injected with an equal volume of PBS. The animals were housed, two 
animals per cage, with a 12:12-h light-dark cycle and an unrestricted food and 




At day 28 after MCT (or PBS) administration, RV pressure was measured as 
published previously [18]. Briefly, the rats were sedated by inhalation of a mixture 
of isoflurane (4%) and oxygen. Subsequently, general anesthesia was induced by 
intraperitoneal (i.p.) injection of a fentanyl–fluanison–midazolam mixture in a dose 
of 0.25 mL/100 g body weight. The mixture consisted of two parts Hypnorm 
(0.315 mg/mL fentanyl+10 mg/mL fluanison; Vital-Pharma, Maarheeze, the 
Netherlands): one part Dormicum (5 mg/mL midazolam; Roche, Mijdrecht, the 
Netherlands) and one part saline. The animals were placed on a controlled 
warming pad to keep body temperature constant. After a tracheotomy was 
performed, a cannula (18G, Biovalve, Vygon, Ecouen, France) was inserted, and 
the animals were mechanically ventilated using a pressure-controlled respirator 
and a mixture of air and oxygen. The animals were placed under a 
stereomicroscope (Zeiss, Hamburg, Germany). After a midsternal thoracotomy 
was performed, a combined pressure-conductance catheter (model FT212, 
SciSense, London, Ontario, Canada) was introduced via the apex into the RV and 
positioned towards the pulmonary valve. The catheter connected to a signal 
processor (FV898 Control Box, SciSense) and RV pressures were recorded 
digitally. All data were acquired at a sample rate of 2,000 Hz and analyzed off-line 
by dedicated software (SciSense).  
 
 




Mesenchymal stem cell isolation and culture 
Four weeks after MCT treatment (60 mg/kg, n=10) adult donor rats were 
anesthetized with isoflurane and killed by i.v. injection of KCl (100 mmol/L). 
Femurs and tibiae were removed and cleaned of all connective tissue and 
attached muscles. The proximal ends were clipped and bones placed in 
microfuge tubes supported by plastic inserts cut from 200 μL pipette tips. 
Microfuge tubes were briefly centrifuged at 13,000 rpm for 1 min. The marrow 
pellets were resuspended in 10 mL of growth medium [Dulbecco’s modified 
Eagle’s medium (DMEM; Invitrogen, Breda, the Netherlands), supplemented with 
15% fetal bovine serum (FBS; Invitrogen), penicillin (50 U/L), streptomycin (50 
µg/L), and amphotericin B solution (0.25 µg/mL; Sigma-Aldrich)] supplemented 
with 6% heparin (400 IE/mL). This suspension was centrifuged again at 1000 rpm 
for 10 min. Next, the pellet was resuspended in 7 mL of growth medium 
supplemented with 5.75 µg/mL DNase I (Sigma-Aldrich). The cells were plated in 
25-cm2 culture flasks (Becton Dickinson, Franklin Lakes, NJ, USA) and the culture 
was kept in a humidified hypoxic incubator CO2/O2 (5%/5%) at 37ºC. The non-
adherent cells were replated after 6 h. Two days later, non-adherent cells were 
removed by changing the medium to 12 mL of fresh growth medium. The medium 
was refreshed twice a week until the primary cultures were confluent. The 
advantages of culturing MSCs in a hypoxic environment have been documented 
frequently [19-23]. 
Skin fibroblasts   
Skin fibroblasts (SFs) were grown from pieces of skin of healthy rats anesthetized 
by excess CO2 and killed by i.v. injection of KCl (100 mmol/L). Skin samples were 
transferred to porcine gelatin (Sigma-Aldrich)-coated flasks, and cultured in 
DMEM containing 100 U/mL penicillin, 100 μg/mL streptomycin, and 10% fetal 
bovine serum (FBS, all from Invitrogen) in a normoxic incubator (20% O2 and 5% 
CO2) at 37°C. Outgrowth of cells was visible 2 days after culture initiation. Three 
days later the skin pieces were removed and the skin fibroblasts were detached 
with trypsin-EDTA solution (Invitrogen), and reseeded in new culture flasks. For 
intravenous infusion into rats which had had MCT administration 14 days earlier, 
we used passage 4-6.  
 
Cell injection 
Before injection, the cells were trypsinized and labelled with the viable fluorescent 
dye CM-DiI according to the manufacturer’s recommendations (CellTrackerTM, 
Molecular Probes, Invitrogen). At day 14, each rat was fixed on its back, and 
anaesthetized with isoflurane. The jugular vein in the neck was prepared free. A 
venous catheter (20G, Biovalve) was introduced in the vein. Through this catheter 
1 mL of cell suspension (106 cells/mL) was injected slowly. This suspension 
contained MSCs from rats with MCT-induced PAH or SFs from healthy rats. After 
removal of the catheter, the vein was pressed for 5 min to allow closure of the 
puncture and the skin was closed. The control animals received i.v. injections of 1 
mL of PBS. 
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Tissue preparations 
After hemodynamic measurements, lungs and heart were removed, snap-frozen 
in liquid nitrogen, and stored at –80°C until isolation of RNA. For histology 
studies, the trachea was cannulated (18G, Biovalve), and the lungs were fixed in 
situ via the trachea cannula with buffered formaldehyde (4% paraformaldehyde in 
PBS, pH 7.4) at a pressure of 25 cm H2O for 5 min. After removal of lungs and 
hearts, lungs were fixed (additionally) in formaldehyde for 24 h at 4°C, and 
embedded in paraffin after dehydration in a graded alcohol series and xylene.  
 
Real-time RT-PCR 
Total RNA was isolated from lung tissue homogenates using guanidium-phenol-
chloroform extraction and isopropanol precipitation (RNA-Bee, Tel-Test Inc., Bio-
Connect BV, Huissen, the Netherlands). The RNA sample was dissolved in 
RNase-free water and quantified spectrophotometrically. First-strand cDNA 
synthesis was performed with the SuperScript Choice System (Life Technologies, 
Breda, the Netherlands) by mixing 2 µg total RNA with 0.5 µg of oligo(dT)12-18 
primer in a total volume of 12 µL. After the mixture was heated at 70°C for 10 min, 
a solution containing 50 mmol/L Tris-HCl (pH 8.3), 75 mmol/L KCl, 3 mmol/L 
MgCl2, 10 mmol/L DTT, 0.5 mmol/L dNTPs, 0.5 µL RNase inhibitor, and 200 U 
Superscript Reverse Transcriptase was added, resulting in a total volume of 20.5 
µL. This mixture was incubated at 42°C for 1 h; total volume was adjusted to 100 
µL with RNase-free water and stored at –80°C until further use. For real-time 
quantitative PCR, 1 µL of first-strand cDNA diluted 1:10 in RNase-free water was 
used in a total volume of 25 µL, containing 12.5 µL 2x SYBR Green PCR Master 
Mix (Applied Biosystems, Foster City, CA, USA) and 200 ng of each primer. 
Primers, designed with the Primer Express software package (Applied 
Biosystems), are:  
      
 
Interleukin-6:      forward  5’-ATATGTTCTCAGGGAGATCTTGGAA-3’   
                      reverse   5’-TGCATCATCGCTGTTCATACAA-3’ 
TNFα:     forward  5’- ACAAGGCTGCCCCGACTAT-3’   
                      reverse   5’-CTCCTGGTATGAAGTGGCAAATC-3’ 
Endothelin-1:   forward  5’-TGTGCTCACCAAAAAGACAAGAA-3’    
                      reverse   5’-GGTACTTTGGGCTCGGAGTTC-3’  
VEGF-A:  forward  5’-GCGGATCAAACCTCACCAAA-3’     
                      reverse   5’-TTGGTCTGCATTCACATCTGCTA-3’  
NOS-2:      forward  5’-GCTGCATGTGACTCCATCGA-3’     
                      reverse   5’-TCTCCATTGCCCCAGTTTTT-3’ 
NOS-3:      forward  5’-CCCTGCCAACGTGGAGAT-3’     
                      reverse   5’-ATCAAAGCGGCCATTTCCT-3’  
Tenascin-C: forward  5’-TCACAGCTCTCGATGGTCCAT-3’   
                      reverse   5’-TGGCCAAGGCTTCTGAGTCT-3’ 
MMP2:     forward  5’-CCCACGAAGCCTTGTTTACC-3’   
                      reverse   5’-GAAGCGGAACGGGAACTTG-3’ 
MMP9:     forward  5’-TCCGCAGTCCAAGAAGATTTTC-3’   
                      reverse   5’-GCACCGTCTGGCCTGTGTA-3’ 
β-actin:     forward  5’-GGCTCCTAGCACCATGAAGATC-3’    
                      reverse   5’- GAGCCACCAATCCACACAGA-3’ 
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PCR reactions, consisting of 95°C for 10 min (1 cycle), 94°C for 15 s, and 60°C 
for 1 min (40 cycles), were performed on an ABI Prism 7900 HT Fast Real Time 
PCR system (Applied Biosystems) of the Leiden Genome Technology Center. 
Data were analyzed with the ABI Prism 7900 sequence detection system software 
(version 2.2) and quantified with the comparative threshold cycle method with -
actin as a housekeeping gene reference [24].  
 
Histochemical analysis 
Fixed lung tissue, embedded in paraffin, was cut into 4-μm-thick sections and 
stained with hematoxylin-phloxin-saffron for determination of thickness of alveolar 
septa. 
 
Tracing the DiI-labeled stem cells in the lungs 
Four µm thick sections of lung tissue were deparaffinised in Ultraclear (Klinipath, 
Duiven, the Netherlands) and rehydrated in decreasing series of graded alcohols 
(100-25%), followed by two 5-min washes in distilled water and TBS (150 mmol/L 
NaCl, 10 mmol/L Tris-HCl, pH 8.0). Subsequently, nuclei were stained with 10 
µg/mL Hoechst 33342 solution (Molecular Probes, Invitrogen) for 10 min at room 
temperature. Sections were washed three times with TBS and mounted with 
Vectashield (Vector Laboratories, Burlingame, CA, USA).  
 
Antibodies 
Primary antibodies used were mouse anti α-smooth muscle actin (ASMA) 
antibody (S2547, Sigma-Aldrich), mouse anti-ED1 antibody (gift from Dr. E. de 
Heer, Department of Pathology, LUMC) to stain for interstitial 
monocytes/macrophages, mouse anti-myeloperoxidase (MPO) antibody (Thermo 
Fisher Scientific, Waltham, MA, USA) for neutrophil identification, and rabbit anti-
CC10 antibody (C5828-03, United States Biological, Swampscott, MA, USA) to 
identify Clara cells. 
Secondary HRP conjugated antibody were goat anti-mouse-IgG conjugated to 
HRP (sc2005, Santa Cruz Biotechnology, Santa Cruz, CA, USA), or goat anti-
rabbit-IgG conjugated to HRP (sc2004, Santa Cruz Biotechnology). Substrate 
was 3,3’-diaminobenzidine (DAB)(Pierce, Perbio Science, Etten-leur, the 
Netherlands) or NovaRed (Vector Laboratories). 
 
Immunoperoxidase staining protocol 
Tissue was deparaffinized in Ultraclear two times for 10 min each, followed by 
100% ethanol 2 times for 5 min each. The sections were rehydrated in decreasing 
graded alcohols (from 96% to 50%) for 3 min each and washed twice for 5 min 
each in distilled water and PBS. To inhibit endogenous peroxidase activity, the 
sections were incubated with 0.3% H2O2 in PBS for 20 min at room temperature. 
Next, the sections were boiled in 1.8% citrate buffer in a microwave for 12 min at 
98°C. The next step was incubation in blocking solution, consisting of 5% bovine 
serum albumin (BSA) in PBS, for 1 hour at room temperature. Subsequently, 
sections were incubated with primary antibody diluted in PBS containing 1% BSA 
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and 0.05% Tween (100 µL per sample), in a dilution of 1:100, overnight at room 
temperature. The sections were washed in PBS 3 times for 5 min each. Next, the 
sections were incubated with secondary antibody diluted in PBS containing 1% 
BSA and 0.05% Tween (100 µL per sample), in a dilution of 1:200, for 60 min at 
room temperature. After washing, 100 µL DAB was added to the sections (250 µL 
of 10x DAB solution and 2250 µL buffer (Pierce)) for 5 min, and washed again. 
Sections were stained in 1% hematoxylin for 1 min, and rinsed under running tap 
water for 10 min. In the end, to dehydrate the slides, sections were incubated in 
50%, 70% and 96% ethanol for 3 min each, in 100% ethanol 2 times for 5 min, 
and in Ultraclear 2 times for 10 min each. Next, sections were mountedwith D.P.X 
(BDH, Brunschwig Chemie, Amsterdam, the Netherlands), and examined under 




Stained slides were photographed using a microscope (Nikon Eclipse, Nikon 
Europe, Badhoevedorp, the Netherlands) equipped with 10x, 20x, 40x  and 100x 
objectives and a digital camera (model DXM1800, Nikon). This microscope 
performed both light microscopy and fluorescence microscopy. 
  
 
Quantitative image analysis 
Quantitative image analysis was performed with Image-Pro Plus software (Media 
Cybernetics, Silver Spring, MD, USA).  For determination of alveolar septum 
thickness hematoxylin-phloxin-saffron stained lung tissue was photographed at 
high magnification (100x). At locations distant from branch points and arterioles 
alveolar septum thickness was measured with calipers in Image-Pro Plus. For 
determination of precapillary arteriolar wall thickness, ASMA-stained lung tissue 
was photographed at high magnification (100x). Wall thickness of arterioles 
localized at branch points of alveolar septa was measured with calipers in Image-
Pro Plus.       
 
Assessment of RV hypertrophy 
To quantify the degree of right ventricular hypertrophy hearts were harvested, 
followed by the removal of the left and right atrium. Hereafter the right ventricular 
free wall (RV) was dissected, weighted separately from the left ventricle (LV), 
including the interventricular septum (IVS), and frozen immediately in liquid 




The effect of treatment (cell therapy with MSCs, cell therapy with SFs) was 
evaluated by one-way ANOVA followed by Bonferroni’s post-hoc test. SPSS12 for 
Windows (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. 
Differences were considered significant at p<0.05. Values are represented by 
means ± SD, unless stated otherwise. 




RV peak systolic pressure 
At the end of the experimental period, RV peak systolic pressures were 
significantly higher in MCT60 group than in the control group, indicating the 
development of PAH (42±17 vs. 27±5 mmHg in control; p<0.02). In MCT-treated 
rats that had been given cell therapy with MSCs, mean RV peak systolic pressure 
was attenuated (31±4 mmHg) although not significantly different from MCT60, nor 
from control. In the MCT+SF group, the RV peak systolic pressure was 32±6 























Lung weight was 0.96±0.15 g in control animals. Lung weight was significantly 
increased in the MCT60 group to 1.66±0.32 g (p<0.05 vs. control). With stem cell 
therapy, lung weight had decreased to 1.16±0.24 g (p<0.05 vs. MCT60). Lung 
weight in the MCT+SF group was 1.52±0.20 g (p<0.05 vs. control), which was not 
different from MCT60 (Figure 2). The increase in lung weight observed in the 
MCT60 and MCT+SF groups is symptomatic for an increased remodeling of lung 



































Figure 1. RV peak systolic pressures (mmHg) of 
Control, MCT60, MCT+MSC and MCT+SF groups 
are shown. Values are expressed as mean ± SD  
(* p<0.05 vs. Control). 





















In MCT-treated rats RV mass had increased from 143±26 mg to 233±53 mg 
(p<0.05). RV mass of MCT-treated rats that had received MSCs was 162±25 mg 
(p<0.01 vs. MCT60) which was not different from Control. In MCT-treated rats that 
had received SFs RV mass was 183±33 mg (p<0.05 vs. MCT60) which was not 







































Figure 2. Lung weights (g) of Control, MCT60, 
MCT+MSC and MCT+SF groups are shown. 
Values are expressed as mean ± SD 
(* p<0.05 vs. Control, # p<0.05 vs. MCT60).  














Figure 3. Right ventricular weight (RV mass) of 
Control, MCT60, MCT+MSC and MCT+SF groups 
are shown. Values are expressed as mean ± SD 
(* p<0.05 vs. Control, # p<0.05 vs. MCT60). 
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mRNA in pulmonary tissue 
Relative concentrations of mRNA encoding IL6, TNFα and MMP2 have increased 
in lungs of rats with MCT-induced PAH, although only significant for IL6 and 
MMP2 (Figure 4). However, mRNA encoding ET1 and VEGF-A had decreased 
significantly in lungs of rats treated with MCT. In the lungs of rats receiving cell 
therapy relative concentrations of mRNA did not differ, or only slightly, from those 
in rats of the MCT60 group. mRNA encoding NOS2 and NOS3 did not show 







































































































































































































































Figure 4. Right ventricular concentrations of mRNA encoding tumor necrosis 
factor-α (TNFα), interleukin-6 (IL-6), vascular endothelial growth factor-A 
(VEGFA), endothelin-1 (ET-1),  nitric oxide synthase-2 (NOS2), nitric oxide 
synthase-3 (NOS3), tenascine-C (TN-C), matrix metalloproteinase-2 (MMP2) 
and matrix metalloproteinase-9 (MMP9). For each mRNA, myocardial 
concentration is normalized for the concentration found in hearts of PBS-treated 
rats (controls, Cont). * p<0.05 vs. Cont (control), ** p<0.01 vs. Cont (control) 
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Mean pulmonary arteriolar wall thickness 
Mean pulmonary arteriolar wall thickness was significantly increased in MCT60 
group to 343±60 % (p<0.05 vs. control). With MSC therapy, the arteriolar wall 
thickness had decreased to 120±28 % (p<0.05 vs. MCT60). The wall thickness in 
the MCT+SF group was 296±35 % (p<0.05 vs. control), which was not different 
from MCT60 (Figure 5). The increase in pulmonary arteriolar wall thickness 
observed in the MCT60 and MCT+SF groups represents arteriolar medial 







































































Figure 5b. Pulmonary arteriolar wall thickness (%) of Control, MCT60, 
MCT+MSC and MCT+SF groups are shown. Values are expressed as 
mean ± SD (* p<0.05 vs. Control, # p<0.05 vs. MCT60). 
1000x 
Figure 5a. Immunoperoxidase images of paraffin sections of lung 
tissue stained with anti α-smooth muscle actin antibody. 
Representative pulmonary arterioles of Control (panel A), MCT60 
(panel B), MCT+MSC (panel C) and MCT+SF (panel D) are shown. 
A B C D 
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Mean pulmonary alveolar septum thickness 
Mean pulmonary alveolar septum thickness was significantly increased in the 
MCT60 group to 353±56 % (p<0.05 vs. control). With stem cell therapy, the 
alveolar septum thickness was only 109±20 % (p<0.05 vs. MCT60). Alveolar 
septum thickness in the MCT+SF group was 309±28 % (p<0.05 vs. control), 
which was not different from MCT60 (Figure 6). The increase in the mean 
pulmonary alveolar septum thickness observed in MCT60 and MCT+SF groups is 



































A B C D 
Figure 6a. Immunoperoxidase images of paraffin sections of lung tissue 
stained with anti α-smooth muscle actin antibody. Lung histology of Control 










































Figure 6b. Pulmonary alveolar septum thickness (%) of Control, MCT60, 
MCT+MSC and MCT+SF groups are shown. Values are expressed as 
mean ± SD (* p<0.05 vs. Control, # p<0.05 vs. MCT60). 
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Recovery of DiI-labeled MSCs in the lung  
In each rat that received cell therapy with MSCs (at day 14) the lungs were found 
to contain DiI-labeled MSCs at day 28 (Figure 7). Labeled MSCs were located in 
or near the pulmonary arterioles. They were not positive for CC10, thereby 





























Figure 7. Fluorescence images of DiI-labeled MSCs in lungs 
acquired using 200x (top panels) and 400x (bottom panel) 
objectives.DiI-labelled MSCs are stained red, whereas nuclei  
are stained blue. 
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Abundance of ED1-positive and MPO-positive cells in lung 
tissue 
Numbers of MPO-positive cells in lung tissue, nor numbers of ED1-positive cells 
in lung tissue differed between the experimental groups of rats (Figure 8).  





















































Figure 8a. Number of myeloperoxidase (MPO)-positive 
cells per image (0.34 mm2) of lung tissue from rats in 4 
experimental groups. Per bar, 5 images have been scored. 
Indicated are mean values and SD.  
Figure 8b. Number of ED1-positive cells per image 
(0.34 mm2) of lung tissue from rats in 4 experimental 
groups. Per bar, 5 images have been scored. Indicated 
are mean values and SD. 




In the present study we have shown that i.v. injection of MSCs obtained from 
donor rats suffering from PAH into recipient rats with PAH has beneficial effects 
on lungs and heart, such as decreased RV peak systolic pressure, reduced 
pulmonary arteriolar narrowing and alveolar septum thickening, and less RV 
hypertrophy, compared to rats not receiving cell therapy.     
MCT, a plant-derived toxin, causes endothelial cell injury, as observed in reduced 
expression of VEGF and endothelin-1, and subsequently an infiltration of 
mononuclear cells into the perivascular regions of arterioles and muscular arteries 
when injected i.v. in rats. These animals develop severe PAH after exposure to 
MCT [25]. Although typical plexiform lesions are not normally found in MCT-
induced PAH, it is used as a standard model for PAH and primary pulmonary 
hypertension.  
The important role of inflammation in this model has led to several studies 
focusing on immunosuppressive and anti-cytokine treatment, and, therefore, 
raises the question of how inflammation is involved in the installation and 
evolution of PAH lesions in humans. 
Pathological changes in lungs of patients with PAH do not involve the whole 
pulmonary arterial tree, but remain restricted to certain vessel types. The 
concentric obliterative arteriopathy concerns muscular arteries of ≤500 μm in 
diameter, corresponding to the smaller arteries and their down-stream arterioles. 
Different and characteristic lesions, such as medial hypertrophy, intimal fibrosis, 
and typical plexiform lesions, as well as perivascular lymphocytic infiltrates are 
found [27,27]. Also Dorfmüller and coworkers reported that inflammatory 
mechanisms play a significant role in MCT-induced PAH in rats and pulmonary 
arterial hypertension of various origins in humans [28]. As for the MCT-model in 
the rat, typical plexiform lesions of smaller arteries are usually not found, but the 
primary importance of inflammation is illustrated by successful therapies using an 
interleukin-1 receptor antagonist [29] and antibodies to monocyte chemotactic 
protein-1 [30]. In the present study we found significantly increased pulmonary 
expression of IL-6 in rats with MCT-induced PAH, which remained unaffected by 
cell therapy with SFs and with MSCs, although pulmonary IL6 mRNA 
concentration in MCT-treated rats that received MSCs was not significantly 
different from that in control lungs (Fig 4). MCT-induced endothelial cell 
dysfunction is associated with deregulated expression of vasoactive, mitogenic 
and proinflammatory mediators that may cause these changes [31,32]. Although 
we have stained the lung tissue for ED1 and MPO, we did not find ample 
evidence for interstitial accumulation of monocytes/macrophages and neutrophils 
in the lung, respectively. In the lungs of patients with pulmonary hypertension 
there is medial hypertrophy of arteries and increased pulmonary vascular 
resistance. In contrast to the lungs of control subjects, NOS was hardly expressed 
in the vascular endothelium of all type of vessels in the lungs of patients with 
pulmonary hypertension [33]. The arterial expression of NOS correlated inversely 
with the severity of histologic changes. The lack of NOS3-derived NO is 
responsible for proliferation of medial smooth muscle cells [34], which explains 
the simultaneous presence of, and interrelation between, lack of endothelial NOS 
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and arterial/arteriolar wall thickening. In the present study we found no indications 
of a downregulation of NOS3 induced by MCT without or with cell therapy. 
In the lungs of patients with pulmonary hypertension endothelial expression of 
endothelin-1 (ET1) was abundant, predominantly in endothelial cells of pulmonary 
arteries with medial thickening and intimal fibrosis. At sites of increased ET1 
immunoreactivity the ET1 mRNA concentration was high [35]. High levels of ET1 
may induce proliferation of fibroblasts and increase the production of fibrous 
tissue in vitro [36]. In the present study, expression of ET1 in lung tissue of rats 
with MCT-induced PAH is markedly depressed, is unaffected by cell therapy with 
SFs, but has improved somewhat by cell therapy with MSCs.     
In our study, we have observed remodeling of lung tissue in MCT-induced PAH 
as depicted by an increase in lung weights in MCT60 and MCT+SF groups (Fig. 
2). The increase in lung weights observed in these groups is indicative for an 
increased ECM deposition in lung tissue in these groups, rather than pulmonary 
edema [18]. In addition, there was an increase in the mean alveolar septal 
thickness along with a higher incidence of discontinuous alveolar septa leading to 
larger alveolar spaces (Fig. 6). On further histological analysis, the mean 
pulmonary arteriolar wall thickness was significantly increased in MCT60 and 
MCT+SF groups (Fig. 5). With regard to the expression of MMPs in lung tissue, 
we found that MMP9 expression did not differ significantly between the groups, 
while MMP2 expression was significantly increased in MCT60 and MCT+MSC 
groups. Although TNC expression was increased in MCT60 group (1.6 times vs. 
control), the increase was not significant (Fig. 4). Increased expression of TNC 
has been shown to be associated with progression of clinical and experimental 
pulmonary hypertension [37,38]. Furthermore, MMP expression and activity are 
increased in experimental PAH [39]. Cell proliferation and ECM accumulation are 
also prominent features of idiopathic PAH. An important component of these 
changes is ECM remodeling, which results from a complex interplay between the 
synthesis and proteolysis of ECM constituents [40]. Hence any therapy having 
anti-remodeling effects may also be effective in treating PAH in the patients. 
Many treatment options for PAH have been tested so far, but an effective therapy 
is lacking. Cell therapy constitutes a novel therapeutic option for PAH patients. 
Several groups have tested several cell types to treat experimental PAH, 
including endothelial progenitor cells [41], unfractionated bone marrow-derived 
cells [42,43], and mesenchymal stem cells (MSCs)[13]. MSCs are unique in 
possessing (i) a potential to differentiate into other cell types, and (ii) an ability to 
secrete paracrine factors leading to improvements in tissue injury [44]. Stem cell 
therapy using bone marrow-derived MSCs may actively replace differentiated 
cells that were damaged by MCT and/or contribute to tissue repair by secreting a 
wide variety of cytokines and growth factors. Generally the highest levels of 
engraftment are observed in tissues that are severely injured. Nagaya and 
coworkers recovered i.v. administered endothelial progenitor cells (EPCs) 
engrafted in pulmonary arterioles and capillaries of rats with MCT-induced PAH 
and differentiated endothelial cells [45]. With stem cell therapy we found anti-
remodeling effects in the MCT+MSC group including a decrease in lung weights 
(Fig. 2), alveolar septal thickness (Fig. 6) and arteriolar wall thickness (Fig. 5), 
combined with an improvement in pulmonary architecture. 
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In the lungs we found most DiI-labeled MSCs engrafted in or near the arterioles 
(Fig. 7). Their therapeutic effect is, therefore, interpreted to originate from their 
paracrine effect, i.e. the production of cytokines and growth factors. These factors 
promote angiogenesis and may stop the proliferative thickening of arteriolar 
medial layers. I.v. administration of pulmonary artery-derived smooth muscle cells 
that were in vitro transduced with the VEGF-A gene was shown to have a 
substantial therapeutic effect in rats with MCT-induced PAH, whereas the use of 
the same cell type without gene transduction was without effect [46].  
Apparently, the paracrine effects of intrapulmonary engrafted MSCs are more 
important than the differentiation of engrafted MSCs into vascular smooth muscle 
cells, endothelial cells, and/or Clara cells. With the anti-CC10 antibody we were 
unable to find any DiI-labeled MSC in the lung tissue that was CC10 positive.  In 
contrast to the marked benefits of the therapy with i.v. MSCs, the effects obtained 
after injection with SFs were small, if present at all.  Earlier Campbell and 
coworkers have used pulmonary artery-derived smooth muscle cells (PA-SMCs) 
injected i.v. together with MCT and found no therapeutic effect on pulmonary 
artery pressure [47]. If PA-SMCs were injected 2 weeks after MCT administration, 
cell therapy had no effect [46]. I.v. injected skin fibroblasts 3 days after MCT 
administration had no therapeutic effect as assessed 3 weeks later [41].  Using 
skin fibroblasts from healthy rats, injected i.v. in rats 2 weeks after MCT 
administration, we found no significant therapy effect on lung weight, arteriolar 
wall thickness, and alveolar septum thickness, although an unexplained therapy 
effect on RV mass is observed. Compared to injected MSCs, the injected SFs 
had slight therapeutic effects that may be ascribed to their inability to secrete 





In conclusion, i.v. administration of bone marrow-derived MSCs obtained from 
donor rats suffering from PAH into recipient rats with PAH decreases RV peak 
systolic pressure, pulmonary arteriolar narrowing, alveolar septum thickening, and 
RV hypertrophy. Based on these results, the use of autologous bone marrow-






Dr. J.W.A. van der Hoorn (TNO-Prevention & Health, Leiden) is gratefully 
acknowledged for staining lung tissue. The anti-ED1 antibody was a kind gift from 









1. Butler WH, Mattocks AR, Barnes JM. Lesions in the liver and lungs of rats given pyrrole 
derivatives of pyrrolizidine alkaloids. J Pathol 1970; 100: 169-75. 
2. Lafranconi WM, Huxtable RJ. Hepatic metabolism and pulmonary toxicity of 
monocrotaline using isolated perfused liver and lung. Biochem Pharmacol 1984; 33: 2479-
84. 
3. Wilson DW, Segall HJ, Pan LC, Lame MW, Estep JE, Morin D. Mechanisms and 
pathology of monocrotaline pulmonary toxicity. Crit Rev Toxicol 1992; 22: 307-25. 
4. Lamé MW, Jones AD, Morin D, Wilson DW, Segall HJ. Association of 
dehydromonocrotaline with rat red blood cells. Chem Res Toxicol 1997; 10: 694-701. 
5. Reindel JF, Hoorn CM, Wagner JG, Roth RA. Comparison of response of bovine and 
porcine pulmonary arterial endothelial cells to monocrotaline pyrrole. Am J Physiol Lung 
Cell Mol Physiol 1991; 261: L406-L414. 
6. Reindel JF, Roth RA. The effects of monocrotaline pyrrole on cultured bovine pulmonary 
artery endothelial and smooth muscle cells. Am J Pathol 1991; 138: 707-19. 
7. Ghodsi F, Will JA. Changes in pulmonary structure and function induced by 
monocrotaline intoxication. Am J Physiol Heart Circ Physiol 1981; 240: H149-H155. 
8. Mawatari E, Hongo M, Sakai A, Terasawa F, Takahashi M, Yazaki Y, Kinoshita O, Ikeda 
U. Amlodipine prevents monocrotaline-induced pulmonary arterial hypertension and 
prolongs survival in rats independent of blood pressure lowering. Clin Exp Pharmacol 
Physiol 2007; 34:594-600. 
9. Dony E, Lai Y, Dumitrascu R, Pullamsetti SS, Savai R, Ghofrani HA, Weissmann N, 
Schudt C, Flockerzi D, Seeger W, Grimminger F, Schermuly RT. Partial reversal of 
experimental pulmonary hypertension by phosphodiesterase 3/4 inhibition. Eur Respir J 
2008;31:599-610. 
10. Nishida M, Eshiro K, Okada Y, Takaoka M, Matsumura Y. Roles of endothelin ETA and 
ETB receptors in the pathogenesis of monocrotaline-induced pulmonary hypertension. J 
Cardiovasc Pharmacol 2004; 44:187-91. 
11. Obata H, Sakai Y, Ohnishi S, Takeshita S, Mori H, Kodama M, Kangawa K, Aizawa Y, 
Nagaya N. Single injection of a sustained-release prostacyclin analog improves pulmonary 
hypertension in rats. Am J Respir Crit Care Med 2008; 177:195–201.  
12. Clozel M,  Hess P, Rey M, Iglarz M, Binkert C, Qiu C. Bosentan, sildenafil, and their 
combination in the monocrotaline model of pulmonary hypertension in rats. Exp Biol Med 
2006; 231: 967–73. 
13. Kanki-Horimoto S, Horimoto H, Mieno S, Kishida K, Watanabe F, Furuya E, Katsumata 
T. Implantation of mesenchymal stem cells overexpressing endothelial nitric oxide 
synthase improves right ventricular impairments caused by pulmonary hypertension. 
Circulation 2006; 114(suppl I); I-181-I-185. 
14. Baber SR, Deng, Master RG, Bunnell BA, Taylor BK, Murthy SN, Hyman AL, Kadowitz 
PJ. Intratracheal mesenchymal stem cell administration attenuates monocrotaline induced 
pulmonary hypertension and endothelial dysfunction. Am J Physiol Heart Circ Physiol 
2007; 292: H1120-H1128. 
15. Takahashi M, Nakamura T, Toba T, Kajiwara N, Kato H, Shimizu Y. Transplantation of 
endothelial progenitor cells into the lung to alleviate pulmonary hypertension in dogs. 
Tissue Eng 2004; 10: 771-9. 
16. Kinnaird T, Stabile E, Burnett MS, Shou M, Lee CW, Barr S, Fuchs S, Epstein SE. 
Local delivery of marrow-derived stromal cells augments collateral perfusion through 
paracrine mechanisms. Circulation 2004;109:1543-9. 
17. Al-Khaldi A, Al-Sabti H, Galipeau J, Lachapelle K. Therapeutic angiogenesis using 
autologous bone marrow stromal cells: Improved blood flow in a chronic limb ischemia 
model. Ann Thorac Surg 2003;75:204-9. 
                                                                                                           Chapter 6 
 142
18. Hessel MH, Steendijk P, den Adel B, Schutte CI, van der Laarse A. Characterization of 
right ventricular function after monocrotaline-induced pulmonary hypertension in the intact 
rat. Am J Physiol Heart Circ Physiol 2006; 291: H2424-H2430. 
19. Lennon DP, Edmison JM, Caplan AI. Cultivation of rat marrow-derived mesenchymal 
stem cells in reduced oxygenc tension: Effects of in vitro and in vivo osteochondrogenesis. 
J Cell Physiol 2001;187:345-55. 
20. Grayson WL, Zhao F, Bunnell B, Ma T. Hypoxia enhances proliferation and tissue 
formation of human mesenchymal stem cells. Biochem Biophys Res Comm 2007;358:948-
53.  
21. Buravkova LB, Anokhina EB. Effect of hypoxia on stromal precursors from rat bone 
marrow at the early stage of culturing. Bull Exp Biol Med 2007; 143: 411-3. 
22. Rosova I, Dao M, Capoccia B, Link D, Nolta JA. Hypoxic preconditioning results in 
increased motility and improved therapeutic potential of human mesenchymal stem cells. 
Stem Cells 2008;26:2173-82. 
23. Hu X, Yu SP, Fraser JL, Lu Z, Ogle ME, Wang J-A, Wei L. Transplantation of hypoxia-
preconditioned mesenchymal stem cells improves infarcted heart function via enhanced 
survival of implanted cells and angiogenesis. J Thorac Cardiovasc Surg 2008;135:799-808. 
24. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. 
Nucleic Acids Res 2001; 29: e45. 
25. Nishimura T, Faul JL, Berry GJ, Veve I, Pearl RG, Kao PN. 40-O-(2-Hydroxyethyl)-
rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats. Am 
J Resp Crit Care Med 2001; 163: 498–502. 
26. Tuder RM, Groves B, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and 
element of inflammation are present in plexiform lesions of pulmonary hypertension. Am J 
Pathol 1994; 144: 275–85. 
27. Pietra GG. The pathology of primary pulmonary hypertension. In: Rubin L, Rich S, eds. 
Primary pulmonary hypertension. New York, Marcel Dekker, 1997; pp. 19–61. 
28. Dorfmuller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial 
hypertension. Eur Respir J 2003; 22: 358–63. 
29. Voelkel NF, Tuder RM, Bridges J, Arend WP. Interleukin-1 receptor antagonist 
treatment reduces pulmonary hypertension generated in rats by monocrotaline. Am J 
Respir Cell Mol Biol 1994;11:664-75. 
30. Kimura H, Kasahara Y, Kurosu K, Sugito K, Takiguchi Y, Terai M, Mikata A, Natsume 
M, Mukaida N, Matsushima K, Kuriyama T. Alleviation of monocrotaline-induced pulmonary 
hypertension by antibodies to monocyte chemotactic and activating factor/monocyte 
chemoattractant protein-1. Lab Invest 1998;78:571-81. 
31. Loscalzo J. Endothelial dysfunction in pulmonary hypertension. N Engl J Med 1992; 
327: 117–9. 
32. Lopes AA, Maeda NY, Goncalves RC, Bydlowski SP. Endothelial cell dysfunction 
correlates differentially with survival in primary and secondary pulmonary hypertension. Am 
Heart J 2000; 139: 618–23. 
33. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs 
of patients with pulmonary hypertension. N Engl J Med 1995;333:214-21. 
34. Cornwell TL, Arnold E, Boerth NJ, Lincoln TM. Inhibition of smooth muscle cell growth 
by nitric oxide and activation of cAMP-dependent protein kinase by cGMP. Am J Physiol 
Cell Physiol 1994;267:C1405-C1413. 
35. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, 
Masaki T, Duguid WP, Stewart DJ. Expression of endothelin-1 in the lungs of patients with 
pulmonary hypertension. N Engl J Med 1993;328:1732-9. 
36. Kahaleh MB. Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. 
Enhanced production and profibrotic action. Arthritis Rheum 1991;34:978-83. 
 
                                                                                                           Chapter 6 
 143 
37. Jones PL, Cowan K, Rabinovitch M. Tenascin-C, proliferation and subendothelial 
accumulation of fibronectin in progressive pulmonary vascular disease. Am J Pathol 1997; 
150:1349-60. 
38. Jones PL, Rabinovitch M. Tenascin-C is induced with progressive pulmonary vascular 
disease in rats and is functionally related to increased smooth muscle cell proliferation. 
Circ Res 1996;79:1131-42. 
39. Frisdal E, Gest V, Vieillard-Baron A, Levame M, Lepetit H, Eddahibi S, Lafuma C, Harf 
A,  Adnot S, d'Ortho M. Gelatinase expression in pulmonary arteries during experimental 
pulmonary hypertension. Eur Respir J 2001;18:838–45. 
40. Archer S, Rich S. Primary pulmonary hypertension: a vascular biology and translational 
research "Work in progress". Circulation 2000;102:2781–91. 
41. Zhao YD, Courtman DW, Deng Y, Kugathasan L, Zhang Q, Stewart DJ. Rescue of 
monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived 
endothelial-like progenitor cells. Efficacy of combined cell and eNOS gene therapy in 
established disease. Circ Res 2005; 96: 442-50. 
42. Sahara M, Sata M, Morita T, Nakamura K, Hirata Y, Nagai R. Diverse contribution of 
bone marrow-derived cells to vascular remodeling associated with pulmonary arterial 
hypertension and arterial neointimal formation. Circulation 2007;115:509-17. 
43. Raoul W, Wagner-Ballon O, Saber G, Hulin A, Marcos E, Giraudier S, Vainchenker W, 
Adnot S, Eddahibi S, Maitre B. Effects of bone marrow-derived cells on monocrotaline- and 
hypoxia-induced pulmonary hypertension in mice. Resp Res 2007;8:8. 
44. Passier R, Mummery C. Origin and use of embryonic and adult stem cells in 
differentiation and tissue repair. Cardiovasc Res 2003; 58: 324-35. 
45. Nagaya N, Kangawa K, Kanda M, Uematsu M, Horio T, Fukuyama N, Hino J, Harada-
Shiba M, Okumura H, Tabata Y, Mochizuki N, Chiba Y, Nishioka K, Miyatake K, Asahara 
T, Hara H, Mori H. Hybrid cell-gene therapy for pulmonary hypertension based on 
phagocytosing action of endothelial progenitor cells. Circulation 2003;108:889-95. 
46. Campbell AIM, Zhao Y, Sandhu R, Stewart DJ. Cell-based gene transfer of vascular 
endothelial growth factor attenuates monocrotaline-induced pulmonary hypertension. 
Circulation 2001;104:2242-8. 
47. Campbell AIM, Kuliszewski MA, Stewart DJ. Cell-based gene transfer to the pulmonary 
vasculature. Endothelial nitric oxide synthase overexpression inhibits monocrotaline-
induced pulmonary hypertension. Am J Respir Cell Mol Biol 1999;21:567-75. 
                                                                                          







                                                                                       










Intravenous cell therapy with mesenchymal 
stem cells from donor rats with pulmonary 
hypertension reduces right ventricular 
pressure overload and reverses right 
ventricular hypertrophy in recipient rats with 




S. Umar  
P. Steendijk  
Y. P. de Visser  
G. T. M. Wagenaar 
C. I. Schutte 
W. H. Bax  
E. Mantikou 
D. A. Pijnappels 
D. E. Atsma 
M. J. Schalij 
E. E. Van der Wall 













Background: Pulmonary artery hypertension (PAH) is characterized by 
progressive increase in pulmonary artery pressure leading to right ventricular 
(RV) hypertrophy, RV failure and sudden cardiac death. Standard treatment is still 
inadequate for PAH. Stem cell therapy may constitute a new treatment modality 
for PAH patients.  
 
Purpose of the study: To test whether administration of bone marrow-derived 
mesenchymal stem cells (MSCs) obtained from donor rats with monocrotaline 
(MCT)-induced PAH to rats with MCT-induced PAH resulted in (i) decreased 
pulmonary artery pressure, (ii) reversal of RV hypertrophy (RVH), and (iii) 
improvement of RV function. 
 
Methods: At day 1, healthy female Wistar rats received PBS (group 1, n=10) or 
60 mg/kg subcutaneous MCT (groups 2-4, each n=10) to induce PAH. At day 14, 
group 1 (Control) and group 2 (untreated PAH) received intravenous injection of 
PBS, group 3 (MSC-treated PAH) received 106 MSCs (group 3), and group 4 (SF-
treated PAH) received 106 skin fibroblasts. MSCs were obtained from donor rats 
which received MCT (60 mg/kg) 28 days prior to bone-marrow harvesting. SFs 
were obtained from healthy rats. At day 28 the rats were instrumented to assess, 
RV function by combined pressure-conductance catheter. Subsequently, rats 
were sacrificed. RVH was quantified by weighing the RV free wall relative to the 
LV including the interventricular septum (IVS). Immunohistochemistry was 
performed to assess changes in the extracellular matrix of the RV. 
 
Results: Comparing group 2 vs 1 indicated that MCT induced PAH (42±17 vs. 
27±5 mmHg, p<0.05), RVH (RV/(IVS+LV) weight ratio of 0.47±0.12 vs. 0.25±0.04, 
p<0.001) and depressed LV ejection fraction (43±6% vs. 56±11%, p<0.005). MSC 
treatment (group 3) limited PAH (31±4 mmHg; p=0.08 vs. group 2), RVH 
(0.32±0.07; p<0.005 vs. group 2), and normalized RV ejection fraction (52±5%; 
p<0.005 vs. group 2). In group 4, treatment effects on RV pressure, RVH and RV 
function were less pronounced than in group 3. 
 
Conclusion: Treatment with intravenous administration of MSCs obtained from 
donor rats with PAH reduced pressure overload, hypertrophy and RV dysfunction 
in rats with MCT-induced PAH. These results suggest that patients with PAH may 
be treated successfully using autologous MSCs. 
 





Pulmonary arterial hypertension (PAH), which refers to a progressive increase in 
pulmonary artery pressure, is a chronic debilitating disease leading to right 
ventricular (RV) hypertrophy, RV failure and eventually to death [1]. PAH is 
characterized by a progressively severe symptomatology of dyspnea, fatigue, 
chest pain, syncope, and right heart failure. 
In a study on novel therapeutic options for patients with PAH, we have employed 
the monocrotaline (MCT)-induced rat model of PAH, a model which is widely used 
in experimental studies [2,3]. The consequences of two doses of MCT (30 and 80 
mg/kg) on RV function at 28 days after MCT administration were dose-dependent 
(i) RV hypertrophy, (ii) RV dilatation, and (iii) impairment of systolic function, 
without marked effects on RV diastolic function [4]. Earlier, we demonstrated that 
tenascin-C, an extracellular matrix protein that is absent in normal myocardium, is 
abundantly expressed in RV myocardium of rat hearts with MCT-induced PAH [5]. 
In the heart, extracellular matrix proteins are predominantly secreted by 
fibroblasts, whereas the matrix degrading enzymes are produced by many cell 
types, such as fibroblasts, cardiomyocytes and macrophages. In patients with 
severe heart failure myocardial expression of collagenases, like matrix 
metalloproteinase-1 (MMP1) mRNA, was increased [6], and decreased after 
implantation of a left ventricular assist device (LVAD) [7]. In analogy, in the failing 
heart supported by LVAD also other myocardial collagenases, such as cathepsin 
K, demonstrated decreased concentrations [8]. 
The model of MCT-induced PAH is extremely useful to test new drugs to treat 
PAH and to study their mechanisms of action [9]. Many treatment options for PAH 
have been tested so far, but an effective therapy is lacking. Cell therapy 
constitutes a novel therapeutic option for PAH patients. Several groups have 
tested various cell types to treat experimental PAH, including mesenchymal stem 
cells (MSCs). MSCs are unique in possessing (i) a potential to differentiate into 
other cell types, and (ii) an ability to secrete paracrine factors leading to 
improvements in tissue injury [10].  
Intravenous (i.v.) infusion of autologous endothelial progenitor cells (EPCs) to 
patients with idiopathic PAH was shown to be safe and to have beneficial effects 
on exercise capacity and pulmonary hemodynamics [11]. I.v. infusion of bone 
marrow-derived EPCs from Fisher-344 rats, cultured in endothelial growth 
medium for 7-10 days, to syngeneic rats 3 days after MCT administration nearly 
completely prevented the increase in RV systolic pressure. EPCs were recovered 
in the distal pulmonary arterioles and incorporated into the endothelial lining of the 
MCT-injured lung. Delayed i.v. injection of EPCs 3 weeks after MCT 
administration prevented the further progression of PAH in the following 2 weeks 
[12]. However, i.v. injection of unfractionated bone marrow-derived cells from 
donor rats to rats with MCT-induced PAH plus unilateral pneumonectomy had no 
beneficial effect on PAH, pulmonary arterial remodeling, and survival [13]. I.v. 
injection of rat bone marrow-derived mesenchymal stem cells (MSCs) to rats that 
had received MCT one week earlier caused lower peak pulmonary pressure and 
less RV hypertrophy [14]. Even if EPCs were injected into the lungs of dogs with 
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MCT-induced PAH, pulmonary artery pressure and pulmonary vascular 
resistance decreased and cardiac output increased [15].   
To develop a therapeutic strategy in which a patient with developed PAH will be 
treated by i.v. administration of autologous bone marrow-derived MSCs, we 
investigated whether rats with MCT-induced PAH are treated successfully after 
i.v. administration of bone marrow-derived MSCs isolated from rats with MCT-
induced PAH. As a reference cell type we chose skin fibroblasts (SFs) of healthy 
rats, used by Zhao et al. [12] to distinguish between stem cells and differentiated 
cells in terms of therapeutic effect of rats with PAH.  
To analyse the effects of MCT-induced PAH and cell therapy in this model, we 
measured (i) RV pressures, (ii) RV volumes and RV ejection fraction, (iii) RV 
hypertrophy, (iv) expression of genes associated with myocardial hypertrophy, 
such as β-myosin heavy chain, pro-atrial natriuretic peptide and pro-B-type 
natriuretic peptide, (v) RV myocardial expression of tenascin-C and collagens I 
and III, and (vi) RV myocardial concentrations of collagenolytic enzymes, such as 
matrix metalloproteinase-1 (MMP1), cathepsin K and cathepsin S, in normal rat 




Materials and Methods 
 
Animal model 
All animals were treated in accordance with the national guidelines and with 
permission of the Animal Experiments Committee of the Leiden University 
Medical Center. Healthy, adult, female Wistar rats (200-250 g body weight; 
Harlan, Zeist, the Netherlands) were randomly assigned to four experimental 
groups. At day 1, group 1 received subcutaneous (s.c.) PBS (Control, n=10), the 
other groups received a single s.c. injection of MCT (Sigma-Aldrich, Zwijndrecht, 
the Netherlands; 60 mg/kg, n=10 each group). At day 14, group 1 and 2 received 
1 ml PBS intravenously (i.v.), rats from group 3 were treated by i.v. administration 
of 106 MSCs, whereas rats from group 4 received 106 skin fibroblasts (SFs). The 
animals were housed, two animals per cage, with a 12h/12h light/dark cycle and 
an unrestricted food supply. The rats were weighed three times per week.  
 
Mesenchymal stem cell isolation and culture 
To obtain MSCs, donor rats were injected s.c. with MCT (60 mg/kg, n=5) and 
anaesthetized with isoflurane and killed by i.v. injection of KCl (100 mmol/L) after 
28 days. Femurs and tibiae were removed and cleaned of all connective tissue 
and attached muscle. The proximal ends were clipped and bones placed in 
microfuge tubes supported by plastic inserts cut from pipette tips. Microfuge tubes 
were briefly centrifugated at 13,000 rpm for 1 min. The marrow pellets were 
resuspended in 10 mL of growth medium [Dulbecco Minimal Essential Medium 
(DMEM) supplemented with 15% fetal bovine serum (FBS; Invitrogen, Breda, the 
Netherlands), penicillin (50 U/L), streptomycin (50 g/L), and amphothericin B 
solution (0.25 μg/mL, Sigma-Aldrich)] supplemented with 6% heparin (400 IE/ml). 
This suspension was centrifuged again at 1000 rpm for 10 min. Next, the pellet 
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was resuspended in 7 mL of growth medium supplemented with 5.75 µg/mL 
DNase I (Sigma-Aldrich). The cells were plated in a 25-cm2 culture flasks (Becton 
Dickinson, Franklin Lakes, NJ, USA) and the culture was kept in a humidified 
hypoxic incubator CO2/O2 (5%/5%) at 37°C. The non-adherent cells were replated 
after 6 h. Two days later, non-adherent cells were removed by changing the 
medium to 12 mL of fresh growth medium. The medium was refreshed twice a 
week until the primary cultures were confluent. Previously it was reported that 
MSCs cultured in 2%-5% O2 have increased proliferation rate and upregulated 
VEGF expression compared to MSCs cultured in ambient air, while maintaining 
their multi-lineage potential [16-20]. As far as differentiation capacity of MSCs is 
concerned, hypoxia was shown to have positive [16] as well as negative effects 
on osteogenic differentiation [19,21-23]. 
Before injection, the cells were trypsinized and labelled with the viable fluorescent 
dye CM-DiI according to the manufacturer’s recommendations (CellTrackerTM, 
Molecular Probes, Invitrogen). 
In vitro assays of MSCs 
MSCs from MCT-treated rats and healthy rats, grown in hypoxic or normoxic 
incubator were tested for (i) proliferation rate, (ii) membrane protein repertoire by 
FACS, (iii) production and secretion of VEGF, and (iv) capacity of adipogenic and 
osteogenic differentiation. In addition, it was tested what effects the major 
metabolite of MCT, dehydromonocrotaline (dhMCT), has on proliferation and 
VEGF production/secretion by MSCs, by incubation of MCSs with dhMCT in vitro. 
 
Proliferation rate of MSCs 
MSCs isolated from bone marrow of healthy rats and bone marrow of rats with 
MCT-induced PAH were grown at 5% oxygen and at 20% oxygen in 96-well 
plates. At two moments in time, spaced 4 days, media were poured off, and cells 
were analysed with the XTT assay (Roche, Almere, the Netherlands). The assay 
is based on the cleavage of the tetrazolium salt XTT in the presence of an 
electron-coupling reagent, producing a soluble formazan salt. This conversion 
only occurs in viable cells. The measured absorbance directly correlates to the 
cell number.   
 
Flow cytometry of MSCs 
MSCs isolated from bone marrow of healthy rats and bone marrow of rats with 
MCT-induced PAH were grown in 5% oxygen and 20% oxygen incubators, and 
analysed for surface marker expression by flow cytometry. The MSCs were 
detached using trypsin/EDTA (Bio-Whittaker Europe, Verviers, Belgium) and 
resuspended in PBS containing 0.5% bovine serum albumine (Sigma-Aldrich), 
and divided in aliquots of 5x104 cells. Cells were then incubated for 30 min at 4C 
with fluorescein isothiocyanate (FITC)- or phycoerythrin (PE)-conjugated 
antibodies against rat CD34, CD29, CD44, CD45, CD106 (all from Becton 
Dickinson) and CD90 (Serotec, Kidlington, Oxford, UK). Labeled cells were 
washed and analyzed using a FACSort flow cytometer (BD Pharmingen, San 
Jose, CA, USA), equipped with a 488-nm argon ion laser and a 635-nm red diode 
laser. Isotype-matched control antibodies (BD Pharmingen) were used to 
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determine background fluorescence. At least 5000 cells per sample were 
acquired and data were processed using CellQuest software (BD Pharmingen). 
Generally, MSCs are found to be positive for CD29, CD44, CD90 CD105 and 
CD106, and negative for CD34 and CD45 (unpublished observations). 
  
Production and secretion of VEGF by MSCs 
MSCs isolated from bone marrow of healthy rats and bone marrow of rats with 
MCT-induced PAH were grown at 5% oxygen in 96-well plates. At two moments 
in time, spaced 4 days, media were poured off, and cells were analysed for 
protein content using the bicinchonic acid (BCA) protein assay (Pierce, Etten-
Leur, the Netherlands). The media were assayed for VEGF using a rat VEGF 
assay kit (rat base kit supplied with rat VEGF microparticle concentrate, R&D 
Systems Europe, Abingdon, UK). VEGF concentrations in the media were 
expressed as ng per mg of cellular protein.  
 
Adipogenic and osteogenic differentiation of MSCs    
MSCs isolated from bone marrow of healthy rats and bone marrow of rats with 
MCT-induced PAH grown in a 5% oxygen incubator were characterized using 
established differentiation assays [24]. Briefly, 5000 MSCs per well were plated in 
a 12-well culture plate, and exposed to adipogenic or osteogenic induction 
medium. Adipogenic differentiation medium consisted of a regular culture medium 
(DMEM supplemented with 15% FBS, 100 U/L penicillin and 100 µg/mL 
streptomycin, 1 µg/mL amphothericin B solution) supplemented with 5 µg/mL 
insulin, 1 µmol/L dexamethason, 50 µmol/L indomethacin and 0.5 µmol/L 3-
isobutyl-1-methylxanthine (IBMX) (all from Sigma-Aldrich), and was refreshed 
every 3-4 days for a period of 3 weeks. Lipid accumulation was assessed by Oil 
Red O staining of the cultures (15 mg Oil Red O/mL of 60% isopropanol) and light 
microscopy. Osteogenic differentiation medium consisted of culture medium 
supplemented with 10 mmol/L -glycerophosphate, 50 µg/mL ascorbic acid and 
10 nmol/L dexamethason (all from Sigma-Aldrich), and was refreshed every 3-4 
days for a period of 2 weeks. Afterwards, the cells were washed with phosphate-
buffered saline (PBS), and calcium deposits were visualized by staining of the 
cells for 2-5 min with 2% Alizarine Red S in 0.5% NH4OH (pH 5.5). 
 
Effects of dehydroMCT on MSCs in vitro  
Dehydromonocrotaline (dehydroMCT) was prepared from MCT by chemical 
oxidation using o-chloranil according to Mattocks et al. [25]. Mass spectrometric 
analyses have shown that 25-30% of the input MCT was converted to 
dehydroMCT by this method [26]. Proliferation of MSCs from healthy rats in the 
absence and presence of 50 μmol/L dehydroMCT was determined by XTT assay 
(Roche) over a 4-day interval. 
                   
Skin fibroblasts   
Skin fibroblasts (SFs) were grown from pieces of skin of healthy rats anesthetized 
by CO2 and killed by i.v. injection of KCl (100 mmol/L). Skin samples were 
transferred to porcine gelatin (Sigma-Aldrich)-coated flasks, and cultured in 
DMEM containing 100 U/mL penicillin, 100 μg/mL streptomycin, and 10% FBS (all 
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from Invitrogen) in a normoxic incubator (20% O2 and 5% CO2) at 37°C. 
Outgrowth of cells was visible 2 days after culture initiation. Three days later the 
skin pieces were removed and the skin fibroblasts were detached with trypsin-
EDTA solution (Invitrogen), and reseeded in new culture flasks.  
For intravenous infusion into rats which had had MCT administration 14 days 
earlier, we used passage 4-6. Prior to injection into the jugular vein, the SFs were 
labeled with a DiI derivative according to the recommendations of the supplier 
(CellTracker CM-DiI, Molecular Probes, Invitrogen). Per rat, 106 SFs in 0.5 mL of 
PBS were injected in the jugular vein.  
 
Cell injection 
At day 14, the rats were anaesthetized with isoflurane, the left jugular vein was 
cannulated (20G, Biovalve, Vygon, Ecouen, France), and 1 mL of cell suspension 
(106 cells/mL) or an equal amount of PBS (control animals) was injected slowly in 
approximately 30 s. The cell suspensions contained either MSCs from rats with 
MCT-induced PAH or SFs from healthy rats. Next, the canula was removed, the 




RV function was measured as published previously [4]. Briefly, the rats were 
sedated by inhalation of a mixture of isoflurane (4%) and oxygen. Subsequently, 
general anesthesia was induced by intraperitoneal (i.p.) injection of a fentanyl—
fluanison–midazolam mixture in a dose of 0.25 mL/100 g body weight. The 
mixture consisted of two parts Hypnorm (0.315 mg/mL fentanyl+10 mg/mL 
fluanison; Vital-Pharma, Maarheeze, the Netherlands): one part Dormicum (5 
mg/mL midazolam; Roche, Mijdrecht, the Netherlands) and one part saline. The 
animals were placed on a controlled warming pad to keep body temperature 
constant. A tracheotomy was performed, a cannula (18G, Biovalve) was inserted, 
and the animals were mechanically ventilated using a pressure-controlled 
respirator and a mixture of air and oxygen. The animals were placed under a 
stereomicroscope (Zeiss, Hamburg, Germany), and the left jugular vein was 
cannulated for infusion of hypertonic saline (10%) to determine parallel 
conductance. A midsternal thoracotomy was performed, and a combined 
pressure-conductance catheter (model FT212, SciSense, London, Ontario, 
Canada) was introduced via the apex into the RV and positioned towards the 
pulmonary valve. The catheter was connected to a signal processor (FV898 
Control Box, SciSense) and RV pressures and volumes were recorded digitally. 
All data were acquired at a sample rate of 2,000 Hz and analyzed off-line by 
dedicated software. The slope factor α was calculated as the cardiac output 
determined by the uncalibrated conductance catheter divided by the cardiac 
output determined by LV echocardiography (VisualSonics, Toronto, Ontario, 
Canada). 
 
Hemodynamics   
Heart rate, stroke volume, cardiac output, RV end-diastolic volume, RV end-
systolic volume, RV ejection fraction, RV end-diastolic pressure, RV end-systolic 
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pressure, and RV peak-systolic pressure were determined from steady state 
pressure-volume loops. In addition, stroke work (SW) was obtained as the area of 
the pressure-volume loop, and the maximal rates of RV pressure upstroke and fall 
(dP/dtmax and dP/dtmin, respectively) were calculated. The relaxation time constant 
(τ) was assessed as the time constant of monoexponential decay of RV pressure 
during isovolumic relaxation [27].  Effective pulmonary arterial elastance (Ea), as a 
measure of RV afterload, was calculated as RV end-systolic pressure divided by 
RV stroke volume. 
RV end-systolic and end-diastolic pressure-volume relations (ESPVR and 
EDPVR) and the preload recruitable stroke work relation (PRSW: RV-stroke work 
vs. RV end-diastolic volume) were determined from pressure-volume loops 
recorded during transient preload reduction by occlusion of the inferior vena cava. 
End-systolic elastance Ees, the linear slope of the ESPVR, and Mw , the slope of 
the PRSW, are load-independent measures of systolic ventricular function. 
Diastolic stiffness was determined as the slope of the EDPVR, Eed [28]. 
 
Tissue preparations 
After hemodynamic measurements heart and lungs were taken out. From each 
heart the ventricles were isolated, the RV was cut free, and the remainder was 
split into the intraventricular septum (IVS) and the left ventricle (LV). These three 
parts of ventricular tissue were weighed, and each was split in three parts for 
individual storage (i) at -80oC for RNA isolation, (ii) at -80oC to prepare 
homogenates, and (iii) in formaline (4%) to perform histochemical analysis.  
 
Assessment of RV hypertrophy 
As an indicator of right ventricular hypertrophy the weight ratio of RV/(LV + IVS) 
was calculated. Independently, we determined the length and width of 25-50 
cardiomyocytes per group (control, MCT60, MCT+MSC and MCT+SF) isolated 




Total RNA was isolated from heart tissue homogenates using guanidium-phenol-
chloroform extraction and isopropanol precipitation (RNA-Bee, Tel-Test Inc., Bio-
Connect BV, Huissen, the Netherlands). The RNA sample was dissolved in 
RNase-free water and quantified spectrophotometrically. The integrity of the RNA 
was studied by gel electrophoresis on a 1% agarose gel, containing ethidium 
bromide. Samples did not show degradation of ribosomal RNA by visual 
inspection under ultraviolet light. First-strand cDNA synthesis was performed with 
the SuperScript Choice System (Life Technologies, Breda, the Netherlands) by 
mixing 2 µg total RNA with 0.5 µg of oligo(dT)12-18 primer in a total volume of 12 
µL. After the mixture was heated at 70°C for 10 min, a solution containing 50 
mmol/L Tris·HCl (pH 8.3), 75 mmol/L KCl, 3 mmol/L MgCl2, 10 mmol/L DTT, 0.5 
mmol/L dNTPs, 0.5 µL RNase inhibitor, and 200 U Superscript Reverse 
Transcriptase was added, resulting in a total volume of 20.5 µL. This mixture was 
incubated at 42°C for 1 h; total volume was adjusted to 100 µL with RNase-free 
water and stored at –80°C until further use. For real-time quantitative PCR, 1 µL 
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of first-strand cDNA diluted 1:10 in RNase-free water was used in a total volume 
of 25 µL, containing 12.5 µL 2x SYBR Green PCR Master Mix (Applied 
Biosystems, Foster City, CA, USA) and 200 ng of each primer.  
Primers, designed with the Primer Express software package (Applied 
Biosystems), were:  
Primers (orientation: 5’-3’) 
 
            Forward    reverse 
 
proANP       CCAGGCCATATTGGAGCAAA            AGGTTCTTGAAATCCATCAGATCTG 
proBNP       GAAGCTGCTGGAGCTGATAAGAG    TGTAGGGCCTTGGTCCTTTG 
α-MHC       CTTCAAGCTCAAGAATGCCTATGA    TGCACATTTTTACCCCCTTCTC 
β-MHC       AGGCCCAGAAACAAGTGAAGAG       GGCACGGACTGCGTCATC 
β-actin       GGCTCCTAGCACCATGAAGATC        GAGCCACCAATCCACACAGA 
 
PCR reactions, consisting of 95°C for 10 min (1 cycle), 94°C for 15 s, and 60°C 
for 1 min (40 cycles), were performed on an ABI Prism 7900 HT Fast Real Time 
PCR system (Applied Biosystems). Data were analyzed with the ABI Prism 7900 
sequence detection system software (version 2.2) and quantified with the 
comparative threshold cycle method with -actin as a housekeeping gene 
reference [29].  
 
(Immuno)histochemistry 
After fixation, heart tissue samples were embedded in paraffin. Blocks were 
embedded in upright position to distinguish the endocardium, the midwall, and the 
epicardium of the RV and LV free wall in cross-sections. Tissue was cut into 4-m 
thick sections and dried for at least 24 h at 37°C. After 10 min incubation at 60°C, 
sections were deparafinized in Ultraclear (Klinipath, Duiven, the Netherlands) for 
5 min and rehydrated in decreasing graded alcohols (100-25%) followed by two 5-
min washes in distilled water and TBS (150 mmol/L NaCl, 10 mmol/L Tris-HCl, pH 
8.0).  
To study the distribution of myocardial collagen I, collagen III, and tenascin-C, 
sections were exposed to immunohistochemistry. Inhibition of endogenous 
peroxidase activity was obtained by 20 min incubation in 0.3% hydrogen peroxide 
in PBS. The sections were incubated in citrate buffer at 97°C for 10 min, to 
retrieve antigens and subsequently washed in PBS, 5 times for 3 min, and in 
PBS-Tween for 2 times. Sections were incubated for 3h at room temperature with 
(i) rabbit anti-collagen I antibody (1:200; ab24133, Abcam, Cambridge, UK), (ii) 
rabbit anti-collagen III antibody (1:200; ab7778, Abcam), and (iii) rabbit anti-
tenascin-C antibody (1:200; sc20932, Santa Cruz Biotechnology, Santa Cruz, CA, 
USA), followed by goat anti-rabbit IgG conjugated to HRP (1:200, sc3837, Santa 
Cruz Biotechnology). After series of three washes in PBS and once in PBS-
Tween, 1% BSA, and 0.05% Tween, the slides were developed with 
diaminobenzidine (DAB) solution (Pierce, Perbio Science, Etten-leur, the 
Netherlands). Nuclei were counterstained using hematoxylin for 2 min, followed 
by dehydration with graded alcohols and clearance in xylene. Finally, the sections 
were mounted with D.P.X. (BDH, VWR International, Lutterworth, Leicestershire, 
UK), covered with glass cover slips, and examined in a light microscope (Nikon 
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Eclipse, Nikon Europe, Badhoevedorp, the Netherlands) equipped with a digital 
camera (Nikon DXM 1800). Images were analyzed using Image-Pro Plus 
software (Media Cybernetics, Silver Spring, MD, USA). Per section, at least 16 
images were acquired and analyzed to compensate for variations within a section.  
 
Western blotting 
Myocardial samples for biochemical analysis were freeze-dried, and 
homogenized in homogenising buffer (0.1 M Tris-HCl and 0.1% (v/v) Tween-20, 
pH 7.5), using a Potter tube (Kimble/Kontes, Vineland, NJ, USA). Homogenates 
(1 %, w/v) were stored in aliquots at -80°C. Protein concentrations were 
determined by bicinchoninic acid protein (BCA) assay (Pierce, Etten-Leur, the 
Netherlands). 
For western blot analysis the heart homogenate were separated on a 12% Bis-
Tris NuPage gel (Invitrogen) and blotted on a PVDF membrane (GE Healthcare, 
Diegem, Belgium).  Non-specific binding sites were blocked by incubating the 
membranes in a blocking solution 20 g/L ECL Advance Blocking Agent (GE 
Healthcare) in TBS-Tween (10 mmol/L Tris-HCl, pH 8.0, 150 mmol/L NaCl, 0.05% 
Tween) for 1 h on an orbital shaker. Subsequently, membranes were incubated 
with (i) rabbit anti-MMP1 antibody conjugated to HRP (1:20,000, ab53142, 
Abcam), (ii) goat anti-cathepsin S antibody (1:20,000, sc6503, Santa Cruz 
Biotechnology) followed by donkey anti-goat IgG conjugated to HRP (1:10,000, 
sc2020, Santa Cruz Biotechnology), and (iii) rabbit anti-cathepsin K antibody 
(1:20,000, #3588-100, BioVision, Mountain View, CA, USA) followed by goat anti-
rabbit IgG conjugated to HRP (1:10,000, sc3837, Santa Cruz Biotechnology). 
Subsequently, the membranes were washed four times in TBS-Tween, and 
incubated with a chemiluminescent reagent (ECL Advance kit, GE Healthcare) for 
5 min. Light emission was detected by exposure to Hyperfilm ECL (GE 
Healthcare). The Western blot band intensities were quantified by the Molecular 
Imager ChemiDoc XRS system (Bio-Rad, Veenendaal, the Netherlands).  
 
Cardiomyocyte isolation 
A separate series of 20 rats were given the same experimental treatments (n=5 
per group) as mentioned earlier. At day 28, the rats were anaesthetised and the 
thorax was opened. The heart was taken out quickly and immediately put into ice-
cold, oxygenated Tyrode solution. The aorta was connected to the cannula of a 
Langendorff perfusion set-up (AD Instruments, Spechbach, Germany). The heart 
was perfused for 5 min with an oxygenated Tyrode solution at constant pressure 
(70 mmHg) at 37º C and resumed beating. The perfusion fluid was replaced by an 
oxygenated, low Ca2+ perfusion fluid. Contractions disappeared within 30 s. After 
5 min of low calcium perfusion, the perfusion was continued in a recirculating 
manner at a perfusion pressure of ~60 mm Hg. At that time collagenase (0.06%, 
Worthington, Lakewood, NJ, USA) was added. Thirty min later, the flow rate was 
too high to maintain a perfusion pressure of 60 mm Hg. Then, the heart was 
removed, and the RV was separated from the LV (including IVS) using a scalpel. 
RV and LV were cut in small pieces, incubated in a fresh collagenase (0.06%) 
solution, and dissociated in a waterbath shaker at 37ºC. Thereafter, sedimented 
cardiomyocytes were resuspended and stored at 37ºC in fresh HEPES-buffered 
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salt solution containing (in mmol/L) NaCl 125, KCl 5, MgSO4 1, KH2PO4 1, CaCl2 
1.8, NaHCO3 10, HEPES 20, glucose 5.5, pH 7.4. The average fraction of rod-
shaped cardiomyocytes was 80%. The percentage of rod-shaped cardiomyocytes 
decreased by about 10% during 6 h at 37º C. Per heart, roughly 50 intact, non-
contracting, rod-shaped cardiomyocytes from RV as well as LV were 




To assess the effect of treatment (cell therapy with MSCs, cell therapy with SFs 
vs. treatment by PBS) differences between groups were evaluated by one-way 
ANOVA followed by Bonferroni’s post-hoc test (SPSS12 for Windows, SPSS Inc., 
Chicago, IL, USA). Differences were considered significant at p<0.05. Values are 
represented by means  SD, unless stated otherwise. 
 





Proliferation rate of MSCs 
MSCs from healthy rats proliferated roughly 2 times more rapidly than MSCs from 
MCT-treated rats if grown at 5% oxygen (p=0.028) but if grown at 21% oxygen 
this difference was absent (p=0.576). The use of an incubator with 5% oxygen 
was associated with higher proliferation rates of MSCs than in case using 21% 
oxygen, whether they originated from healthy rats or MCT-treated rats (≈3-fold, 
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Figure 1. Top left panel. Proliferation of MSCs in 4-day intervals. MSCs from healthy rats and 
MSCs from rats with MCT-induced PAH were grown in an incubator with 5% oxygen, 5% CO2 
and 90% nitrogen (5% O2) or in an incubator with 5% CO2 and air (21% O2).  If grown in 5% 
oxygen, MSCs from healthy rats proliferated ≈2 times more rapidly than MSCs from rats with 
MCT-induced PAH (p=0.028), but if grown in 21% oxygen, proliferation rate did not differ 
between the two groups of MSCs (p=0.576).  
Top right panel. Surface marker profile of MSCs from bone marrow of healthy rats and of 
MSCs from bone marrow of rats with MCT-induced PAH. Both types of MSCs were cultured in a 
5% O2/5% CO2 incubator.  
Bottom panel. VEGF concentration in the culture medium of MSCs isolated from healthy rats 
(healthy MSC) and isolated from rats with MCT-induced PAH. The stem cells were grown for 4 
days in culture medium. After that time medium and cells were split, medium was analyzed for 
VEGF concentration, and cells were analyzed for protein content. Medium VEGF concentration 
is expressed as pg of VEGF in the medium per mg of cellular protein.    
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FACS analysis of MSCs 
Comparison of FACS data obtained from MSCs isolated from rats with MCT-
induced PAH with those obtained from MSCs from healthy rats, revealed minor 
differences in the repertoire of surface markers (Figure 1, top right). Both types of 
MSCs were cultured in a 5% O2/5% CO2 incubator.  
 
VEGF production and secretion from MSCs 
MSCs from healthy rats and MSCs of rats with MCT-induced PAH were grown in 
an 5% O2/5% CO2 incubator in 96-well plates for 4 days. At t=0 and t=4 days 
media were analysed for VEGF concentration, and cells were analysed for protein 
content. MSCs from rats with MCT-induced PAH had 2-fold higher VEGF 
secretion than MSCs from healthy rats (p<0.02) (Figure 1, bottom panel). Addition 
of 50 μmol/L of dehydroMCT, the toxic metabolite of MCT, slightly depressed 
VEGF secretion from both types of MSCs, but these decreases were not 
significant.  
 
Differentiation potential of MSCs  
MSCs from healthy rats and from rats with MCT-induced PAH, grown in a 5% 
O2/5% CO2 incubator, were investigated for adipogenic and osteogenic 
differentiation capacity. Adipogenic and osteogenic differentiation capacities, 
present in MSCs obtained from healthy rats, were well preserved in MSCs 






















Figure 2. Differentiation into adipogenic phenotype  (upper panels) and osteogenic 
phenotype (bottom panels) of MSCs isolated from healthy rats (left panels) and 
isolated from rats with MCT-induced PAH (right panels). 
MSCs from healthy rats           MSCs from MCT-treated rats
osteogenic differentiation assay
adipogenic differentiation assay




The rats were weighed 3 times per week. The net body weight gain of rats with 
MCT-induced PAH in 4 weeks was less than that of control rats (18.1±6.9 g vs. 
28.1±8.2 g, p<0.05). The body weight gain in the MCT+MSC group was 20.6± 8.2 
g, which was not significantly different from the MCT60 group, nor from the 
control group. The body weight gain in the MCT+SFB group was 17.9±8.1 g (n.s. 





















RV peak systolic pressure 
At the end of the experimental period, RV peak systolic pressures were 
significantly higher in MCT group than in the control group, indicating the 
development of PAH (41.5±16.9 vs. 27.2±4.9 mmHg in control; p<0.05). If MCT-
treated rats had been given cell therapy with MSCs, mean RV peak systolic 
pressure was attenuated (30.7±4.4 mmHg) although not significantly (p=0.08 vs. 
MCT60; n.s. vs. control).  If MCT-treated rats had been given cell therapy with 
SFBs, mean RV peak systolic pressure was 32.1±5.7 mmHg (n.s. vs. MCT60; n.s. 
vs. control) (Figure 4a).  
 
 
RV function  
Consistent with previous studies, MCT induced PAH and changes in RV volumes 
and ejection fraction. The hemodynamic effects are evident from the significant 
differences between the Control group and the MCT60 group: RV ejection fraction 
decreased, whereas RV peak pressure, RV end-systolic volume and RV end-



























Figure 3. Increase in body weight in 4 weeks of the 4 
groups of rats (control, MCT60, MCT+MSC and 
MCT+SFBs). Indicated are mean values ± SD.  
(* p<0.05 vs. Control, # p<0.05 vs. MCT60). 




Table 2. Hemodynamic data of the rats that have been treated without or with MCT, and 
with and without additional cell therapy using MSCs or SFs. Data is collected at 28 days 
after MCT (or control) treatment.  
 
  Control MCT60 MCT+MSC MCT+SF 
Right 
Ventricle 
     
Heart rate HR (bpm) 330±26 341±36 327±26 348±26 
Stroke 
volume 
SV (µL) 228±50 234±64 287±37 259±29 
Cardiac 
output 
CO (mL/min) 74±13 79±20 93±10* 90±9 
Ejection 
fraction 
EF (%) 56.2±11.2 42.8±6.2* 52.1±5.2 49.1±11.1 
End-systolic 
volume 




EDV (µL) 427±150 556±183 557±99 554±143 
End-systolic 
pressure 









27.2±4.9 41.5±16.9* 30.7±4.4 32.1±5.7 
dP/dt max dPdtMax 
(mmHg/s) 





1334±385 1912±860 1675±493 1551±252 
Stroke work SW 
(mmHg.µL) 



























21±7 25±15 19±5 23±7 
 
* p-value < 0.05 vs. Cont 
# p-value < 0.05 vs. MCT60 
 
 
The animals that received MCT and were subsequently treated with MSCs 
showed much less pronounced differences in pressure and volume compared to 
the Control group. This indicates that MSC treatment substantially modified the 
effects of MCT. Compared to the MCT60 group, the MCT+MSC group showed 
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higher RV ejection fraction (Fig. 4b), higher stroke volume, and lower RV end-
diastolic pressure, although these changes did not reach statistical significance. 
The MCT-induced changes in RV end-systolic and end-diastolic volumes, 
































Right ventricular hypertrophy 
As a measure of RV hypertrophy we calculated the weight ratio of RV/ (LV+IVS). 
At 28 days after MCT, rats had developed RV hypertrophy with a RV/ (IVS+LV) 
weight ratio of 0.47±0.12 vs. 0.25±0.04 in control rats (p<0.001). In PAH rats 
treated with MSCs, RV/ (IVS+LV) weight ratio was near normal (0.32±0.07; 
p<0.005 vs. MCT60; n.s. vs. control). In PAH rats treated with SFBs, RV/ 



























































































Figure 4a. RV peak systolic pressures, b. Ejection fraction (EF), c. RV 
end-systolic volumes (RVESV), and d. RV end-diastolic volumes (RVEDV) 
of the 4 groups of rats (control, MCT60, MCT+MSC and MCT+SFB). 






















Length and width of isolated RV cardiomyocytes were increased in rats that had 
received MCT compared to PBS-treated rats (Table 1).  Although in control hearts 
RV cardiomyocyte dimensions are smaller than those of LV cardiomyocytes 
(significant difference for cardiomyocyte width only), in MCT-treated rats RV 
cardiomyocyte dimensions are larger than those of LV cardiomyocytes (significant 
differences for both width and length). Cell therapy with MSC reduces RV 
cardiomyocyte dimensions to levels that do not differ from dimensions of LV 
cardiomyocytes. Surprisingly, also the hearts of rats that had cell therapy with 
SFs showed equal dimensions of RV and LV cardiomyocytes (Table 1).    
Table 1. Dimensions of cardiomyocytes isolated from hearts of rats treated without or with 





LV cardiomyocytes   
mean±SD (n) 
 
P RV vs LV  
Cardiomyocyte length (μm) 
Control    99±19 (200)    102±20 (166) 0.087 
MCT60 108±24 (221) * 100±18 (209) <0.001 
MCT+MSC 103±19 (201)  103±19 (232) 0.999 
MCT+SFB 102±21 (204) # 103±18 (176) 0.618 
    
Cardiomyocyte width (μm) 
Control 16.8±3.0 (200)   17.7±3.1 (166) 0.005 
MCT60 18.2±3.0 (221)  * 17.5±3.1 (209) 0.017 
MCT+MSC 17.3±3.2 (201)  # 17.8±3.2 (232) 0.106 
MCT+SFB 16.9±3.2 (204)  # 17.4±2.8 (176) 0.083 
    
 
*  p<0.05 vs. Control 
#  p<0.05 vs. MCT60 
Figure 5. RV/ (LV+IVS) weight ratio of the hearts 
of the 4 group of rats (Control, MCT60, 
MCT+MSC, and MCT+SF). Indicated are mean 
values ± SD. 
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mRNA in RV myocardium 
RV myocardial concentrations of mRNAs encoding ANP and BNP were increased 
in rats with MCT-induced PAH compared to control rats, although not significantly 
(Figure 6). In RV myocardium of MCT-treated rats, mRNA of αMHC increased 
and mRNA of βMHC decreased, although not significantly, compared to PBS-






































Figure 6  
Right ventricular concentrations of mRNA encoding α- and β-myosin heavy 
chain (αMHC and βMHC, respectively), pro-atrial natriuretic peptide (ANP), and 
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Extracellular matrix proteins 
In normal RV and LV myocardium tenascin-C concentrations are very low (figure 
7). However, in RV myocardium of rats of the MCT60 group tenascin-C 
concentration is increased considerably (p<0.005 vs. control), whereas in the 
corresponding LV myocardium the tenascin-C concentrations remained low. In 
RV myocardium of rats from the MCT+MSC group the tenascin-C is as low as the 
tenascin-C concentration in the accompanying LV myocardium, which levels are 
not significantly different from corresponding values in control myocardium (Table 
3). Myocardial collagen I and III concentrations were increased in RV myocardium 
of the MCT60 group, compared to the LV myocardium of the same hearts. Upon 
therapy with MSCs RV myocardial concentrations of collagen I and III remained 
elevated (both n.s. vs. MCT60), although comparison between RV and LV was 




Table 3. Myocardial concentrations of extracellular matrix proteins in RV and LV of rats 
that have been treated without or with MCT, and without or with additional therapy using 
MSCs 
 




      
Collagen I (pixels protein/total pixels) 




0.078 ± 0.015 n.s. n.s. 




0.034 ± 0.004 n.s. n.s. 
PRV vs. LV n.s. 0.003 0.006   
Collagen III (pixels protein/total pixels) 




0.124 ± 0.026 0.006 n.s. 




0.095 ± 0.007 n.s. n.s. 
PRV vs. LV n.s. <0.001 n.s.   
Tenascin-C (arbitrary units) 
RV 4475 ± 950 20138 ± 
2469 
6029 ± 875 <0.001 <0.001 
LV 4540 ± 696 5877 ± 859 5221 ± 752   
PRV vs. LV n.s. <0.001 n.s.   
      



































Concentrations of tenascin-C in RV and LV myocardium of three groups of rats (Control, MCT60, and 
MCT+MSC) (lower panel). Upper panels present immunohistochemical images of myocardial tenascin-
C in RV myocardium of control, MCT60 and MCT+MSC rats. Indicated are mean values ± SEM of 16-64 
analyzed images. 
* p<0.005 vs. RV of the same group.  




To answer the question whether RV failure is associated with increased 
myocardial collagenase activity that would allow RV dilatation, we analyzed 
myocardial concentrations of MMP1, cathepsin S and cathepsin K in RV 
myocardium of three groups of rats (control, MCT60, and MCT+MSC). These 
enzymes demonstrated no significant changes in RV myocardium between the 
groups (Table 4). In the MCT60 group myocardial concentrations in RV and LV 
did not differ significantly. 
 
 
Table 4. Myocardial concentrations of three collagenolytic enzymes, matrix 
metalloproteinase-1 (MMP1), cathepsin S and cathepsin K in RV and LV of rats that have 
been treated without or with MCT, and without or with additional therapy using MSCs. 
  





      
MMP1 (pixels protein/total pixels) 
RV 1.005±0.085(4) 1.122±0.141(4) 1.121±0.192(8) n.s. n.s. 
LV 1.098±0.185(4) 1.200±0.230(4) 1.061±0.282(8) n.s. n.s. 
PRV vs. 
LV 
n.s. n.s. n.s.   
      
Cathepsin S (pixels protein/total pixels)        
RV 0.924±0.344(5) 0.812±0.157(4) 0.717±0.222(8) n.s. n.s. 
      
Cathepsin K (pixels protein/total pixels)      
RV 1.082±0.477(4) 1.430±0.676(3) 1.340±0.571(6) n.s. n.s. 
      





In this study we showed that i.v. administration of MSCs from donor rats with PAH 
to acceptor rats with MCT-induced PAH decreases RV peak systolic pressure, 
improves RV function, and prevents RV hypertrophy, at least to a great extent.  
Pulmonary hypertension often occurs as a consequence of an isolated pulmonary 
arteriolar vasculopathy, and then is called pulmonary artery hypertension (PAH) 
[1]. Increased pulmonary vascular resistance imposes an overload to the RV, 
ultimately leading to RV failure. Although the distribution of ventilation/perfusion 
relationships in PAH patients is close to normal, arterial pO2 is usually low, as is 
the venous oxygen saturation [30-32]. Although administration of 60 mg/kg MCT 
had resulted in a significant decrease of RV ejection fraction, several biochemical 
markers of RV overload were not conclusively positive. Expression of βMHC, 
proANP and proBNP mRNA in RV myocardium of rats in the MCT60 group was 
increased, but not significantly different from control. On the other hand, in 
overloaded RV myocardium several extracellular matrix proteins, such as 
tenascin-C, collagen I and collagen III, showed upregulated expression, whereas 
RV myocardial concentrations of three collagenolytic enzymes such as MMP1, 
cathepsin K and cathepsin S, were not significantly changed.           
Current therapies of PAH include (i) prostacyclin analogues [33,34] such as 
epoprostenol [35,36], (ii) calcium channel blockers [37,38], (iii) angiotensin-
converting enzyme [39], (iv) endothelin receptor antagonists such as bosentan 
[40,41], (v) phosphodiesterase-5 inhibitors such as sildenafil [32,42,43], and (vi) 
lung transplantation [44].  
In experimental models of PAH several groups have shown that cell therapy using 
bone marrow-derived endothelial-like progenitor cells [12], bone marrow-derived 
MSCs [14], and umbilical cord blood mononuclear cells [45] given i.v. to rats with 
MCT-induced PAH resulted in lower pulmonary artery pressure, less RV 
hypertrophy, and improved survival. Bone marrow-derived cells obtained from 
rats injected with 5-fluorouracil 3 days earlier were able to reverse PAH, RV 
hypertrophy and medial hypertrophy in pulmonary arterioles [46]. The i.v. 
administration of MSCs in vitro transduced with the endothelial nitric oxide 
synthase (eNOS) gene into rats with MCT-induced PAH appeared more effective 
than i.v. administration of unmodified MSCs [14]. Similar results have been 
obtained with endothelial-like progenitor cells that after i.v. injection into MCT-
treated rats were more effective in reversing PAH if transduced with the eNOS 
gene than if unmodified [12]. Likewise, pulmonary artery-derived smooth muscle 
cells that have been transduced in vitro with the eNOS gene, administered i.v. 
simultaneously with MCT, prevented the development of PAH, whereas 
pulmonary artery-derived smooth muscle cells transduced with a control vector 
did not [47].  The cell type carrying the eNOS gene is apparently not important, as 
even fibroblasts transfected with the eNOS gene were effective in reversing 
established PAH [48]. These results imply a major role for NO in vasodilation and 
regeneration of damaged lung tissue.  
To date, the only clinical study reporting i.v. cell therapy in patients with PAH is a 
randomized study by Wang and coworkers who described a significant 
improvement of 6-minute hall walk distance after i.v. administration of autologous 
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endothelial progenitor cells in comparison with conventional therapy [11].  Other 
routes of administration of cells leading to successful therapeutic effects of cell 
therapy on PAH include intratracheal administration [49] and intra-parenchymal 
injection [15]. 
To mimic a therapeutic strategy in which a patient with PAH is treated by i.v. 
administration of autologous bone marrow-derived MSCs, we used MSCs that 
have been isolated from bone marrow of rats with MCT-induced PAH and injected 
i.v. to rats that had MCT treatment 14 days earlier. MSCs isolated from bone 
marrow of rats with MCT-induced PAH differed from MSCs isolated from bone 
marrow of healthy rats in several aspects. Proliferation rate was lower and VEGF 
secretion was higher, but potential of adipogenic and osteogenic differentiation 
and surface marker profile were not changed markedly in MSCs from rats with 
MCT-induced PAH, as compared to MSCs from healthy rats. In the present study 
we demonstrated that the therapy of rats with MCT-induced PAH with MSC from 
rats with MCT-induced PAH was successful, as RV systolic pressure was 
reduced, RV hypertrophy was reduced, and RV function was improved, compared 
to rats with MCT treatment without cell therapy.  
The mechanism of action of i.v. cell therapy with MSCs is not yet elucidated. As to 
the localization of DiI-labeled MSCs in the lung, 14 days after i.v. injection of 106 
MSCs per rat, no evidence of massive integration into arteries and bronchi have 
been obtained. Association and integration of MSCs with pulmonary arterioles 
have been noticed, but this can hardly explain the substantial therapeutic efficacy 
of MSCs in MCT-induced lung damage. The therapeutic actions of MSCs 
engrafted in injured lungs are considered to be the result of paracrine effects [50]. 
Particularly the secretion of cytokines and growth factors is the basis of 
angiogenic and reverse remodeling reactions. One important paracrine factor is 
VEGF that induces angiogenesis by inducing proliferation, differentiation and 
chemotaxis of endothelial cells [51,52].  In situations of vascular trauma cytokines 
and growth factors, such as VEGF, promote recruitment of endothelial 
(progenitor) cells to promote vascular healing and repair [53,54]. Administration of 
pulmonary artery-derived smooth muscle cells to rats with MCT-induced PAH had 
therapeutic effects only if transduced in vitro with the VEGF-A gene [55]. 
Likewise, i.v. administration of fibroblasts transfected with the VEGF-A gene were 
effective in reversing established PAH, whereas untransduced fibroblasts were 
not [48]. The relationship between pulmonary vascular remodeling and lack of 
VEGF is demonstrated by Fujita and coworkers who showed that in mice 
overexpressing TNFα development of PAH is associated with decreased VEGF 
mRNA in lung tissue [56]. Surprisingly, the stem cells used in the present study, 
the MSCs from bone-marrow of rats with MCT-induced PAH, produced even 
more VEGF in vitro than the MSCs from bone-marrow of healthy rats. This finding 
may explain the potent therapeutic effects of the MSCs from MCT-treated rats.      
Several groups have shown that i.v. administration of pulmonary artery-derived 
smooth muscle cells [47], skin fibroblasts [12] or bone marrow-derived 
mononuclear cells [13] to rats with MCT-induced PAH had no appreciable effect 
on RV systolic pressure and pulmonary artery remodeling. As a reference cell 
type we chose skin fibroblasts (SFs) of healthy rats, also used by Zhao et al. [12] 
to illustrate their lack of effectivity to treat PAH in MCT-treated rats. However, we 
have observed some beneficial effects of injected SFs from healthy rats on RV 
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systolic pressure, RV hypertrophy, and RV function, although these effects were 
less pronounced than observed with MSCs from rats with MCT-induced PAH. We 
could not detect i.v. injected SFs trapped in the lung and/or the RV myocardium, 
but any therapeutic effect of injected SFs on PAH and RV hypertrophy should be 
explained by paracrine effects on the pulmonary arterioles, thereby decreasing 




In conclusion we have found that intravenous administration of MSCs from rats 
with PAH to acceptor rats with MCT-induced PAH decreased PAH, prevented RV 
hypertrophy, and improved RV function. These results suggest that patients with 
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Purpose: In the present study we analyzed mechanisms of excitability of right 
ventricular myocytes (RVMCs) isolated from the adult rat heart, making use of the 
naturally occurring variability of excitability of these cells. We focused on the role 
of voltage-activated K+ currents (Ikv) in shaping the current pulse-evoked action 
potential (AP) and in generating sustained depolarizing current-induced 
automaticity (DIA). 
  
Methods: Membrane potentials and currents were measured with the whole-cell 
patch-clamp technique in current- and voltage-clamp configuration, respectively, 
with standard-normal intra- and extracellular solutions. Simulation experiments 
were carried out with a computer model describing the electrophysiology of the 
RVMC of the rat (Pandit et al., 2001, 2003). 
 
Results: The resting conditions were characterized by a resting membrane 
potential (RMP) of ~-70 mV, a membrane resistance at RMP of ~111 M, and a 
membrane capacitance (Cm) of ~173 pF (17-20 cells). Voltage-clamp 
experiments revealed the variable expression of voltage-activated Na+ current 
(Inav), inward rectifier K+ current (Ikir) and voltage-activated K+ current (Ikv), 
including the transient current It and sustained current Iss (20 cells). L-type 
calcium current (IcaL) was recognized during inactivation of Inav and Ikv by a 
holding potential of –40 mV. APs evoked by current-clamp pulses were variable in 
amplitude and duration, probably due to the variable (endo-, meso- and 
epicardial) origin of the myocytes. AP-properties are described for two example 
groups: (1)  High-peak/Long-duration APs (HL-APs) with AP-peak amplitudes of 
30-40 mV and  AP-durations of 50-110 ms at half AP-height,  and (2) Low-
peak/Short-duration APs  (LS-APs) with peaks of -10 to +10 mV and durations of  
20-30 ms. AP-amplitude and duration  in the whole population were negatively 
correlated with It expression, indicating that activation of  It upon activation of  
Inav lowers the degree of activation of IcaL during AP-generation. DIA was 
usually recorded as an after-effect of  the first AP upon applying the sustained 
current, but it was always transient with 1-6 afterwaves within the first 1.6 s. DIA 
was critically dependent on the strength of  the sustained current and occurred at 
membrane potentials >-40 mV, where all Ina and most Ikv are becoming 
inactivated.  DIA was inhibited by 10 mol/L nifedipine (n=4) but was not clearly 
dependent on the size of It. This indicates that the automaticity mechanism of DIA 
largely depends on the properties of IcaL as an inward current. Model 
experiments reproduced the decrease of AP-duration with an increase in It and 
revealed a DIA-mechanism based on IcaL deinactivation and Iss deactivation at 
depolarized potentials. 
 
Conclusion: We discuss these results in terms of their implications for 
understanding normal RVMC excitability and for arrhythmogenic mechanisms in 
heart failure.  
 
 





While investigating in a recent study the effect of stem cell therapy on heart failure 
related changes in the electrophysiology of right ventricular myocytes (RVMCs) 
from hearts of rats with experimental pulmonary arterial hypertension, we were 
confronted with a much greater variability in excitability in these RVMCs, normal 
or diseased, than anticipated from the literature (Lee et al., 1997 and Pandit et al., 
2001 & 2003). For example, one group of cells had a strongly reduced excitability 
as apparent from very low peak-height (at membrane potential Vm<0 mV) and 
short-duration (~25 ms) action potentials (APs), while another group had normal 
peak-height (at Vm~+40 mV) and very long-duration (~100 ms) APs. This 
hampered comparison of the excitability properties of RVMCs from normal, 
diseased and stem cell-treated animals and required a preliminary 
electrophysiological study of RVMCs from normal rats to characterize and explain 
this variability. 
One of the reasons why RVMCs are heterogeneous in their excitability properties 
is that they have a mixed histological endo-, meso- and epicardial origin (Clark et 
al., 1993; Antzelevitch et al., 2000). From a mechanistic point of view, variability 
may be a great source of information for understanding the functional 
consequences of electrophysiological differences between heart cells. This is of 
particular importance, as insights in mechanisms of normal and abnormal AP-
shaping and of regular and irregular heart rhythm generation are still limited, 
despite intensive experimental and theoretical research on this subject (Pandit et 
al., 2001, 2003; Pogwizd and Bers, 2004; Antoons et al., 2007). Therefore, we 
have analyzed the variability in excitability of normal adult rat RVMCs by 
systematically comparing the current-clamp properties of the cells (excitability) 
with the voltage-clamp properties (ion channel expression) of the same cells 
under standard-normal conditions. Besides studying AP-shaping by the various 
ion channel types, we also studied the ionic mechanism of generating 
depolarizing current-induced automaticity (DIA), a mode of excitability of 
ventricular myocytes that has been studied before as a model for 
arrhythmogenesis ‘from abnormal automaticity’ mainly in other species of 
mammals than the rat (Katzung, 1975; Malecot et al., 1985; Peters et al., 2000). 
By contrasting the DIA-mode excitability under sustained current stimulation with 
that of current-pulse evoked APs in patch-clamp experiments and by theoretical 
modeling, we aimed to answer questions about the particular role of  Kv-currents 
(Ikv) in pulse-evoked AP-shaping and in generating DIA.  
Because we were primarily interested in the role of the electrical membrane 
properties in cardiomyocyte excitability, we excluded intracellular calcium 
dynamics by using the calcium buffer EGTA. This also prevented a significant role 
of the sodium/calcium-exchanger (NCX) in the measured myocyte excitability (cf. 
Pogwizd and Bers, 2004). 
The model of Pandit et al. (2001, 2003) was used to explore mechanistic 
explanations of the observed excitability properties of rat RVMCs. A particular 
result was that the model simulations revealed that DIAs occurred as a result of 
the kinetic properties of IcaL and Iss.  
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The present results provide a basis for analyzing differences in excitability 
between ventricular myocytes from normal rats and from rats with experimental 
heart failure. They may also provide clues for a better understanding of 
mechanisms of heart failure- related ventricular arrhythmias. 
 
 
Materials and Methods 
 
Animals and ventricular myocyte isolation 
Rats were treated in accordance with the national guidelines and with permission 
of the Animal Experiments Committee of the Leiden University Medical Center. 
The animals were housed, two animals per cage, with a 12:12-h light-dark cycle 
and an unrestricted food and water supply. Three-month old female Wistar rats 
weighing 200-250 g (Harlan, Zeist, the Netherlands) were used. 
 
Cardiomyocyte isolation 
The rat was anaesthetised, and the thorax was opened. The heart was taken out 
quickly and immediately transferred to ice-cold, oxygenated Tyrode solution. The 
heart was mounted to a Langendorff perfusion set-up and then perfused for 5 min 
with an oxygenated Tyrode solution at constant pressure (70 mmHg) at 37º C. 
The perfusion fluid was replaced by an oxygenated, low calcium (10 mol/L) 
perfusion fluid. Contractions disappeared within 30 s. After 5 min of low calcium 
perfusion, the perfusion was continued in a recirculating manner at a perfusion 
pressure of 60 mm Hg. At that time collagenase (0.06%) was added. Thirty min 
later, the flow rate was too high too maintain a perfusion pressure of 60 mm Hg. 
Then, the heart was removed and the right ventricle (RV) was separated from the 
left ventricle and the interventricular septum. RV was cut in small pieces, 
incubated in a fresh collagenase (0.06%) solution, and dissociated in a waterbath 
shaker at 37º C. After sedimentation of the myocytes, sedimented myocytes were 
resuspended and stored at 37º C in fresh HEPES-buffered salt solution containing 
(in mmol/L) NaCl 125, KCl 5, MgSO4 1, KH2PO4 1, CaCl2 1.8, NaHCO3 10, 
HEPES 20, glucose 5.5, pH 7.4. The average fraction of rod-shaped myocytes 
was 80 %. The percentage of rod-shaped myocytes decreased by about 10 % 
during 6 h at 37º C.  
 
Whole-cell patch-clamp experiments 
Membrane potentials (Vm) and membrane currents (Im) of right ventricular 
myocytes (RVMCs) from 22 cells from 5 rats were measured with the patch-clamp 
technique in the whole-cell current-clamp and voltage-clamp configuration, 
respectively. The recordings were performed at 21°C with an L/M-PC amplifier 
(List-Medical, Darmstadt, Germany), set at 3 KHz filtering. pClamp/Clampex8 
software (Axon Instruments, Molecular Devices, Sunnyvale, CA, USA) was used 
for data acquisition and off-line analysis. The bath solution contained (in mmol/L)  
NaCl 137,  KCl 5, MgCl2 1, CaCl2 1.8, HEPES 10, and glucose 11, pH 7.4, while 
the pipette solution contained (in mmol/L) Na2ATP 6,  KCl 115, MgCl2 1, EGTA 5 
and HEPES 10, pH 7.4). Pipette resistance (Rpip) was 2.80.4 M (n=20), seal 
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resistance (Rseal) was 4.11.3 G (n=13), and series resistance (Rser) was 
6.63.1 M (n=20). Pipette potential offsets (Vpips) developing during the 
experiments were usually between +1 and  –2.3 mV, and were not corrected for. 
Larger offsets were corrected in 3 cells. 
In order to be able to check Rser and Cm-measurements, Rser was not 
compensated and the slow capacitive transients were not cancelled. Rser-values 
apply to the immediately preceding or following voltage-clamp tests, because 
Rser tended to increase during the experiment. Whole-cell recordings after 
gigasealing (n=20) were accepted for analysis if the membrane potential 
stabilized within a few minutes and if the membrane resistance measured in 
voltage-clamp at –60 mV (Rm(-60)) was >100 M  (to avoid leaky membranes). 
Voltage-drop artifacts across Rser during current-clamp stimulation (usually <10 
mV) were corrected for, except when they were <2 mV. Voltage errors across 
Rser during voltage-clamp were usually <30 mV (<5nA times 6M).  
This was only considered acceptable for large driving forces, such as during Ikv 
recording at +60 mV, where the ideal driving force (Vm-Ek)=144 mV and the real 
driving force is <20% smaller because of the <30-mV drop in voltage across Rser.  
This kind of measurement error was confirmed in our model simulations (see 
below). We, therefore, realize that our Rser-values are too large to reliably 
measure maximal values of  Inav, Ikir and Ikv. So, the average values of these 
currents presented in Table 1, measured at potentials where contamination with 
other currents is small, should still be considered as underestimates. 
Nevertheless, the Rser values were good enough to allow identification of these 
currents and to detect the activation potentials of these currents for current 
detection levels within 0.5 nA (<2% voltage error).  
For a rough quantitative measurement of Ikv, its peak, Ikvp, was measured at +60 
mV, not only because its driving force is large at that potential, but also because  
Inav and IcaL are minimal at that potential, since their reversal potentials are 
close to +60 mV (see Figs. 3 and 5). The amplitude of It was determined by 
subtracting the sustained Ikv (Iss) at 60 mV, approximated by the current at t=180 
ms, from the peak Ikv (Ikvp). This procedure also included subtraction of leak 
current in the calculation of Itp. To minimize disturbing effects of variability in Itp-
values related to a variability in cell size, Itp values were corrected for cell size by 
dividing Itp by Cm. 
 
 
Modeling   
We have used the computer model of the rat ventricular myocyte made by Pandit 
et al. (2001, 2003) to explore both the excitability mechanism of current-pulse 
evoked action potentials (pAPs) and that of depolarizing-current induced 
automaticity (DIA) in the RVMC of the adult rat.  
The model of Pandit et al. (2001, 2003) is a Hodgkin-Huxley type membrane 
model coupled to an intracellular ion-dynamics model via the intracellular 
concentrations of Ca, Na and K. It can be used in a left-epicardial and left-
endocardial myocyte version (Pandit et al., 2001) and in a right-epicardial one 
(Pandit et al., 2003).  
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The membrane model is largely based on published experimental work and 
contains the currents identified in the present experiments (Ikir, Inav, Ikv (It and 
Iss), IcaL) together with two other currents of smaller amplitude (If and 
background current Ib) and with the electrogenic currents of the ion transporters 
the sodium-calcium exchanger (NCX), the Na+, K+-ATPase and the plasma 
membrane calcium ATP-ase (PMCA). Dr. Pandit has kindly provided us with a list 
of misprint-corrections (including 5 obvious sign errors in exponentials) to allow us 
to make proper runs with the model (personal communication, 2008). 
We have extended the model with the electrical connection of the pipette to the 
cell in order to be able to account for the non-ideal voltage- and current-clamp 
properties of the measurements (large series resistance Rser). We have used the 
model as a plasma membrane model uncoupled from intracellular calcium 
signaling and ion changes by setting the intracellular concentrations of [Ca2+]i=79 
nmol/L, [Na]i=10.7 mmol/L, and [K]i=139.3 mmol/L, which  conditions approximate 





Groups of observations are described as means  SD (n), unless mentioned 
otherwise. Correlation analysis is performed with nonparametric (Spearman) 
tests. We used the SPSS software (SPSS Inc., Chicago, IL, USA). A p-value 










Basic electrical properties of adult rat RVMCs   
Basic electrical membrane properties such as the RMP, Rm and Cm determine 
the excitability properties of an excitable cell. RMP determines the number of 
available Nav, Cav and Kv channels by controlling the degree of inactivation of 
these channels, while Rm and Cm determine the effectiveness of current stimuli 
to excite a cell. Therefore, we first consider those properties of our RVMCs under 
our standard-normal conditions, including the variabilities of these properties.   
The RMP recordings were rather stable around –70 mV (see Table 1). Initially, 
RMP values (RMPi) were around –60 mV (range –40 to –71 mV), but after a few 
minutes these values stabilized to an RMP=-69.5  2.4 mV (n=20) and remained 
near that value for at least 15 min (see Table 1). A RMP of ~-70 mV, not far 
above the calculated Nernst potential for the K+ gradient (-84 mV), is consistent 
with a major role of Kir-channels in establishing RMP.  
Rm was measured in current-clamp with depolarizing 50- or 100-pA current 
pulses from RMP as well as with 10-mV depolarizing voltage-steps in voltage-
clamp from a holding potential Vh= –60 mV: Rm(rmp)= 11167 M (n=17), while 
Rm(-60)= 384296 M (n=20) (Table 1) for the selected cells (criterium Rm(-
60)>100 M), consistent with an RMP mainly resulting from activation of Ikir-
channels.  
Cm-values were obtained from capacitive current responses to 10-mV 
depolarizing voltage-clamp steps and were Cm= 17365 pF (n=20) (Table 1). 
Thus, the membrane time constant of the cells around RMP was ~20 ms 
(Rm(rmp).Cm), implicating latency times around 20 ms for AP-generation with 
just-above threshold current stimuli, consistent with the records in Fig. 1b and 2b.  
The measurements imply a variability, in which RMP is remarkably constant 
between myocytes with a variation coefficient of 3%, compared to coefficients of 
Rm(rmp), Rm(-60) and Cm of 60%, 77% and 38%, respectively. 
 
Group-1 RVMCs with High-peak/Long-duration pulse-evoked 
action potentials (HL-APs)  
The differences in AP-properties between example group 1, group 2  and the 
remaining cells with intermediate properties enabled us to analyze current-clamp 
behaviour (excitability) in terms of voltage-clamp properties for groups of RVMCs 
with different excitability. 
The first example of excitability is that of a myocyte with a high-peak (at +38mV) 
and long-duration AP (70-100ms at half height) (HL-AP) evoked by a short current 
pulse from a resting membrane potential RMP~-72 mV (Fig. 1b, c). The fast 
depolarizing and slow delayed repolarizing phase gives the typical asymmetrical 
shape of a mammalian cardiac AP with plateau-phase. Five out of 13 cells had 
APs of the HL-AP type further described below, i.e. with APPs of 30-40 mV and 









Fig. 1.  Voltage- and current-clamp properties of an adult rat right ventricular myocyte (RVMC) with a 
high-peak and long-duration current-pulse evoked action potential (group 1 with HL-APs).  All records 
are from the same cell. 
(a) Superimposed voltage-clamp current-records from the cell  evoked by voltage steps of  180 ms 
duration from the holding potential Vh=-80 mV to membrane potential (Vm) values of –120 mV and 
higher up to +60 mV, with increments of  +20 mV. The resting intervals between the steps (at Vh=–80 
mV) were 5 s.  The voltage activated inward (negative) fast sodium current (Inav) is large compared to 
the maximal currents of the inward rectifier potassium current (Ikir) and the voltage-activated  
(positive)  potassium current (Ikv).   The short current peaks preceding the Ina, Ikv and Ikir records are 
the rapid capacitive current transients charging the membrane capacitance to the applied potentials. 
The initial resting potential (RMP) was –68 mV but stabilized later between –72 and -76 mV. Seal 
resistance (Rseal) was 6 GΩ, membrane capacitance (Cm) was 150 pF, membrane resistance at –60 
mV (Rm(-60mV)) was  400 MΩ, and series resistance (Rser) was 5 MΩ.  
(b) Superimposed Vm records (bottom records) upon short (20 ms) current-pulse stimulations with 
increasing intensities (0 to 500 pA, with 100-pA increments, see top records). Resting interval between 
the pulses was 5 s. Notice that the Vm-threshold for evoking an AP is ~-50 mV, while the current 
threshold is just above 100 pA. The first evoked AP is a bit shorter in duration than the two subsequent 
APs. The small instantaneous voltage changes in the records (order of 1 mV, consistent with an 
Rser=5MΩ) at the start and stop  of the pulses are the voltage changes over Rser, which are also 
visible in Fig. 1c and 1d. 
(c) Superimposed action potential (AP) records (bottom records), evoked by a 10-pulse/1-Hz train of 
20-ms/400-pA current-pulses (top records).  The shortest AP is the first AP, the 9 subsequent longer 
APs show some variation in repolarization time. Thus, the AP of this cell has largely adapted its APD 
to the train after ~1 s.  
(d) Superimposed Vm records (bottom records) upon sustained depolarizing current stimulation with 
current steps of 1.6-s durations and increasing amplitudes with 50-pA increments from 0 to 250 pA 
(top records). Resting intervals between the current steps were 5 s. Notice that the amplitude and the 
number of waves in the damped oscillations decrease with increased current induced depolarization. 
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The voltage-clamp currents (Fig. 1a), evoked by voltage steps from a holding 
potential Vh=-80 mV,   show various current types. First, a sustained inward-
rectifier K+ current (Ikir; sustained over 180 ms with some degree of inactivation in 
this case) upon voltage steps downward to –100 and –120 mV. Second, a large 
and fast voltage-activated, transient inward Nav-current (Inav) upon steps to -40 
mV. The first signs of Inav-activation are visible upon a depolarizing step to –60 
mV, while maximal Inav occurs at  –40 mV with an Inav-peak current (Inavp) 
more negative than -10nA. Small sustained (over 180 ms) outward currents are 
visible at Vm-steps to >-20 mV and are considered here as Kv-currents (Ikv, 
mainly the sustained Iss), based on Pandit et al. (2001, 2003). Thus, in absolute 
value, the maximal Inavp is here much larger (>~5x) than the absolute value of 
the maximal inward-rectifier K+ peak current (Ikirp=-2.4 nA at –120 mV) and the 
maximal voltage activated (outward-rectifier) K+ current (Iss~+1.5 nA at +60 mV). 
A small inward L-type voltage-activated calcium current (IcaL) must be present in 
the whole-cell currents (Pandit et al., 2001) but cannot easily be recognized under 
these standard recording conditions, because it is masked by Inav and Ikv (see 
Fig. 5). Furthermore, the outward currents do not show a prominent transient Ikv, 
It, as in the second example of a normal RVMC below. For an I-V curve 
representing the three main current components of this cell (Ikir, Lnav and Iss) 
see Fig.3. 
Fig.1b shows the excitable behaviour of the selected RVMC upon application of 
short (20ms) current pulses of increasing amplitude from 0 to 500 pA. For such a 
pulse-evoked AP (pAP), the firing threshold of the membrane potential was 
around –50 mV at ~200-pA stimulation, consistent with activation of  Inav at ~-50 
mV in our voltage-clamp recordings (Fig.1a) and with the literature (Pandit et al., 
2001). pAP depolarization accelerated with earlier threshold crossing by the 
stronger pulses, while  the  pulse-evoked action potential duration (pAPD at half 
height) increased by  a decelerated repolarization at the stronger pulses.  
Since APD often depends on the rate of AP firing (Pandit et al., 2001), APD was 
measured in a train of 10 APs (tAPs) evoked with supramaximal pulses (~2x the 
threshold current pulse amplitude) at a frequency of 1 Hz (Fig. 1c). Supramaximal 
stimulation was evident from the constantness of the peak amplitudes of the tAPs 
(tAPP=38 mV) and the absence of latency fluctuations. Fig. 1c shows indeed rate 
adaptation of tAPD to the train of 1 Hz by a significant tAPD increase after the first 
(shortest) tAP. This increase was not necessarily monotonic in a 1-Hz train. tAPD 
at 50% AP height  of the 1st AP (tAP1D50) was 70 ms and increased to 
tAP10D50=90 ms at the 10th pulse after an overshoot of  tAPD50max=100 ms.  
The mean tAP1P, tAP1D50 and tAP1D50max of the 5 HL-APs were 33 mV, 70 
ms and 92 ms, respectively. 
 
Depolarizing-current induced automaticity in the HL-AP group 
A peculiar type of RVMC excitability was seen as repetitive AP firing upon 
depolarizing the cell with a sustained (1.6-s lasting) current. This depolarizing-
current induced automaticity (DIA) is shown in Fig. 1d. DIA occurred in all RVMCs 
tested (n=18), was usually transient in nature (damped membrane potential 
oscillation), and was critically dependent on the degree of current-induced 
depolarization. The highest tendency to fire APs occurred at the lowest possible 
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depolarization just above –50 mV. Fig.1d shows that the higher depolarizations 
(at the higher sustained currents) cause stronger damped oscillations with fewer 
and smaller-amplitude APs or membrane potential waves. The oscillation at the 
lowest current amplitude (100 pA) occurs in this cell at a frequency of ~3.1 Hz. It 
starts with an initial depolarization, which develops too slowly to reach the 
threshold for triggering a fast full-blown sodium-channel based AP, because the 
Nav-channels largely inactivate before becoming activated (cf. Pandit et al., 2001 
for the properties of Nav-activation and inactivation). Nevertheless, the current-
induced depolarization proceeds by closure of the inward-rectifier channels until 
the higher L-type calcium-channel threshold is reached around –30 mV (Pandit et 
al., 2001).  Because these calcium channels do not appreciably inactivate during 
the preceding depolarization, they are able to generate a typical slow calcium AP, 
which repolarizes by calcium channel inactivation and presumably by activation of  
residual (not yet inactivated) Kv-channels (cf. Pandit et al., 2001, for the CaL and 
Kv-activation and inactivation properties). The duration of the first spontaneous 
AP, sAP, for 18 cells is sAP1D50~88 ms (see Table 1), thus in the range of 
durations of HL-APs (50-110 ms). However, the AP cannot return to the normal 
Kir-channel determined RMP, because of the applied sustained depolarizing 
current. This return of the membrane potential (Vm) to values of  –50 to –30 mV 
allows recovery from CaL-channel inactivation causing repeated CaL-channel 
activation and generation of a repeated AP (Pandit et al., 2001). Thus, this 
mechanism is similar to that of early afterdepolarizations (EADs) in the 
repolarizing phase of APs in ventricular myocytes of hypertrophic and failing  
hearts or from LQT-syndrome hearts (Rudy, 2000; Antzelevitch et al., 2000). 
Therefore, the DIA may be seen as a series of repetitive EADs in normal heart 
cells.  
Interestingly, DIA shows that Cav-channel excitability may be uncoupled from 
Nav-channel excitability in the slow onset of DIA and maintained during DIA when 
AP-firing continues above –50 mV, where all Nav-channels are inactivated 
(Pandit et al., 2001; cf. Fig. 5b). At one higher applied current amplitude (150 pA), 
depolarization occurs fast enough to trigger an Inav-initiated AP as in Fig. 1b or c, 
but repolarization cannot be completed because of the sustained current, so that 
repeated APs can occur at the same frequency (~3.1 Hz) as at 100 pA, but with 
lower and sooner declining amplitudes and from a higher depolarized Vm~-30 
mV, where more average CaL-channel inactivation occurs (Pandit et al., 2001). A 
one-step higher depolarizing current (200 pA) shows such a strong damping of 
Vm-oscillation, that only one significant small wave is generated after the initial 
normal AP from a depolarized level of ~-25 mV. At 250 pA the after-oscillation of 
the initial AP from a depolarized level of –20 mV is almost completely 
suppressed.  
The average number of spontaneous APs or waves in the DIA during the 1.6-s 
sustained stimulation was 3.6 (range 2-6), a little higher than that in the general 
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Table 1.  Electrophysiological properties of right ventricular myocytes of the adult 
rat. 
------------------------------------------------------------------------------------------------------------------------- 
   Average SD  unit  n 
RMPi   -60.8  7.3  mV  20 
RMP   -69.5  2.4  mV  20 
Cm   172.9  65.2  pF  20 
Rm(-60)   384.1  296.3  MΩ  20 
Rm(rmp)  111.2  66.8  MΩ  17 
Inavp(-40)  -7.1  3.2  nA  20 
Ikirp(-120)  -2.9  1.0  nA  20 
Ikvp(60)   2.9  1.6  nA  20 
Iss(60)    1.2  0.5  nA  20 
Itp(60)   1.7  1.3  nA  20 
Itp(60)/Cm  9.1  6.6  pA/pF  20 
Tit(60)   46.8  5.6  ms  6 
tAP1P   19.6  17.3  mV  13 
tAP1D50  41.0  28.4  ms  13 
tAPD50max  61.2  44.2  ms  13 
sAP1P   20.6  11.0  mV  18 
sAP1D50  88.3  37.8  ms  18 
sAPMDP  -31.2  9.2  mV  18 
#sAPs/Waves  2.9  1.6    18 
------------------------------------------------------------------------------------------------------------------------- 
 
Table 1.  Electrophysiological properties of right ventricular myocytes of the adult rat. 
RMPi, initial resting membrane potential (mV), measured within 1 min after whole-cell establishment. 
RMP, stabilized resting membrane potential (mV), measured a few minutes after whole-cell 
establishment.  
Rm(rmp), membrane resistance  (M) measured in current-clamp with a depolarizing 100-pA current 
step from RMP (~-70 mV). 
Cm, membrane capacitance (pF), measured on-line in voltage-clamp with a 10-mV depolarizing 
voltage step from a holding potential Vh=-60 mV with the use of  the  pClamp-protocol MemTest. 
Rm(-60), membrane resistance (M) measured in voltage-clamp with a 10-mV depolarizing voltage 
step from a holding potential Vh=-60 mV (same protocol to measure Cm). 
Inavp(-40), peak sodium current (nA), measured at –40 mV test potential. 
Ikirp(-120), peak inward rectifier K+ current (nA), measured at –120 mV test potential. 
Ikvp(60), peak voltage-activated outward K+ current (nA), measured at +60 mV test potential. 
Iss(60), sustained voltage-activated outward K+ current (nA), measured at +60 mV at t=180 ms, the 
time that the transient phase of  Ikv is largely over. 
Itp(60), the difference (nA) between Ikvp(60) and Ikvs(60). 
Itp(60)/Cm, Itp(60) normalized for variability in Cm. 
Tit(60), the time constant (ms) of decay of It at the 60-mV test potential , measured as the time 
elapsed between the peak of  It and Itp/e. 
tAP1P, the peak amplitude (mV) of the first AP of a train of  10 APs, evoked by 20-ms supramaximal 
(>1.5 current threshold) current pulses at 1 Hz. 
tAP1D50, the AP-duration at 50% AP-amplitude (APP-RMP) of AP1 of the 10-AP 1-Hz train of APs. 
tAPD50max, the maximal AP50-duration (ms) of the 10-AP 1-Hz train of APs. 
sAP1P, the peak amplitude (mV) of the first spontaneous AP after the initial current-step evoked AP or 
occurring at lower currents without an initial AP. 
sAP1D50, the AP-duration (ms) at 50% AP-amplitude of  sAP1. 
sAP1MDP, the maximal (negative) diastolic potential (mV) after sAP1. 
#sAPs/Waves, the number of spontaneous APs or waves during a 1.6-s sustained current stimulation, 
i.e. the broad APs or subsequent waves with >10-mV amplitude, measured from the interpolated 
MDPs after the APs/Waves, and occurring  after the initial current-step evoked AP or occurring at 
lower currents without an initial AP. 
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Characteristic for all DIAs is a considerable gap between the maximal (-negative) 
diastolic potentials (MDPs) of the DIA-oscillations and the last preceding Vm-
response in the protocol not giving rise to DIA (see also Fig. 2d). This must be 
due to depolarization-induced closure of the Kir-channels causing an abrupt 
increase in the membrane resistance and thereby an abrupt increase in the 
current-step induced depolarization, as shown in Fig. 6c. 
In conclusion, we found and compared two types of current-evoked excitation in a 
subset (group 1) of our normal RVMCs. The first one is represented by the 
classical short-pulse evoked Inav-initiated and IcaL-extended HL-APs and the 
second one is represented by spontaneously occurring Inav-independent, 
apparently Icav-driven (see further evidence below) slow action potentials 
induced by sustained current stimulation. 
 
Group-2 RVMCs with Low-peak/Short-duration pulse evoked 
action potentials (LS-APs) 
Fig. 2 presents a quite different type of RVMC excitability: the cell has a strongly 
expressed Ikv combined with a low-peak/short-duration AP (LS-AP, see Fig. 
2b,c),  despite a relatively large Inav (Inavp at –40 mV <-10 nA, Fig.2a). 
Nevertheless, DIA is preserved (Fig. 2d).  
The voltage-clamp records (Fig. 2a) reveal an increased size of Ikir and Ikv, 
compared to the example group-1 RVMC in Fig. 1a, but now there is a 
pronounced expression of  the transient component of Ikv, It. This makes the 
peak of Ikv at 60 mV more than 2x larger than that in the group-1 example RVMC 
(Fig. 1a). The more pronounced It in this group and in two other cells of the 
population allowed us to measure the time constant of inactivation of It at +60 mV 
for 7 cells, which was ~47 ms (see Table 1). Ikir has similar properties as in Fig. 
1a, but the peak amplitude is almost doubled and the inactivation at  –120 mV is 
less pronounced. The doubling of Ikir and Ikv in Fig. 2 compared to those 
presented in Fig.1 must be largely due to variability between the cells  because 
Cm in Fig. 2 is only 7% larger and Rser is only 8% smaller than in Fig. 1  (see 
Figure  legends). Fig. 3 shows the I-V curve derived from the records in Fig. 2a 
with explanations below.  
Analysis of the records in Fig. 2b gives a clue on the role if It in depressing and 
shortening the pAPs in group-2 RVMCs. A local response occurs upon a pulse of 
300 pA (4th record from below) bringing Vm to a value around an increased firing 
threshold of ~–40 mV. The low-peak AP-responses to the subsequent pulses of 
increasing strength repolarize faster than the local response to the 300-pA pulse, 
which indicates that It has been activated during these pAPs. As the regenerative 
upswing of the pAP occurs relatively slowly, It is activated rapidly enough (Pandit 
et al., 2001) to antagonize excitation during the initial AP-development. Thus, the 
increased It expression appears to depress and shorten the AP in LS-AP 
myocytes around –70 mV.  
The other three group-2 RVMCs showed a similar but more pronounced picture of 
reduced excitability. The pAPP-values were lower (-10 to 0 mV) and the APs were 
no longer all-or-nothing but rather graded responses, which repolarized earlier in 
the higher responses, consistent with progressive It activation at Vm>-30 mV (cf. 
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Fig. 2a). These responses looked rather aborted APs – through It activation- than 
depressed APs.  
In one extra LS-RVMC the aborted AP with an APP=–10 mV and APD50=28 ms 
changed to a higher-peak and shorter AP (APP=12 mV and APD50=13 ms) when 
the RMP spontaneously hyperpolarized from RMP=-66 mV to –72 mV, indicating 
that the exact RMP-value around –70 mV is an important determinant of 
excitability. This observation was confirmed by similar effects of membrane 




   
 
Fig. 2. Excitability of a group-2 RVMC with lowered and shortened pulse-evoked APs (LS-type) by 
strong It expression, but with preserved DIA. 
(a) Voltage-clamp current records as in Fig. 1a. Notice the increased It expression compared with the 
HL-myocyte in Fig. 1a. The initial resting potential (RMP) was –60 mV but stabilized later between –65 
and -68 mV (see Fig. 2b, c and d, with c preceding b in time). Rseal= 7 GΩ, Cm=161 pF, Rm (-
60mV)=300 MΩ,  Rser=4.6 MΩ.  
(b) Vm records (bottom records) and applied-current records (top records) as in Fig. 1b.  The APs 
have a low peak (0-10 mV) and short duration (LS-APs) compared to the APs in Fig. 1b, c. Notice a 
local response at liminal stimulation (3rd pulse) and that the subsequent APs upon the 4th and 5th pulse 
repolarize faster than the local response, indicating increased Ikv-activation by those pulses. 
(c) AP-records and current-pulse records during 10-pulse 1-Hz stimulation as in Fig. 1c. Notice the 
practical absence of frequency adaptation of the LS-type AP compared to that of the HL-type AP (cf. 
Fig. 1 c). 
 (d) Vm records and applied-current records to evoke DIA as in Fig. 1d. The Vm-oscillation is more 
damped than in Fig. 1d. Notice that a well-developed fast Nav-channel based AP is missing in the 
beginning of all records; but that slow Cav-channels based sustained-depolarization induced APs are 
present in the three upper records.  
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Reduced excitability around and above RMP=-70 mV is consistent with the 
inactivation curve of Inav, which shows already 80% inactivation at –70 mV, 
where inactivation of It is just beginning (Pandit et al., 2001). Thus, the strongly 
increased It expression in LS-AP RVMCs depresses Nav-dependent excitability of 
these cells around –70 mV, which is in contrast to what happens in HL-APs (Fig. 
1). Furthermore, the faster AP-repolarization upon steady hyperpolarizing LS-AP 
RVMCs from RMP>-70 to RMP<-70 mV must be at least partly due to making 
more Iss channels available by de-inactivation (Pandit et al., 2001). Another 
striking difference between AP-properties of group-2 and group-1 myocytes is the 
absence of frequency adaptation in group-2 cells as shown in Fig. 2c. 
 
DIA in the LS-AP group 
The depressed AP with the accelerated repolarization would prevent the 
generation of the slower Cav-channel based APs, if these Cav-channels would be 
present in the cell.  
Fig. 2d indeed shows that this group-2 RVMC has these calcium channels 
expressed because it is able to generate slow IcaL-based APs during DIA. In all 4 
LS-type RVMCs the DIA was transient with 2 or 3 APs/waves. The occurrence of 
the slow APs after the initial depressed AP at the beginning of the higher current 
steps can be understood from the stronger and longer-lasting current-induced 
depolarizations counteracting the repolarizing influence of It-activation and 
allowing It-inactivation.  
 
In summary, a relatively strong It is able to inhibit the Inav-based beginning of the 
action potential of group-2 RVMCs by starting a premature repolarization process. 
This premature repolarization then prevents the generation of the IcaL-based 
slower AP-component. Thus, APD regulation by It-controlled IcaL-activation 
implies, at least partly, It-controlled Inav-activation. However, during continuous 
current-induced membrane depolarizations to Vm>-40 mV It inactivates and can 
no longer prevent the occurrence of the slow spontaneous APs during DIA.  
 
I-V relationships 
In order to better illustrate the voltage-dependencies of the main currents of our 
right ventricular myocytes, we show in Fig. 3 current-voltage (I-V) curves of the 
two myocyte types, having HL- or LS-APs. The curves were derived from the 
voltage-clamp records in Figs. 1a and 2a (see legend for further information). The 
I-V curves show the increased expression in the LS-myocyte of Ikv (best 
measured at +60 mV), in particular of It, and the range of Ikir sizes for both cell 
types at voltages <-80 mV. Activation of It in the LS-cell occurs at Vm>-40 mV, 
consistent with Pandit et al. (2001). The absolute size of the maximal Inav at 
around -40 mV is only a rough underestimation of the real current size due to 
inadequate voltage-clamp conditions (too large Rser-values). Nevertheless, the 
curve reliably shows that Inav is activated at Vm>-60 mV, consistent with Pandit 
et al. (2001). IcaL is unrecognizable in the total whole-cell currents of the two cells 
plotted because of the presence of Ikv, but its presence can be revealed upon 
depolarizing voltage steps from een holding potential of –40 mV, as shown below 
in Fig. 5. For comparison, the I-V curve derived from that experiment has been 
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plotted in Fig.3 to illustrate how this hidden negative IcaL contributes to the total 
whole-cell current of a myocyte. The plot shows that IcaL activates in the same 
voltage range as It, consistent with Pandit et al. (2001). To visualize the real size 
of the outward (positive) Ikv current of a cell in the range of -40<Vm<60 mV, its 
negative IcaL (0 to –1.1 nA) should be subtracted from the  total positive I-V curve 
in that Vm-range to obtain the real, more positive current of Ikv. 
 
 
Fig. 3.  I-V curves of the two types of myocytes with HL and LS-APs. 
The curves consist of three unconnected parts, because the current amplitudes have been measured 
at different time points for different voltage ranges during the records. The left part (-120 to -80 mV) 
relates to that part of the I-V relationship representing maximal inward Ikir(Vm). The middle part (-60 to 
0 mV) represents maximal inward Inav(Vm), while the right part (-20 to +60mV) represents maximal 
outward current, largely resulting from Ikv(Vm) . The latter current is, however, mixed with the inward 
current IcaL, which deforms the records except at +60 mV (~EcaL). For comparison, a IcaL(Vm) curve  
from another myocyte from the experiment of Fig. 5b has been  added to the figure. All 3 cells plotted 





It affects pulse-evoked APs rather than DIA-APs 
Comparison of Figs. 1-2 suggests that an increase in It expression lowers and/or 
shortens pulse-evoked APs, but not  the initial DIA-APs, consistent with the idea 
that It is largely inactivated during DIA (cf. Pandit et al., 2001). This hypothesis 
was tested by plotting and comparing the peaks and durations of the first APs in 
the short 1-Hz trains (tAP1P and tAP1D50; Fig. 4a,b) and of the first spontaneous 
APs during DIA (sAP1P and sAP1D50; Fig. 4c,d) as a function of the peak of It, 
measured at 60 mV (Itp60) and normalized to cell size by dividing Itp60 by the 
membrane capacity Cm. 




Fig. 4.  The effect of  Itp, normalized for cell-size (via Cm), at 60 mV on APP and APD for pulse-train 
evoked first APs (tAP1s,  left frames, a and b) and for first spontaneous APs during DIA (sAPs, right 
frames, c and d) in the whole population. The two example-groups of myocytes with HL-APs and LS-
APs are indicated in the figure. Notice the overall decline of tAP1P and tAP1D with an increase in 
normalized Itp and an absence of such a decline  in the sAP1P and sAP1D values (for statistics see 
text). Notice also that the values of sAP1P and sAP1D are similar to the values of tAP1P and tAP1D at 
low normalized Itp-values. For definitions of the abbreviations, see the legend of Table 1. 
 
 
The plots show lower tAP1P (Fig. 4a) and tAP1D50 (Fig.4b) values with an 
increase in Itp60/Cm (Spearman’s correlation coefficient rs=-0.569 and -0.817, 
resp.). This correlation is absent in the corresponding plots of sAP1P (Fig. 4c) 
and sAP1D50 (Fig. 4d) (rs=0.003 and 0.168, resp.). tAP1 peaks decline from 
values ~30mV to values below 0 mV, while sAP1 peaks remain around 20 mV. 
Furthermore, tAP1 durations decrease from around 70 ms to values around 20 
ms, while sAP1-durations remain high around 70 ms. This means that It-
expression is an important determinant in APD regulation of pulse-evoked APs, 
but not in APD-regulation of DIA-APs.  It also implies that, in general, the short 
pulse-evoked APs are not short as a result of a lack of IcaL-expression, as, if It 
inactivates under DIA-conditions, broad IcaL-based APs can appear. The location 
of the data points with the higher values of Itp60/Cm may need a right-shift 
because of underestimation of Itp due to imperfect voltage-clamp, but such a shift 
is not expected to affect the outcome of the used correlation test, because the 
Spearman test is based on rank correlation. 
Fig. 4b shows another interesting property of pulse-evoked APs. They only show 
AP-lengthening in a 1-Hz train (frequency adaptation) for values of Itp60/Cm 
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below a certain value (~9pA/pF), i.e. for APDs already longer than the short APD 
(~20 ms) as observed at the higher Itp60/Cm values. 
 
 
IcavL measured under conditions of Inav and Ikv-inactivation 
To establish the expression of L-type Cav-channels in our myocytes under our 
experimental conditions, we recorded IcaL under the standard/normal conditions 
of the AP-recordings of Figs. 1-2 at a holding potential of Vh=-40 mV. At that 
potential the masking effect of other currents on IcaL is minimal, because Inav is 
completely inactivated, It largely and IcaL only slightly (cf. Pandit et al., 2001).  
Fig. 5 shows the results of such an experiment for a myocyte with properties 
intermediate between those of groups 1 and 2. In the control experiment of Fig. 
5A it can be seen that Ikir, Inav and Ikv dominate the recordings at Vh=-80 mV, 
making IcaL invisible. However, IcaL is clearly recognizable at Vh=-40 mV in Fig. 
5B, where Inav is completely and It is largely inactivated. Ikir is not much affected, 
as expected. The inactivation of Inav and It was largely reversible upon re-
application of Vh=-80 mV (see legend of Fig. 5). 
 
  
Fig. 5.   Properties of  IcaL measured under conditions of  inactivation of Inav and Ikv for a RVMC with 
properties intermediate between those of  groups 1 and 2.   
(a) Control recordings of membrane currents at a holding potential Vh=-80 mV, showing voltage-
dependent activation of Ikir, Inav and Ikv as in Fig. 2a. Conditions at the start of these recordings 
were: RMP=-71 mV, Cm=160 pF, Rm(-60)=160 M, and Rser=12 M. 
(b) Membrane current recordings evoked as in (a), but from a Vh=-40 mV. At that Vh Inav is 
completely inactivated and Ikv largely, but IcaL only slightly. IcaL is first clearly evoked at –20 mV, is 
maximal at 0 mV,  becomes smaller at more depolarized potentials and is zero at 60 mV. The 
inactivating effect of Vh=-40 mV on Inav and Ikv was largely reversible upon return of Vh to –80 mV 
(not shown here). Inav recovery was 57% and Ikv recovery 77%. Ikir did not recover, indicating a run 
down of the experimental conditions.  
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In this myocyte, IcaL activates above –40 mV, is maximal at 0 mV and reverses at 
+60 mV. The I-V curve of this current is plotted in Fig. 3 for comparison with the 
total current I-V curves of a HL and LS-cell. The peak amplitude at Vm=0 mV, 
IcaLp(0),  is  –1.1 nA and this peak decays approximately exponentially with an 
inactivation time constant icaL(0) of  ~35 ms. The precise course of the I-V curve 
may be slightly different from the plot in Fig. 3 because of incomplete inactivation 
of It at –40mV. 
Similar IcaL-properties were found in one other cell and are consistent with other 
studies (Clark et al., 1993; Lee et al., 1997). 
 
DIA involves L-type calcium-channel based excitability 
Given the literature about DIA in various rodents (cf. Katzung, 1975; Malecot et 
al., 1985; Peters et al., 2000) and about the properties of expressed ion channels 
in rat ventricular myocytes (cf. Pandit et al., 2001, 2003), cardiac L-type calcium 
channels (Cav1.2) are the primary candidate for generating the spontaneous slow 
APs during DIA in rat RVMCs. They even may provide the pacemaker 
mechanism for current-induced automaticity, or at least contribute to it. Therefore, 
we have studied the effect of the cardiac CaL-channel (Cav1.2) blocker nifedipine 
on DIA. The concentration used was 10 mol/L, because this concentration is 
supposed to inhibit almost 100% of the cardiac L-type Cav-channels at our resting 
membrane potentials of about –70 mV, without having disturbing aspecific effects 
on other channels (Hille, 2001).  
Fig. 6 shows the results of such an experiment. The RVMC tested showed the 
three primary current types observed in the previous cell examples (Ikir, Inav and 
Ikv), but resembled more to group-2 RVMCs than to group-1 RVMCs, because 
Ikv had a clear It-component (Fig. 6a). This caused a smaller APP (~13 mV) than 
in group 1. Application of 10 mol/L nifedipine completely abolished DIA (Fig. 6c). 
The same stimulus protocol now resulted in Ikir and Ikv dominated responses of  
Vm. Ikir closure upon depolarization was now evident from the gap in the 
responses between zero current stimulation and stimulation with 50-pA current. 
Ikv activation was evident from the abrupt stop in the time course of the current-
step induced depolarization at voltages of –35 mV and higher. Inactivation of the 
It component is visible in the records at Vm values of –30 mV and higher as a 
delayed development of depolarization, consistent with the transient nature of It in 
the voltage-clamp responses in Fig. 6a. The survival in 10 mol/L nifedipine of 
Inav,  Ikir and Ikv with its It component is visible in Fig. 6d for a different cell, 
recorded in the solution of the cell in Fig. 6a-c after loosing that cell. The change 
in the precise initial time course of Ikv may be the result of the removal of the 
interference of IcaL with the recorded Ikv or due to non-ideal voltage-clamp 
conditions.  
These effects have been found in total for 4 cells and are consistent with 
comparable experiments on DIA in cardiomyocytes of other mammals (Peters et 
al., 2000). We conclude therefore that L-type calcium channels provide the inward 
currents for the slow APs in the DIA. A second conclusion is that both the Ikir and 
Ikv-channels in some way contribute to the occurrence and mechanism of  DIA. 
Kir-channels contribute, because it is the depolarization-induced closure of Kir-
channels which brings the cell in the DIA-mode and a lack of reactivation keeps 
                                                                                                           Chapter 8                         
 
 191 
the cell in the DIA-mode. Kv-channels must contribute in some way to DIA, 
because they are being activated and inactivated in the voltage range in which 
the slow APs occur. One significant role of It turns out to delay DIA, when a slow 





Fig. 6. The effect of 10 mol/L nifedipine on depolarizing-current induced automaticity (DIA) of a 
RVMC with AP-properties (APP~13mV) between those of group 1 and 2. 
(a) Whole-cell voltage-clamp records, obtained as in Fig. 1a before addition of  nifedipine. Ikir, Inav 
and Ikv with a It component are present. Rseal>1GΩ, Cm=233pF, Rm(-60mV)=152MΩ, Rser=7MΩ.  
(b) DIA with slow APs, evoked from RMP=-70 mV. Records taken before the addition of nifedipine. 
The DIA inducing current steps were too small to evoke an initial full-size AP.   
(c) Vm responses upon the same stimulus protocol as in (b), after the addition of  10 mol/L 
nifedipine. RMP was decreased to ~ -60mV. 
(d) Voltage-clamp records, obtained as in (a), but from another RVMC in the presence of 10 mol/L 
nifedipine and serving as a voltage-clamp equivalent of the records in (c) 
 
 
Exploring cardiomyocyte excitability mechanisms with a 
computer model 
The main two questions studied were whether the model of Pandit et al. (2001, 
2003) in its uncoupled membrane version of the RVMC is able to qualitatively 
reproduce (1) the changes in pAP-shape for different myocytes with variable It, as 
well as  (2) the various types of DIA (weak and strong damping) observed in 
these cells. To answer these questions we ran simulation experiments with the 
model under conditions close to our experimental conditions (extra- and 
intracellular ion concentrations and Rser, see legends of Fig. 7 and 8).  
Fig. 7 concerns the first question and shows that a small-It RVMC has a much 
wider pAP with a higher plateau-phase than a large-It (epicardial) RVMC, 
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consistent with our observations (Figs 1-2 and 4) and consistent with the concept 
of  a mechanism in which the approximate simultaneous activation of  It with IcaL  
(Pandit et al., 2001; Fig. 3) after Inav-activation inhibits IcaL and its depolarizing 
effect on Vm. However, the large-It RVMC does not show strongly reduced 
pAPPs as in Fig. 2b,c or aborted pAPs as in group-2 RVMCs with pAPPs<0mV. 
The latter failure could not be repaired by decreasing Inav or increasing It with a 
factor of 5 suggesting that the kinetics of Inav- and Ikv-activation in the model is 
more separated in time than in the experiments, where Ikv-activation can even 
suppress the initially developing Inav-driven pAP, thus preventing a IcaL-driven 
second part of the AP. Frequency (0.5-5 Hz) adaptation of the AP (lengthening 
with higher pacing rate) was also produced by the model as a consequence of 






Fig.7. Correlation of It-expression in the model RVMC, as reflected in voltage-clamp simulation 
experiments (a, c), with pulse-evoked AP-shapes in current-clamp simulation experiments (b, d). The 
voltage-clamp and current-clamp simulations were carried out with a series resistance Rser=6 MΩ, the 
approximate average Rser value in the experiments. External calcium concentration was as in our 
experiments (1.8 mmol/L). Intra- and extracellular K+ and Na+ concentrations were close to our 
experimental values. Properties of the various ion conductances in the membrane of the epicardial 
RVMC in (c) and (d) were as in Pandit et al. (2003). To simulate a small-It myocyte of the experiments 
(a) and (b), only It of the default epicardial cell was changed to 0.23x of the default value. The 
electrical behaviour of the myocyte membrane was uncoupled from intracellular ion- and calcium-
dynamics by keeping [Ca2+]=79 nmol/L, [Na+]i=10.7 mmol/L , and [K+] = 139.3 mmol/L.  
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A model myocyte with a high It and short AP (the default right epicardial model 
cell) had much less frequency adaptation at 2-5 Hz stimulation than that cell with 
a smaller It (e.g. 0.25x), consistent with the experimental result in Fig. 1b, 2b and 
4b. 
Fig. 8 illustrates the answer to the second question. An epicardial RVMC (with a 
large It) does not clearly exhibit DIA-behaviour when sustained-current stimulation 
with increasing intensities is applied (Fig. 8a). This can, however, be repaired by 
increasing  Iss with a factor of ~4, allowing the generation of DIAs of  2 after-APs 
after the initial AP at intermediate stimulus intensities (Fig. 8b).  
 
 




Fig. 8. Conditions required for the occurrence of DIA in the model of Pandit et al. (2001, 2003) of the 
RVMC of the adult rat (membrane uncoupled from the intracellular calcium dynamics). In all 
simulations [Ca2+]e=1.8 mmol/L and Rser=6MΩ, as in our experiments. The stimulation protocol 
started with a 1.8-s 0.1-nA current stimulus which was repeated with 5-s intervals (to obtain 8 records) 
and with current increments of 0.01 nA. Panel (a) shows the behaviour of the default epicardial RVMC 
(see Pandit et al. 2003) unable to generate DIA. After increasing Iss with a factor of  4, the cell is able 
to generate DIAs at intermediate stimulation intensities (b). Reducing Ikir with 1/3 in panel (c) further 
facilitates DIA in the model cell of panel (b). In panel (d) It of the cell in panel (b) is reduced to 10%, 
causing a longer lasting DIA with broader and higher-amplitude APs.    
 
 
A strong right-shift of the inactivation curve of Iss has a similar effect. Additional 
simulations (not shown here) revealed that these sustained-stimulation induced 
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APs survive the removal of Inav, disappear after removal of IcaL (consistent with 
the experimental result of Fig. 6) and are not or only slightly affected by the 
removal of  If, Icap, Ib, Inaca and Inak. Thus, the induced APs are IcaL-driven and 
require sufficient Iss expression. Increasing the time constant of inactivation of Iss 
turned out to increase the number of APs in the DIA-transient. Removal of the 
window current of IcaL bij shifting the inactivation curve of IcaL 10 to 15 mV to the 
left (not shown here) removes the sustained-current induced APs, indicating that 
the automaticity mechanism resides in the overlap of the activation and 
inactivation curve of IcaL. However, other K+ currents  than Iss are also important 
in the generation of  DIA. Fig. 8c shows that reduction of Ikir facilitates the 
occurrence of DIAs, because they occur at lower stimulation currents  with more 
APs (less damped oscillation). 
Finally, It seems to have an inhibitory effect on the DIAs, because reduction of It 
to 10% of the default value (Fig. 8d) makes the initial AP and subsequent ones 
broader and of larger amplitude and makes the train of induced APs longer 
(weakly damped oscillation). 
These results imply that the variable DIA-phenotype observed in our experiments 
can be qualitatively reproduced from variable combinations of the main 
membrane currents playing a role in this phenomenon, IcaL, Iss, Ikir and It. Thus, 
in principle, the mechanism of DIA resides in the membrane and does not require 
a connection of the membrane with the intracellular calcium (and other ion) 
dynamics. Naturally, such a connection can be expected to serve as an important 
regulator of  DIA, for example because intracellular calcium can control IcaL 
through calcium-induced inactivation (cf. Antoons et al., 2007), a mechanism 
included in a simple form in the complete model of Pandit et al. (2001, 2003).  
A preliminary analysis of these results in terms of gating behaviour of the ion 
channels involved (not shown here) indicates that the automaticity mechanism of 
DIA resides in the window-current properties of IcaL in combination with the 
deactivation properties of Iss. DIA requires AP-repolarization towards a 
membrane potential within the window current range to allow de-inactivation of 
IcaL to provide ‘diastolic’ depolarization by inward IcaL, which is then supported 
by ‘diastolic’ deactivation of Iss to recover from activation during the preceding 
action potential. The strength of sustained stimulation in combination with the 
presence of other active currents, Ikir, It and the sum of the smaller currents,  
determine whether the membrane potential can land after the first AP in the 
window current range of  the membrane potential. The slow inactivation of Iss 
may then determine the length of the AP-train of the transient DIA. The 
differences regarding the phenotype between the DIAs of the different RVMCs of 
the heart may thus result from the variability in the expression of the various ion 
channels.





The principal findings of the present experimental and model study concern (1) 
the role of the transient K+ current It in RVMC action potential (AP) shaping, and 
(2) the roles of  Ikv (It and Iss) and Ikir (inward-rectifier K+ current) in depolarizing-
current induced automaticity (DIA). 
 
It controls AP-duration by controlling Inav as well as IcaL-
activation  
Under our conditions, the transient current It turned out to control the shape of 
current-pulse evoked APs, by starting an initial repolarization process as soon as 
the Inav-initiated depolarization phase of the AP surpasses the activation 
potential of  It around –30 mV (see our voltage-clamp currents and Pandit et al., 
2001). If It would be absent, the AP would develop an Inav-driven AP lasting long 
enough to allow activation of the IcaL around –30 mV. Inav-inactivation would 
then automatically remove the depolarizing influence of the Nav-channels. This 
influence is then replaced by that of the CaL-channels to generate the cardiac 
AP-plateau and lasts as long as IcaL-inactivation and activation of residual Ikv 
(Iss) and background currents allow the CaL-channels to remain active. This 
situation approximates the conditions in the myocytes with HL-APs, where no or 
relatively little It is present, but some Iss. If enough It-channels are   present, they 
limit Inav by activation above –30 mV and thereby the degree of depolarization by 
Inav. At the same time the It-channels provide a hyperpolarizing force, against 
which IcaL-channels have to become activated. This limits the number of 
activated CaL-channels and the degree of depolarization these channels can 
contribute to the membrane. Thus, It-channels have a double-negative influence 
on CaL-channel induced membrane-depolarization during the AP, the first being 
hindrance of Inav-induced depolarization and the second being hindrance of the 
depolarizing action of already-open CaL-channels. In this way, CaL-channel 
activation, and consequently APD, can be controlled by It-channels. In the 
extreme case, as in group-2 APs, It can be so strong, that it even aborts an Inav-
driven AP thereby also preventing IcaL-activation. In a functional myocyte, this 
would also mean electro-mechanical uncoupling.  
This concept of the role of It in cardiomyocyte excitability applies to our 
preparation of rat RVMCs with their RMP~-70 mV, which is 5-10 mV more 
positive than reported by others (cf. Pandit et al., 2003). This seems the reason 
that our simulation experiments with the model of Pandit et al. (2003) did not 
reproduce the depressed and aborted APs in the high-It cells (see below). At the 
more negative RMP=-80 mV Inav is largely de-inactivated (Pandit et al., 2001). At 
that potential the increased It expression in the LS-cells is no longer expected to 
affect APP, but only APD, as shown in our simulations with the Pandit model. 
The above formulation of the mechanism of the regulation of APD by It follows 
from a careful comparison of current-clamp responses to voltage-clamp 
responses of the same cell under the same standard-normal conditions for 
diverse cases (from HL- to LS-APs). It may not be entirely novel, but an explicit 
formulation of this mechanism is required for a proper evaluation of changes of 
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ion channel expression during heart-failure associated remodeling of ion channel 
expression. 
 
Kir-, CaL- and Kv-channels in the automaticity mechanism of 
DIA 
The experimental results show that DIA may occur in rat ventricular myocytes and 
indicate that IcaL and Ikir are important components in the automaticity 
mechanism. Preliminary observations indicate that DIA may also occur in left 
ventricular myocytes of the rat (not shown here). Closure of Kir-channels by 
current-induced depolarization may bring Vm in a voltage range where a IcaL-
driven pacemaker (‘automaticity’) mechanism can arise based on the overlap of 
the activation and inactivation curves of IcaL in these cells (Pandit et al., 2001). In 
this mechanism (see Ishikevich, 2005) the ‘diastolic inward pacemaker current’ 
would result from recovery of IcaL-inactivation in a voltage range where a fraction 
of the activation gates is still open. However, Kv-channels may also participate in 
this automaticity mechanism, but the observed slowly inactivating Kv-channels 
(Kss) are a more likely candidate than the rapidly inactivating Kv-channels (Kt; 
see for the inactivation properties of Kt and Kss, Pandit et al., 2001). A minor role 
for It is consistent with our observation that a rapidly inactivating Kv can only 
transiently suppress and thereby delay DIA. The role of Kss could then be to 
make DIA transient of nature by slowly inactivating (over the course of a few 
seconds) after the onset of DIA. Obviously any other repolarizing or depolarizing 
background or voltage-dependent current would also contribute to the 
automaticity mechanism. Our model simulations indeed revealed that Iss is an 
important participant in the automaticity mechanism of DIA (see below). Our view 
on IcaL as a ‘diastolic pacemaker current’ in DIA and on the accessory roles of 
Kv-channels in the generation of DIA is consistent with earlier interpretations of 
DIA-mechanisms described by Peters et al. (2000). 
 
Origins of variability   
The variability in expression of It between the myocytes was obvious from the 
initial overshoot of Ikv (Ikvp) over the sustained Ikv (Iss, see Figs. 1a, 2a). The 
origin of this Ikvp variability may be assumed to reside largely in the variable 
histological (endo-, meso- and epicardial) origin of the cells (Clark et al., 1993). 
The variability of Ikv below 60 mV may be influenced by variability in the 
expression of IcaL (Lee et al., 1997), which current is present (though 
unrecognizable) in our whole-cell total current recordings (Fig. 5). How this IcaL 
variability affects Ikvp variability remains to be determined in pharmacological 
experiments. Rser-variability is another source of variability affecting the higher 
Ikvp-values around 5nA at +60 mV. 
A possibly important source of variability to be mentioned is the variability in Rm 
between the cells and within the cells in the course of an experiment. This 
variability affects RMP, excitability for current pulse stimulation, as well as 
inducibility of DIAs. The origin of Rm-variability is yet unclear, but may include 
variability in Rseal, in the expression of small unidentified membrane 
conductances and in cytoplasmic factors affecting ion channel function.  
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Besides Ikv variability we found variable Inav and Ikir values. Although Inav may 
be expected to be variably expressed in our cells (Pandit et al., 2001), we did not 
quantify this variability, because of inadequate voltage-clamp conditions (too high 
Rser values) for this purpose. We neither studied here Ikir variability, because our 
focus was primarily on the role of Ikv in action potential generation and 
depolarizing-current induced automaticity. However, the role of Ikir in both 
excitability phenotypes remains of interest because of its repolarizing role in pulse 
evoked action potentials and its permissive role in DIA. 
 
Differences with other studies 
Although our results with respect to the expression of the main ion channel types 
(Kir, Nav, CaL and Kv) generally agree with findings of others who studied adult 
rat RVMCs (see Pandit et al., 2001), there are a few differences. For example our 
RMP is 5-10 mV more positive than reported by others (Lee et al., 1997; Pandit et 
al., 2003), while the APDs are often larger (e.g. 42 ms compared to 14 ms). The 
first difference, the slightly depolarized condition, may certainly explain a large 
part of the increased APDs, because APD is sensitive for depolarization above –
80 mV, probably mainly due to inactivation of  Kv-channels causing diminished 
repolarizing force (Pandit et al., 2001). Preliminary results showed an average 
APD-increase of 2-3 ms per mV depolarization over the membrane potential 
range –80 to –40 mV. The reason of the slight depolarization of the resting 
membrane is unclear but may be due to a difference in experimental conditions. 
Another difference is a larger Cm (~172 pF) than measured by others (e.g. ~90 
pF in Lee et al., 1997). This difference may result from several causes, including 
opposite differences in bias at the selection of cells or in the method of Cm 
measurement. Future experiments should evaluate these differences. 
 
Model results 
The simulations with the model of Pandit et al. (2001, 2003) in its cytoplasma-
uncoupled membrane version qualitatively reproduced the experimentally 
observed dependency of AP-duration on It and that of DIA on IcaL and the 
strength of the depolarizing current, while the participation of Iss was a new 
finding for the model DIA-behaviour. However, we are still far from a quantitative 
reproduction of AP-shapes in pulse-evoked APs and in repetitive AP-firing 
induced by sustained current stimulation. Depressed and aborted pAPs were not 
reproduced and DIA-reproduction required an increase in Iss, despite the fact that 
DIA was a regular finding in almost all cells. Fixing these problems would require 
a careful inspection of the exact activation and inactivation kinetics of Inav, IcaL, It 
and Iss. These limitations of the model indicate that the model of Pandit et al. 
needs updating of its membrane conductance properties with more detailed 
voltage-clamp measurements, which may already be available in the recent 
literature. An example of a further improvement of Pandit’s model for a better 
understanding of frequency adaptation of the ventricular myocyte AP is found in 
Salle et al. (2008). For the DIA the precise de-inactivation properties of IcaL and 
de-activation properties of Iss are of crucial importance, because these currents 
appear to provide the automaticity mechanism of the DIA. However, the currents 
Ikir and It also need to be determined precisely because Ikir is permissive in 
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allowing DIA to occur, while It has both fast and slow components, which both 
may affect DIA, the fast component in initially inhibiting DIA and the slow 
component in contributing to DIA in a similar way as Iss, e.g. in making DIA 
transient. 
The reproduction by the model of the experimental finding that frequency 
adaptation is much more pronounced in small-It myocytes (see Fig. 4b) is of 
functional interest. Frequency adaptation may be considered as being largely due 
to cumulative inactivation of It (Salle et al., 2008). This would imply that small-It 
(non-epicardial) myocytes (i.e. with large AP-durations) would be more sensitive 
to cumulative It-inactivation and would be more inclined to develop pathogenic 
AP-lengthening at high heart rates. 
To our knowledge, this is the first time that the classical phenomenon of 
depolarizing-current induced automaticity, described since Katzung (1975) and 
later also by others in ventricular myocytes in various species of mammals, has 
been analyzed with the use of a quantitative membrane excitability model. The 
results indicate that this type of analysis may increase our understanding of the 
mechanism of abnormal automaticity of myocardial tissue. 
 
Functional implications  
The mechanism described above for the effect of It on APD may have a wider 
meaning than only for heart failure-related APD changes in the rat heart, since It 
is also important in shaping the human cardiac AP (Beuckelmann et al., 1993). So 
far, emphasis in shaping the human cardiac AP was more on the slower acting 
Ikv’s , such as  Ikr and Iks, controlling APD by  cutting off the terminal phase of 
the AP-plateau (Sanguinetti & Tristani Firouzi, 2006) instead of  controlling APD 
by  simultaneous inhibition of  IcaL by It (see I-V curves in Fig. 3), as described 
here for the rat. An exception in this respect is the study of Greenstein et al. 
(2008), which ascribes an important role to It in controlling APD in canine 
ventricular cells 
As described, we observed depressed and aborted APs in high-It myocytes with a 
5-10 mV depolarized RMP~-70 mV (compared to the literature). This implies that 
areas of intact myocardial tissue of cells with increased It, such as epicardial 
cells, can become inexcitable when the membrane becomes 5-10 mV depolarized 
by whatever reason (hyperkalemia, ischemia). This would introduce heterogeneity 
in the tissue, allowing reentry and the development of ventricular arrhythmias. 
Down-regulation of It in hypertrophic and failing hearts, at risk of becoming locally 
depolarized by inadequate perfusion, may thus be seen as an adaptive response 
protecting the tissue against the development of abnormal heterogeneity in 
excitability.  
The mechanism described for DIA may also have a wider meaning than for the rat 
heart alone. This mechanism may underlie DIA as well as EAD in greater 
mammalian species. Although the EAD-mechanism has been sought for in the 
properties of  CaL-channels (Antoons et al., 2007), studies so far have not 
pinpointed that mechanism to the intrinsic pacemaker properties of  CaL-channels 
originating from the overlap between their activation and inactivation curves, 
which seems to apply to all mammalian ventricular myocytes. This may explain 
why EADs have the tendency to occur repetitively (Pogwizd and Bers, 2004). The 
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similarity between DIA and the Vm-oscillations during Torsade de Pointes (TdP) 
arrhythmias (Antzelevitch et al., 2000) suggests that the automaticity-mechanism 
of  DIA may also underly or contribute to TdP  and in this way be responsible for 
the risk of sudden death in patients with long QT-intervals. 
 
Perspective for Experimental Pulmonary Hypertension 
The present study provides the control electrophysiological properties of adult rat 
RVMCs for a comparative study with RVMCs obtained from adult rats with 
experimental pulmonary arterial hypertension (PAH; cf. Lee et al., 1997 and this 
thesis). Our results show great variability in excitability and ion channel 
expression, in particular of It, in adult rat RVMCs, probably arising from the 
precise histological origin of the cells from the right ventricle. In a preliminary 
electrophysiological study of RVMCs from rats  treated with monocrotaline to 
induce PAH, we observed  the same kind of variability as described here for 
control cells: HL-, LS- and intermediate types of action potentials were found in 
current-clamp and a similar variability of  It expression in voltage-clamp 
experiments.. Establishing statistical differences between these groups would 
require large groups of observations. Thus, it would be easier to establish 
statistical differences between the electrophysiological properties of control and 
PAH-cells by comparing subsets of cells of the same origin from the tissue, for 
example cells of mainly epicardial, mesocardial or endocardial origin (cf. Clark et 
al., 1993). Variability remaining despite such a procedure could then be evaluated 
in plots such as Figs. 4. 
The present results suggest to consider two possible roles of Kv-channel 
expression in the arrhythmogenicity of cardiac tissue of the hypertrophic and 
failing heart. One is the role of  Kt-channel expression in creating inexcitable 
areas in the tissue (reentry) upon the occurrence of small depolarizations (~10 
mV) and the other is the role of  Kss-channel expression in the automaticity 
response of the tissue (ectopic beats) upon the occurrence of  larger 
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Summary, Conclusions, Future Perspectives and 
Samenvatting 
 
Summary of the thesis 
The major objectives of research described in this thesis include investigation of 
molecular and cellular mechanisms of cardiac hypertrophy and failure. In a study 
on monocrotaline-induced pulmonary arterial hypertension in rats mesenchymal 
stem cell therapy was tested as a novel option to treat this disease.  
Chapter 1 deals with general introduction of the thesis. It provides information 
about the molecular and cellular characteristics of the healthy heart, the heart with 
hypertrophy and the failing heart. Extracellular matrix  (ECM) composition, 
synthesis and degradation, integrins and integrin signaling, nitric oxide synthases 
(NOSs) and NO are discussed in relation to normal, hypertrophic and failing 
myocardium. In addition, experimental models of myocardial hypertrophy and 
heart failure are described. Particularly, the characterization and pathology of 
right ventricular function in animals with monocrotaline-induced pulmonary 
hypertension are emphasized.  
  
In chapter 2 we hypothesized that pressure overload is “felt” by the myocardium 
through stretch-like effects imposed on integrins, the receptor by which 
cardiomyocytes are attached to the ECM. In the cell model of neonatal rat 
cardiomyocytes (NRCMs) in vitro, we activated the integrins by administration of a 
pentapeptide containing Arg-Gly-Asp (RGD) to test whether integrin stimulation 
leads to NRCM hypertrophy. The pro-hypertrophic effect of RGD-containing 
pentapeptide on NRCMs was compared with the well-known pro-hypertrophic 
effects of 1-adrenoceptor stimulation with phenylephrine. Saline-treated NRCMs 
were used as control. The hypertrophic response was quantified by measuring 
cell surface area (CSA). Phosphorylation of NO-synthase-1 (NOS1) was also 
assessed. CSA was increased by 38% with RGD and by 68% with PE versus 
control. A general NOS-inhibitor (L-NAME) inhibited RGD-induced hypertrophy 
completely, but had no significant effect on PE-induced hypertrophy. The L-
NAME-induced inhibition of RGD-induced NRCM hypertrophy could be overcome, 
at least partly, by co-administration of a NO-donor, nitroprusside. Co-
administration of a NO-donor had no effect on NRCMs incubated with PE + L-
NAME. Ryanodine and BAPTA-AM inhibited RGD-induced hypertrophy 
completely but not that induced by PE, indicating the involvement of intracellular 
Ca2+ ions in the RGD-induced NRCM hypertrophy. NOS-1 phosphorylation was 
increased with RGD by 61%. Hence we concluded that integrin stimulation of 
NRCMs by RGD leads to hypertrophy. Abrogation of RGD-induced hypertrophic 
response upon NOS-inhibition and rescue of this hypertrophic effect by NO-donor 
suggest that integrin stimulation-induced hypertrophy of NRCMs depends upon 
NO, possibly derived from NOS1.  
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In chapter 3 we demonstrated that ventricular failure may be associated with a 
disturbed myocardial collagen turnover. In patients with heart failure, myocardial 
collagen turnover can be assessed by serum concentrations of aminoterminal 
propeptides of type I and type III collagen (PINP and PIIINP) and carboxyterminal 
telopeptide of type I collagen (ICTP) that either represents measures of collagen 
synthesis (PINP, PIIINP) or collagen degradation (ICTP). We investigated the 
effects of cardiac resynchronization therapy (CRT) on myocardial collagen 
turnover in 64 patients with heart failure by comparing PINP, PIIINP and ICTP 
concentrations in serum obtained at baseline and after 6 months of CRT. We 
hypothesized that in patients with heart failure CRT leads to reverse ventricular 
remodeling, associated with a net collagen formation. Forty-six patients (72%) 
showed a >10% reduction in LV end-systolic volume at follow-up and were 
classified as responders to CRT, the other 18 patients (28%) were classified as 
non-responders. Responders demonstrated a mean increase of serum PINP and 
PIIINP during follow-up, by 42% and 12%, respectively. In non-responders, serum 
PINP and PIIINP remained unchanged during follow-up. At baseline, responders 
had significantly lower serum PINP than non-responders (by 21%). ICTP levels of 
responders at baseline tended to be higher than in non-responders (by 70%, 
p=ns), and in both groups ICTP levels did not change upon CRT. We concluded 
that reverse LV remodelling following CRT is associated with increased collagen 
synthesis rate in the first 6 months of follow-up. 
  
It has been known for some time that monocrotaline (MCT)-induced pulmonary 
artery hypertension (PAH) and right ventricular (RV) failure are associated with 
the activation of matrix metalloproteinases (MMPs) in RV myocardium. In chapter 
4 we investigated whether NO plays any role in PAH-induced RV hypertrophy and 
failure. To that purpose, two doses of MCT were used that produced RV 
hypertrophy (RVH) only and RV hypertrophy and subsequent RV failure (RVF), 
respectively. In RVH and RVF, RV weight/ body weight increased by 36% and 
109%, whereas RV ejection fraction decreased by 23% and 57% compared to 
control, respectively. A protein associated with integrins called focal adhesion 
kinase (FAK) became phosphorylated in RVH (2.5-fold compared to control) but 
slightly in RVF (1.15-fold compared to control). Phosphorylation of NOS1-P was 
increased in RVH (3.0-fold compared to control) and in RVF (3.3-fold compared to 
control). MMP-2 was highest in RVH and intermediate in RVF (3.5- and 1.8-fold 
compared to control, respectively). MMP-9 was elevated in RVH and RVF (2.4- 
and 2.9-fold compared to control, respectively). We concluded that activation of 
FAK in RVH points to an integrin-dependent hypertrophic response of the 
myocardium. Activation of NOS1 in failing RV suggests a role of excessive NO in 
the development of failure and activation of MMPs leading to ventricular 
remodeling. 
  
Chapter 5 provides a comprehensive review of novel therapeutic approaches to 
treat PAH. PAH is a life-threatening disease with an important pulmonary 
component that may provide a target to direct therapy. These treatment options 
include a spectrum of pharmacotherapeutic agents. In addition, we discuss the 
emerging trends of using gene and cell therapy for the treatment of PAH. Finally, 
we discuss the possible applications of experimentally tested interventions for 
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therapeutic purposes in humans with PAH. The therapeutic agents include anti-
mitogenic compounds, agents that have pro-endothelial function, agents with 
vasodilatory effects, compounds with pro-angiogenic effects, anti-inflammatory 
agents, agents with anti-oxidant effects, and agents that induce apoptosis of 
pulmonary artery smooth muscle cells. 
Cell therapy is a novel treatment option and autologous mesenchymal stem cell 
(MSC) therapy is expected to be a safe and efficacious option to treat patients 
with PAH. 
  
Chapter 6 describes a study on the effects of stem cell therapy on pulmonary 
pathology associated with MCT-induced PAH in rats. We demonstrated that 
MSCs from donor rats with PAH, injected i.v. into recipient rats that had MCT 
administration 14 days earlier, reduce pulmonary parenchymal damage, medial 
hypertrophy of pulmonary arterioles, and RV hypertrophy. At 28 days after MCT, 
rats had PAH (peak RV pressure had increased from 27.2 to 41.5 mmHg), and 
increased lung weight (by 73%). Lung histology revealed severe narrowing of 
precapillary arterioles, thickening of arteriolar walls (3.4-fold increased vs. 
control), thickening of alveolar septa (3.5-fold increased vs. control), and 
increased RV mass (by 63% vs. control). Treatment with MSCs attenuated PAH 
(to 30.7±4.4 mmHg), and almost normalized lung weight (21% higher than 
control), wall thickness of arterioles (20% higher than control), thickness of 
alveolar septa (9% higher than control), and RV hypertrophy (RV mass 8% higher 
than control). Most beneficial effects of i.v. injected MSCs were less prominent or 
absent in MCT-treated rats i.v. injected with skin fibroblasts. We concluded that i.v 
administration of MSCs from donor rats with PAH to recipient rats with PAH 
decreases RV peak systolic pressure, pulmonary arteriolar narrowing, alveolar 
septum thickening, and RV hypertrophy. These results suggest that autologous 
stem cell therapy may help alleviate pulmonary symptoms of patients with PAH.  
  
In chapter 7 the effects of MCT-induced PAH without and with cell therapy on the 
RV myocardium are described in more detail. At 28 days after MCT, rats had 
depressed LV ejection fraction (from 56 to 42%). In PAH rats treated with MSCs, 
RV ejection fraction was near normal (52%). In MCT-treated rats that had 
received i.v. skin fibroblasts, effects on RV peak systolic pressure, RVH and RV 
function were far less pronounced than in MCT-treated rats that had received 
MSCs. We concluded that i.v. administration of MSCs from donor rats with PAH 
to recipient rats with PAH decreases PAH, reverses RV hypertrophy, and 
improves RV function. These results suggest that patients with PAH may be 
treated successfully using autologous MSCs. 
  
Chapter 8 presents the results of an exploratory study of the electrophysiologic 
properties of adult rat cardiomyocytes isolated from normal RV myocardium. We 
analyzed mechanisms of excitability of RV cardiomyocytes isolated from normal 
adult rat hearts, making use of the naturally occurring variability of excitability of 
these cells. We focused on the role of voltage-activated K+ current (Ikv), including 
the transient current It and the sustained current Iss, in shaping the current-pulse 
evoked action potential (AP) and in generating sustained depolarizing current-
induced automaticity (DIA). Simulation experiments were carried out with a 
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computer model of the right ventricular myocyte of the rat. The model 
experiments reproduced the decrease of AP-duration with an increase in It and 
revealed a DIA-mechanism based on IcaL deinactivation and Iss deactivation at 
depolarized potentials. 
The results provide the electrophysiological baseline-properties of the adult rat 
right-ventricular myocytes, which can serve as the control properties of these cells 
if taken from rats with pulmonary hypertension. A provisional comparison of 
excitability properties of normal RV myocytes with those of PAH RV myocytes 
showed no striking differences between these two call types, e.g. DIA occurred in 
both groups. 
Thus, to date it is still unknown whether and how this mechanism of DIA is 





1.   Stimulation of integrin receptors on the cardiomyocyte membrane leads to 
cardiomyocyte hypertrophy by a nitric oxide-dependent mechanism. 
2.   Activation of signaling cascades involving the activation of FAK and NOS1 
leads to the activation of MMPs in the failing right ventricular myocardium. 
Activated NOS1 in failing right ventricular myocardium suggests a role of 
(i) excessive NO in the development of heart failure, and (ii) MMPs 
leading to ventricular remodeling. 
3.   Reverse left ventricular remodeling following CRT in patients with 
congestive heart failure is associated with increased rate of collagen 
synthesis in the first 6 months of follow-up. 
4.   Intravenous therapy with mesenchymal stem cells from donor rats with 
MCT-induced PAH given to recipient rats with MCT-induced PAH reduces 
right ventricular hypertrophy and improves right ventricular function by 
improving lung pathology associated with PAH. 
5. Insight in the membrane mechanism of depolarization-induced 
automaticity seems of importance for understanding the high risk of 
arrhythmias in patients with heart failure. 
6.  The experiments described in this thesis contribute to the knowledge 
about molecular and cellular characteristics of hypertrophic and failing 
myocardium, and may contribute to therapy of patients with PAH with 
autologous mesenchymal stem cells.  
  
  




1.   Excessive NO production in the failing myocardium may be harmful and 
lead to nitrosylation of ryanodine receptors, rendering them dysfunctional 
as a consequence. More research is needed to define the exact role of 
(excessive) NO in the failing myocardium. 
2.   A variety of therapeutic modalities including drug therapy, gene therapy 
and cell therapy has been tested in several animal models of PAH 
including MCT-induced PAH in rats. Several of these therapeutic options 
have been shown to be effective also in PAH patients leading to improved 
life expectancy and a better quality of life. However, many patients still 
remain symptomatic despite therapy. Cell therapy is a novel treatment 
option, but more animal data should be collected to investigate optimal 
cell type, in vitro cell transduction, route of cell administration, and the 
number of cells to be injected. Autologous mesenchymal stem cell 
therapy is expected to be a safe and efficacious option to treat patients 
with PAH. 





De voornaamste doelstellingen van dit proefschrift betreffen het onderzoek naar 
moleculaire en cellulaire mechanismen die verantwoordelijk zijn voor 
harthypertrofie en hartfalen. In een onderzoek naar pulmonale hypertensie in 
ratten die zijn behandeld met monocrotaline is celtherapie getest met 
mesenchymale stamcellen met het oogmerk deze ziekte bij patiënten te 
genezen.     
  
Hoofdstuk 1 is gewijd aan de inleiding van het proefschrift. Het geeft informatie 
over de moleculaire en cellulaire eigenschappen van het gezonde hart, het 
hypertrofische hart en het falende hart. De samenstelling, synthese en afbraak 
van de extracellulaire matrix (ECM), de integrines en bijbehorende 
signaleringspaden, stikstofoxide synthases (NOS) en stikstofoxide (NO) worden 
besproken in verband met het normale, hypertrofische en falende hart. Ook 
komen experimentele modellen die worden gebruikt voor de bestudering van 
harthypertrofie en hartfalen aan de orde. De nadruk ligt met name op de 
karakterisatie en pathologie van de rechterkamer functie in dieren met pulmonale 
hypertensie op basis van behandeling met monocrotaline.   
  
In hoofdstuk 2 is de hypothese dat drukoverbelasting van het hart door het 
myocard wordt “gevoeld” via rek-achtige effecten door de integrines, een familie 
van receptoren waarmee de cardiomyocyt gehecht is aan bestanddelen van het 
ECM. In het celmodel van neonatale rattenhart cardiomyocyten (NRCM) in vitro 
hebben we de integrines gestimuleerd met een pentapeptide dat het RGD-motief 
bevat, Arg-Gly-Asp, om te testen of integrine stimulatie leidt tot NRCM 
hypertrofie. Het pro-hypertrofische effect van het RGD-bevattende pentapeptide 
op NRCM is vergeleken met het goed gedocumenteerde pro-hypertrofische effect 
van α1-adrenoceptor stimulatie met fenylefrine (PE). NRCM die met fysiologisch 
zout zijn behandeld dienden als controle. De hypertrofische respons is 
gekwantificeerd door meting van het celoppervlak (CSA). Ook is gemeten 
hoeveel stikstofoxide synthase-1 (NOS1) gefosforyleerd is. Onder invloed van 
RGD steeg de CSA met 38% en onder invloed van PE met 68%, ten opzichte van 
controle. Een remmer van NOS, L-NAME, remde de door RGD gestimuleerde 
hypertrofie van NRCM volledig, maar had geen effect op de door PE 
gestimuleerde hypertrofie van NRCM. Remming van de door RGD gestimuleerde 
hypertrofie van NRCM met behulp van L-NAME kon, tenminste gedeeltelijk, 
worden doorbroken door toevoeging van een NO-donor, nitroprusside. 
Toevoeging van nitroprusside had geen effect op NRCM die met PE en L-NAME 
werden behandeld. Ryanodine en BAPTA-AM remden de door RGD 
gestimuleerde hypertrofie van NRCM volledig, maar niet de door PE 
gestimuleerde hypertrofie van NRCM, hetgeen betekent dat intracellulaire Ca2+ 
ionen betrokken zijn bij de door RGD gestimuleerde hypertrofie van NRCM. 
Onder invloed van RGD steeg het percentage gefosforyleerd NOS-1 met 61%. 
De conclusie van dit onderzoek was dat integrine stimulatie van NRCM met RGD 
leidt tot cardiomyocyt hypertrofie. Stopzetten van dit proces met behulp van een 
NOS remmer en het proces weer aan de gang krijgen met behulp van een NO-
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donor doet ons vermoeden dat de door RGD gestimuleerde hypertrofie van 
NRCM afhankelijk is van NO, waarschijnlijk NO afkomstig van NOS1.  
  
In hoofdstuk 3 laten we zien dat hartfalen geassocieerd kan zijn met een 
verstoord collageen metabolisme. In patiënten met hartfalen kan de omzetting 
van collageen worden gemeten aan de hand van de serum concentraties van de 
aminoterminale propeptides van type I en type III collageen (resp. PINP en 
PIIINP) en het carboxyterminale telopeptide van type I collageen (ICTP) die 
maten zijn van hetzij collageen synthese (PINP, PIIINP) of collageen degradatie 
(ICTP). In 64 patiënten met hartfalen onderzochten wij de effecten van cardiale 
resynchronisatie therapie (CRT) op myocardiale collageen omzetting door meting 
van PINP, PIIINP en ICTP in serum verkregen vóór en 6 maanden na start van 
CRT. De hypothese was dat in patiënten met hartfalen CRT leidt tot 
kamerverkleining (na kamerdilatatie) die samen gaat met een toename van de 
myocardiale collageen concentratie. Zesenveertig patiënten (72%) vertoonden 
een >10% afname van hun linkerkamer eind-systolisch volume na 6 maanden en 
zij werden op basis hiervan responders genoemd. De andere 18 patiënten (28%) 
werden non-responders genoemd. Responders lieten een gemiddelde toename 
van serum PINP en PIIINP zien in de eerste 6 maanden, met resp 42% en 12%. 
In non-responders veranderden de serum PINP en PIIINP concentraties niet in de 
eerste 6 maanden. Voor aanvang van CRT hadden de responders significant 
lagere (met 21%) serum PINP concentraties dan non-responders. Serum ICTP 
concentraties van responders voor aanvang van CRT waren hoger (met 
70%) dan die van non-responders, maar dit verschil was statistisch niet 
significant. In beide groepen veranderden de serum ICTP concentraties niet in de 
eerste 6 maanden. Onze conclusie was dat kamerverkleining (na kamerdilatatie) 
onder invloed van CRT geassociëerd is met een toegenomen myocardiale 
collageen synthese in de eerste 6 maanden van CRT. 
  
Al lange tijd is bekend dat de door monocrotaline (MCT) opgewekte pulmonale 
hypertensie (PAH) en rechterkamer hypertrofie in ratten geassocieerd zijn met 
activatie van matrix metalloproteinases (MMP) in rechterkamer (RV) myocard. In 
hoofdstuk 4 onderzochten wij of NO een rol speelt in de door PAH opgewekte 
RV hypertrofie en RV falen. Om dat te onderzoeken, gebruikten we twee doses 
MCT: een lage dosis om alleen RV hypertrofie te veroorzaken (RVH) en een hoge 
dosis om naast RV hypertrofie ook RV falen (RVF) te veroorzaken. In ratten met 
RVH en RVF was de ratio RV gewicht/lichaamsgewicht toegenomen met resp. 
36% en 109%, terwijl de RV ejectiefractie was afgenomen met resp. 23% en 
57%, ten opzichte van controle. In RV myocard van ratten met RVH steeg het 
fosforyleringspercentage van een met integrines geassocieerd eiwit, focal 
adesion kinase (FAK), met een factor 2,5, maar in RV myocard van ratten met 
RVF steeg FAK-P met slechts 15%. De fosforylering van NOS1 in myocard van 
ratten met RVH en in myocard van ratten met RVF steeg met een factor van resp. 
3,0 en 3,3. RV MMP-2 in ratten met RVH was toegenomen met een factor 3,5 en 
in ratten met RVF toegenomen met een factor 1,8 ten opzichte van controle. RV 
MMP-9 was toegenomen in ratten met RVH en RVF met een factor van resp. 2,4 
en 2,9. Onze conclusie was dat FAK activatie in ratten met RVH wijst op een 
integrine-afhankelijke hypertrofische respons van het myocard. Activatie van 
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NOS1 in het falende RV doet ons vermoeden dat excessieve NO concentraties 
betrokken zijn bij de ontwikkeling van myocardfalen en de activatie van MMPs die 
de kamerdilatatie inleiden.    
  
Hoofdstuk 5 geeft een uitgebreid overzicht van therapieën van PAH in 
proefdieren waarover recent is gerapporteerd. PAH is een levensbedreigende 
ziekte waarbij de longen in belangrijke mate betrokken zijn. Deze betrokkenheid 
van de longen biedt een aangrijpingpunt voor therapie. De grote verscheidenheid 
aan therapieën berust voor een groot gedeelte op geneesmiddelen. Hiertoe 
behoren anti-mitogene middelen, stoffen met endotheel-beschermende werking, 
vasodilatoren, stoffen die de angiogenese bevorderen, anti-inflammatoire stoffen, 
anti-oxidanten en stoffen die de apoptose van gladdespiercellen in de pulmonaal 
arteriën bevorderen. Ook komen moderne therapieën van PAH aan de orde zoals 
gen- en celtherapie. Dit hoofdstuk wordt afgesloten met een bespreking van de 
mogelijke toepassingen van experimenteel geteste interventies op patiënten met 
PAH. Behandeling van patiënten met PAH met autologe mesenchymale 
stamcellen (MSCs) uit beenmerg is waarschijnlijk veilig en succesvol en zou in 
die patiëntengroep kunnen worden getest.   
  
Hoofdstuk 6 beschrijft een onderzoek naar de effecten van stamcel therapie op 
de long pathologie van ratten met PAH die is opgewekt met MCT. Wij hebben 
aangetoond dat MSCs die zijn geïsoleerd uit beenmerg van donor ratten met door 
MCT opgewekte PAH, na intraveneuze inspuiting in ontvanger ratten die 14 
dagen eerder waren behandeld met MCT leidden tot (1) minder schade aan het 
longparenchym, (2) minder hypertrofie van de pulmonale arteriolen en (3) minder 
RV hypertrofie, dan waargenomen in ratten met door MCT opgewekte PAH die 
geen stamcel therapie ondergingen. Op het moment van analyse, 28 dagen na 
behandeling met MCT was de piek-systolische druk in de pulmonaal arterie 
gestegen van 27.2 tot 41.5 mmHg en het longgewicht toegenomen met 73%. 
Histologische analyse van de longen liet ernstige vernauwing van de precapillaire 
arteriolen zien, verdikking van de wand van de arteriolen (toename met een factor 
3,4), verdikking van de arteriolaire septa (toename met een factor 3,5), en een 
toename van het RV gewicht (met 63%), ten opzichte van controle. Behandeling 
van deze ratten met MSCs, 14 dagen na MCT behandeling, leidde tot verlaging 
van de piek-systolische druk in de pulmonaal arterie (30.7±4.4 mmHg), een 
vrijwel normaal longgewicht (21% hoger dan controle), minder verdikking van de 
arteriolaire wand (20% hoger dan controle), minder verdikking van de alveolaire 
septa (9% hoger dan controle) en minder RV hypertrofie (RV gewicht 8% hoger 
dan controle). Naast ratten met PAH die wel of niet zijn behandeld met MSCs en 
controle ratten, is nog een vierde groep ratten bestudeerd. Deze groep is 14 
dagen na MCT behandeling intraveneus ingespoten met huidfibroblasten van 
gezonde ratten. Deze ratten lieten veel minder grote reacties, of in het geheel 
geen reacties, zien op longpathologie, piek-systolische druk in de pulmonaal 
arterie en RV hypertrofie. Onze conclusie was dat intraveneuze toediening van 
MSCs, geisoleerd uit beenmerg van donor ratten met PAH, aan ontvanger ratten 
met PAH leidde tot (1) lagere piek-systolische druk in de pulmonaal arterie, (2) 
minder ernstige long pathologie en (3) minder RV hypertrofie. Deze resultaten 
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ondersteunen een toekomstige toepassing van therapie met autologe MSCs in 
patiënten met PAH.   
  
In hoofdstuk 7 zijn de effecten van PAH op de rechterkamer functie van ratten 
die zijn behandeld met MCT, met of zonder celtherapie, beschreven. Op het 
moment van analyse, 28 dagen na behandeling met MCT, was de RV 
ejectiefractie gedaald van 56% naar 42%. In ratten met PAH waarbij 14 dagen na 
MCT MSCs zijn toegediend was de RV ejectiefractie vrijwel normaal (52%). 
Ratten waarbij 14 dagen na MCT behandeling huidfibroblasten zijn ingespoten, 
lieten minder grote verbeteringen op RV functie zien dan ratten die MSCs 
ingespoten kregen. Deze resultaten geven aan dat patiënten met PAH geholpen 
kunnen zijn met intraveneuze stamcel therapie gebruik makend van autologe 
MSCs. 
  
Hoofdstuk 8 beschrijft een onderzoek naar de electrofysiologische 
eigenschappen van cardiomyocyten die zijn geïsoleerd uit RV myocard van 
gezonde ratten. Dit onderzoek moet de basis bieden voor een later onderzoek 
waarin electrofysiologische eigenschappen van cardiomyocyten die zijn 
geïsoleerd uit RV myocard van gezonde ratten worden vergeleken met 
electrofysiologische eigenschappen van cardiomyocyten die zijn geïsoleerd uit 
RV myocard van ratten met PAH. In RV cardiomyocyten van gezonde 
rattenharten maakten we gebruik van de normaal aanwezige variabiliteit in 
exciteerbaarheid van deze cellen. Wij concentreerden ons op de rol van de 
spanningsafhankelijke K+ stroom (Ikv), inclusief de kort-durende stroom It en de 
lang-durende stroom Iss, op de actiepotentiaal die wordt opgewekt door korte 
stroompulsjes en op de automaticiteit die wordt opgewekt door lange, 
depolarizerende stroompulsen. In dit vooronderzoek zijn mogelijke mechanismen 
van door hartfalen geïnduceerde aritmieën onderzocht door meting van de 
exciteerbaarheid van cardiomyocyten die zijn geïsoleerd uit de RV van het 
normale rattenhart. Een biofysisch model van de RV cardiomyocyt van het 
rattenhart dat in 2001 in de literatuur gepubliceerd is was de basis voor het 
ontwikkelen van een computermodel waarmee de membraanstromen en 
membraanspanningen kunnen worden gesimuleerd. Met dit model hebben we de 
reciproke relatie tussen actiepotentiaalduur en It stroom gereproduceerd. Ook 
leverde dit model een mechanisme voor de automaticiteit die wordt opgewekt 
door lange, depolarizerende stroompulsen. Met name de deinactivatie van IcaL 
en de deactivatie van Iss tijdens depolarisatie lijken voor deze automaticiteit 
verantwoordelijk. Het is nog niet bekend of dit mechanisme van automaticiteit 




1.   Stimulatie van integrines op het membraan van cardiomyocyten bevordert 
hypertrofie van de cardiomyocyt via een mechanisme dat stikstofoxide 
afhankelijk is.  
2.   Signaaltransductie paden waarin activatie van focal adesion kinase en 
stikstofoxide synthase-1 optreedt veroorzaken de activatie van matrix 
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metalloproteinases in het falende rechter kamer myocard van ratten met 
pulmonale hypertensie. Geactiveerd stikstofoxide synthase-1 in het 
falende myocard doet vermoeden dat hartfalen geassocieerd is met (1) 
excessieve concentraties van stikstofoxide en met (2) geactiveerde matrix 
metalloproteinases die betrokken zijn bij het optreden van kamerdilatatie. 
3.   Kamerverkleining (na kamerdilatatie) als gevolg van cardiale 
resynchronisatie therapie in patiënten met hartfalen is geassocieerd met 
een toename van de myocardiale collageen synthese in de eerste 6 
maanden na start van therapie.  
4.   Intraveneuze toediening van mesenchymale stamcellen van donor ratten 
met door monocrotaline opgewekte pulmonale hypertensie aan ontvanger 
ratten met door monocrotaline opgewekte pulmonale hypertensie 
vermindert de bloeddruk in de pulmonaal arterie, vermindert de rechter 
kamer hypertrofie en verbetert de rechter kamer functie, verbeteringen 
die sterk gerelateerd zijn aan verbetering van de long pathologie. 
5. Inzicht in het membraanmechanisme van depolarisatie-geinduceerde 
automatie lijkt van belang voor een beter begrip van het hoge risico op 
aritmieen in patiënten met hartfalen. 
6. De experimenten die in dit proefschrift zijn beschreven zijn bedoeld als 
bijdrage aan de kennis omtrent moleculaire en cellulaire mechanismen 
die verantwoordelijk zijn voor harthypertrofie en hartfalen. Wij hopen dat 
deze experimenten ook mogen bijdragen aan de introductie van 
stamceltherapie voor patiënten met pulmonale hypertensie met behulp 




1.   Overmatige stikstofoxide concentraties in het falende hart zijn 
waarschijnlijk schadelijk en kunnen leiden tot nitrosylering van o.a. 
ryanodine receptoren waardoor ze Ca2+ ionen lekken tijdens diastole. Het 
is aan te bevelen in de toekomst de effecten van overmatige stikstofoxide 
concentraties in en op het falende myocard te bestuderen. 
2.   Verscheidene therapeutische modaliteiten inclusief farmacotherapie, 
gentherapie en celtherapie zijn getest in diermodellen van pulmonale 
hypertensie, zoals de door monocrotaline opgewekte pulmonale 
hypertensie in ratten. Een aantal van deze therapieën hebben hun 
waarde al in patiënten met  pulmonale hypertensie bewezen, hetgeen 
geleid heeft tot een verbeterde levensverwachting en een betere kwaliteit 
van leven. Echter, vele patiënten met pulmonale hypertensie blijven 
symptomatisch ondanks therapie. Voor hen zou celtherapie een uitkomst 
kunnen zijn, maar vooralsnog is er behoefte aan meer onderzoek naar 
het optimale celtype, naar de vraag of de toe te dienen cellen in vitro nog 
een voorbehandeling moeten ondergaan, naar de route van celtoediening 
en naar het optimale aantal in te spuiten cellen. Niettemin verwachten wij 
dat intraveneuze therapie met autologe mesenchymale stamcellen veilig 
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